Functional insights into ABC-F proteins that mediate antibiotic resistance in Gram-positive bacteria by Sharkey, Liam Karl Robert
 
 
  
 
 
Functional insights into  
ABC-F proteins that mediate antibiotic 
resistance in Gram-positive bacteria 
 
 
Liam Karl Robert Sharkey 
Submitted in accordance with the requirements for the degree of 
Doctor of Philosophy 
 
The University Of Leeds 
 
School of Molecular and Cellular Biology 
 
Faculty of Biological Sciences 
 
September 2015 
ii 
 
  
The candidate confirms that the work submitted is his own and that appropriate credit has 
been given where reference has been made to the work of others. 
This copy has been supplied on the understanding that it is copyright material and that no 
quotation from the thesis may be published without proper acknowledgement. 
©2015, The University of Leeds, Liam Sharkey 
  
iii 
 
  
Acknowledgments  
Firstly, I would like to thank my two supervisors, Dr Alex O’Neill and Dr Thomas Edwards for 
their guidance and advice throughout the duration of this project. I am extremely grateful 
for their continued support, particularly during the difficult early period of this study. 
I feel very lucky to have worked with so many excellent scientists during my PhD, both within 
the O’Neill lab and the faculty as a whole. I would particularly like to thank Georgina Cox, 
Victoria Savage, Nicola Ooi, Arya Gupta, and Justin Clarke, for technical help and advice 
relating to this project.  
I owe my profound enjoyment of the past four years to all of the members of the O’Neill lab 
and Garstang 8.52, past and present. We are a diverse group and yet I have never been 
surrounded by more like-minded people. It has been a pleasure working with all of you. I 
would particularly like to mention my partner Karinna, whose constant support and 
encouragement has been immeasurably important to me. I am very grateful to Alex for 
inviting her to come and work in our lab!  
Finally, I would like to dedicate this thesis to my family. You have always believed in me and 
I couldn’t have done it without you. 
 
 
 
 
 
iv 
 
  
Abstract 
Members of the ABC-F subfamily of ATP-binding cassette (ABC) proteins mediate resistance 
to a broad array of clinically-important antibiotic classes that target the ribosome of 
Gram-positive pathogens. The mechanism by which the ABC-F proteins mediate antibiotic 
resistance is poorly defined, although two hypotheses have been proposed; drug efflux and 
ribosomal protection. Here, this mechanism of resistance was investigated using a 
combination of bacteriological and biochemical techniques. Results obtained from the 
bacteriological assays provided preliminary data in support of ribosomal protection. 
Subsequently, the heterologous expression and purification of two ABC-F proteins, Vga(A) 
and Lsa(A), allowed the function of these proteins to be assessed in staphylococcal 
transcription-translation (T/T) reactions. Addition of Vga(A) and Lsa(A) to T/T assays subject 
to antibiotic inhibition caused drug specific, dose-dependent, rescue of translation. Several 
previously described resistance phenotypes attributed to these proteins were successfully 
recapitulated in T/T assays, corroborating the idea that rescue of translation observed in vitro 
is representative of the action of these proteins in whole cells. Finally, ribosome binding 
assays showed Lsa(A) to be capable of displacing antibiotics from staphylococcal ribosomes. 
Collectively, the experiments described in this thesis provide the first direct evidence to 
support a mechanism of ARE ABC-F resistance based on ribosomal protection. 
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1. Introduction 
1.1 The importance of antibacterial agents and the rise of antibiotic resistance 
The advent of modern antimicrobial chemotherapy represented a seminal moment in the 
ongoing fight against infectious disease. Prior to the widespread integration of antibiotics 
into the toolkit of modern medicine, clinicians lacked effective options for the treatment of 
bacterial infections and bacterial pathogens were a major cause of morbidity and mortality. 
In 1930, around 1 in 5 deaths in the USA was attributable to conditions associated with 
bacterial infection such as pneumonia, tuberculosis, gastrointestinal disease, and childbirth-
associated septicaemia (Murphy, 1931). However, by the end of the 20th century, lower 
respiratory tract infections were the only bacterially associated disease to be ranked among 
the top 10 causes of death within the USA (Wenzel and Edmond, 2000). Similarly, in 1941 
staphylococcal bacteraemia was associated with an 80% mortality rate, but by 2004 only 20% 
of systemic staphylococcal infections resulted in death (van Hal et al., 2012, Skinner and 
Keefer, 1941). These dramatic decreases in mortality associated with bacterial infections 
coincide with entry into the “antibiotic era”, which began with the introduction of Salvarsan 
for treatment of syphilis in the 1910s (Aminov, 2010), and the subsequent introduction of 
the sulphonamides and penicillin into widespread clinical use during the 1930s and 40s 
respectively (Domagk, 1986, Chain et al.). The following three decades (1940 – 1970) 
represented a “Golden Era” of antibiotic discovery, in which the majority of antibiotic classes 
in clinical use today were identified (Aminov, 2010), heralding an end to the “age of 
pestilence” and enabling modern medical procedures such as anti-cancer chemotherapy, 
organ transplantation and routine surgery (Omran, 2005).  
The enormous progress made in the field of antimicrobial chemotherapy during the 20th 
century is now in danger of being compromised. The increasing prevalence of bacterial 
strains resistant to multiple classes of antibiotics threatens to bring about a post-antibiotic 
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era, in which clinicians once more lack the necessary tools to treat bacterial infection and 
deaths resulting from bacterial disease begin to increase. As of 2014, antimicrobial resistance 
is estimated to result in 700 000 deaths annually world-wide, with this figure predicted to 
rise as high as 10 million if current trends in development of antibiotic resistance are left 
unchecked, these figures include infections caused by drug resistant malaria and HIV in 
addition to bacteria (HM Government review on antimicrobial resistance, 2014). In the 
developing world, community acquired infections such as tuberculosis caused by drug 
resistant Mycobacterium tuberculosis pose a significant challenge; the estimated 480,000 
cases of drug resistant TB in 2013 threaten to erode the current treatment success rate of 
86% (WHO, 2014). Whereas, within industrialised nations infections caused by multi-drug 
resistant bacteria within are predominantly hospital-associated, with the so called ESKAPE 
pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, 
Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp.) posing a 
particular threat (Boucher et al., 2009).  
The clinical impact of antibiotic resistance is exacerbated by a lack of new antibiotic classes 
coming to market. Between 1940 and 1970 more than 20 new classes of antibiotics were 
developed, but since then only three novel classes have entered the clinic (Coates et al., 
2011). Additionally, the development of analogues of existing classes is not proceeding 
quickly enough to match the accumulation of resistance (Boucher et al., 2009, Coates et al., 
2011). The combination of the increasing frequency of infections caused by drug-resistant 
bacteria and the lack of new antibiotics has led to numerous calls to action (Commission, 
2011, Wise, 2011, Spellberg et al., 2008). These reports all emphasise the urgent need to 
develop new classes and analogues of antibiotics, particularly those active against 
Gram-negative bacteria. A complementary strategy to develop inhibitors of resistance 
mechanisms to be used in combination with existing antibiotics has also been proposed 
(Pages et al., 2005, Drawz and Bonomo, 2010). Efforts to develop antibiotics and inhibitors 
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to circumvent currently existing resistance can be informed and accelerated by a thorough 
understanding of how antibiotic-resistance mechanisms work. 
1.1.1 Antibiotic targets and mechanisms of antibiotic resistance 
Antibiotics act by interfering with essential cellular biochemistry and physiology, thereby 
causing cell death or cessation of growth. In order to exert these effects, the majority of 
antibiotics inhibit or compromise one of five essential cellular targets; the cell membrane, 
nucleic acid synthesis, folic acid biosynthesis, peptidoglycan biosynthesis, or protein 
synthesis (Figure 1.1) (Wright, 2010). As these bacterial targets are either absent or different 
in eukaryotic cells, antibiotics are able to selectively inhibit bacteria whilst causing minimal 
toxicity to a mammalian host.  
It was already understood in the early years of the antibiotic era that bacteria could in some 
cases resist the growth-inhibitory and lethal effects of antibiotics, a situation that can 
compromise treatment of infection in the patient (Abraham and Chain, 1940). The 
considerable threat that this poses to effective antibacterial chemotherapy has prompted 
intensive research efforts towards understanding the phenomenon of antibiotic resistance. 
An important facet of these efforts has been to dissect the mechanisms underlying antibiotic 
resistance; in other words, to establish exactly how bacteria evade the inhibitory action of 
antibiotics. Aside from yielding information that is of fundamental biological interest and 
providing novel insights into evolution, these studies also serve an important practical 
purpose; they offer essential intelligence for those engaged in antibacterial drug discovery 
to enable the development of new approaches to circumvent or overcome antibiotic 
resistance. 
The ability of a bacterium to resist inhibition or killing by an antibiotic may result from 
inherent properties of the cell (‘intrinsic’ or ‘natural’ resistance), or may evolve in a bacterial 
population that was previously antibiotic-susceptible (‘acquired’ resistance). In both cases, 
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the mechanism by which resistance is ultimately achieved are the same; by preventing, or 
mitigating the effects of, an antibiotic binding to its cellular target. However, this effect can 
be achieved in a number of ways; the mechanisms by which bacteria resist antibiotics can be 
grouped into four major categories, and are summarised in Figure 1.1. 
The work described in this study is concerned with a group of antibiotic resistance proteins 
that mediate resistance to ribosomally-targeted protein synthesis inhibitors. Accordingly, 
antibiotics that target the ribosome, and resistance mechanisms to these antibiotics, are 
discussed in more detail below (Sections 1.2 and 1.3).  
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Figure 1.1. The major sites of antibiotic action, and mechanisms by which bacteria resist antibiotics. The majority of antibiotics elicit their inhibitory effects 
through action at one of the following cellular targets; the cell membrane or cell wall, DNA or RNA synthesis, folic acid biosynthesis, or protein synthesis (left 
of figure). Bacteria resist these inhibitory effects through alteration of the antibiotic, alteration of the antibiotic target, utilisation of an alternative molecule 
to bypass the inhibitory effect to the drug, and/or, decreasing cellular permeability and/or increasing efflux to decrease drug accumulation within the cell 
(right of figure). Figure adapted from (Wright, 2010). 
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1.2 The ribosome as an antibiotic target 
Protein synthesis is essential for bacterial growth. Growing cells use ~50% of the energy they 
consume to make proteins, and 20–40% of protein synthesis in Escherichia coli (E. coli) is 
devoted the production of ribosomes and other translation factors (Russell and Cook, 1995). 
The ribosome is an RNA-based macromolecular machine around which the multi-step 
process of protein synthesis is centred. It provides a platform on which amino acids are 
polymerised into polypeptides according to the genetic information contained within 
messenger RNA (mRNA). Given the vital nature of protein synthesis, and the key role of the 
ribosome within this process, it is perhaps unsurprising that the ribosome is one of the main 
antibiotic targets in the bacterial cell. 
The bacterial 70S ribosome is composed of two subunits; a smaller 30S subunit, made up of 
the 16S ribosomal RNA (rRNA) and 21 proteins, and a larger 50S subunit containing two 
rRNAs (the 23S and 5S rRNAs) and 33 different proteins (Schluenzen et al., 2000, Wilson and 
Nierhaus, 2005). The 30S subunit contains the decoding centre, where anti-codons within 
mRNA are paired with cognate transfer RNA (tRNA). By contrast, the 50S subunit provides 
the peptidyl-transferase centre (PTC), which catalyses formation of the peptide bond, and 
the peptide exit tunnel, where nascent polypeptides leave the ribosome. At the interface 
between the two subunits lies three pockets which bind tRNA; the acceptor site (A-site), the 
peptidyl site (P-site) and the exit site (E-site) (Ban et al., 2000, Wilson and Nierhaus, 2005).  
Protein synthesis can be divided into four phases; initiation, elongation, termination, and 
recycling. During initiation, the 30S and 50S subunits assemble, forming the 70S ribosome 
and establishing the reading frame of mRNA through positioning of the initiator tRNA (fMet-
tRNA) on the start codon in the P- site. This process is promoted by three initiation factors; 
IF1, IF2 and IF3. The elongation step involves the cyclic movement of tRNA from the A- to P- 
to E- site. At the A-site incoming amino-acyl tRNA, which is brought to the ribosome by 
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elongation factor Tu (EF-Tu), is screened and selected in accordance with the corresponding 
codon being displayed by mRNA. The P-site contains the peptidyl-tRNA, however, during 
catalysis of peptide bond formation in the PTC, the growing peptide chain is transferred from 
the peptidyl-tRNA in the P-site to the amino-acyl tRNA in the A-site. A second elongation 
factor, EF-G, drives translocation of tRNAs from the P- to E- site and A-to P site, leaving the 
A-site free to accommodate the next incoming tRNA. Eventually, the mRNA at the A-site will 
display a stop codon, resulting in progression to the termination and recycling phases. During 
termination, release factors 1  and  2 (RF1 and RF2) act to hydrolyse the peptidyl-tRNA bond, 
releasing the nascent polypeptide to leave through the polypeptide exit tunnel in the 50S 
subunit. Finally, a third release factor (RF3) causes dissociation of RF1 and RF2 and the 70S 
ribosome is split into its constituent subunits by EF-G in tandem with the ribosome recycling 
factor. The ribosomal subunits and ribosome associated factors, are then free to begin 
another round of protein synthesis (Schmeing and Ramakrishnan, 2009, Wilson, 2014a, 
Starosta et al., 2014) (see Figure 1.2 for an overview of translation). 
Despite the complexity of protein synthesis, the majority of antibiotics that target this 
process act to inhibit elongation. This is true of all clinically important classes of protein 
synthesis inhibitors, namely the aminoglycosides, amphenicols, fusidic acid, lincosamides, 
macrolides, oxazolidinones, type A and B streptogramins, and tetracyclines (Figure 1.2) 
(Wilson, 2009, Wilson, 2014). Although some compounds do target the initiation phase (e.g. 
avilamycin, edeine, evernimicin, kasugamycin, pactamycin, thermorubin, and thiostrepton), 
due to problems of poor solubility and toxicity they are not currently in clinical use (Wilson, 
2014a). Inhibitors of termination and recycling frequently have a more pronounced effect 
during elongation, with the exception of fusidic acid and blasticidin S, which inhibit recycling 
and termination, respectively, at lower concentrations than are required to inhibit 
elongation (Suematsu et al., 2010, Svidritskiy et al., 2013).  
8 
 
  
 
 
 
Figure 1.2. Sites of antibiotic inhibition during protein synthesis. During initiation of translation, the 30S and 50S 
ribosomal subunits assemble to from the 70S ribosome and the fMet-tRNA is positioned on the start codon in the 
P- site. At the 30S subunit, this phase of translation is inhibited by edeine (EDE), kasugamycin (KSG), pactamycin 
(PCT), and thermorubin (THB), while avilamycin (AVN), evernimicin (EVN), and thiostrepton (THS) act at the 50S 
subunit. The elongation cycle requires delivery of the cognate tRNA into the A-site, a process that is inhibited by 
antibiotics of the tetracycline class (TET). Peptide bond formation between the peptidyl-tRNA at the P-site and 
amino-acyl tRNA at the P-site occurs at the PTC and is inhibited by amphenicols (AMP), blasticidin S (BLS), 
oxazolidinones (OXA), pleuromutilins (PLU), puromycin (PUR), type A streptogramins (SGA), and sparsomycin 
(SPA). Translocation of tRNAs is catalysed by EF-G and is inhibited by antibiotics of the aminoglycoside (AMG) 
class and fusidic acid (FUS), although this antibiotic primarily acts to prevent recycling. Elongation of the nascent 
chain is the target of antibiotics in the macrolide (MAC), ketolide (KET), and type B streptogramin (SGB) class. 
Although, it should be noted that selected macrolides also inhibit peptide bond formation. Termination of protein 
synthesis is inhibited by peptidyl-transferase targeted antibiotics such as BLS, CAM, PUR and SPA, whereas, FUS 
acts to trap EF-G in complex with the ribosome and thereby prevent recycling. Figure adapted from (Wilson, 
2014). 
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1.2.1 Antibiotics that target the ribosome 
Although the ribosome is a large and complex structure, the sites at which antibiotics bind 
to mediate their inhibitory effects are relatively few. In the 30S subunit, antibiotics primarily 
bind close to the positions at which mRNA and tRNA are accommodated into the ribosome. 
In this manner, they mediate inhibition of translation by either blocking the association of 
tRNAs with the A-site, as is the case for tetracyclines, or by preventing translocation, as 
exemplified by aminoglycosides (Brodersen et al., 2000). Within the 50S subunit, the 
majority of antibiotic classes exert their inhibitory effects through binding sites in the vicinity 
of the PTC. Exceptions include the orthomycins and thiopeptides, which target sites away 
from the PTC and interfere with the association of initiation and elongation factors (Belova 
et al., 2001, Mikolajka et al., 2011). The binding sites of antibiotics at the PTC overlap the 
binding sties of A-site tRNA (amphenicols, lincosamides, oxazolidinones, puromycin, and 
sparsomycin), P-site tRNA (blasticidin S), both A- and P-site tRNA (pleuromutilins and type A 
streptogramins), or are found adjacent to the PTC at a constriction in the peptide exit tunnel 
(macrolides, type B streptogramins) (Figure 1.3). At the PTC, antibiotic binding acts to 
interfere with the correct positioning of the amino-acyl moieties at the ends of tRNAs, 
thereby inhibiting peptide bond formation (Polacek and Mankin, 2005, Wilson, 2009, Wilson, 
2014). By contrast, type B streptogramins and 14-membered ring macrolides do not interfere 
with the PTC reaction, but instead act to prevent exit of the growing peptide chain from the 
ribosome, prompting premature termination of protein synthesis and the release of 
peptidyl-tRNA from the ribosome (Di Giambattista et al., 1989, Hansen et al., 2002, Mao and 
Robishaw, 1971). 
The structures of a representative member of each class of ribosomal antibiotic that has been 
used in clinical or veterinary medicine are shown in Figure 1.4, Page 11. 
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Figure 1.3. The points at which the majority of antibiotics bind the 50S subunit of the ribosome. The PTC 
(indicated) is the target of amphenicols, blasticidin S, lincosamides, oxazolidinones, pleuromutilins, puromycin, 
streptogramin As, and sparsomycin. Whereas, macrolides and streptogramin Bs bind in proximity to a constriction 
in the peptide exit tunnel (indicated). A schematic of the 50S subunit is shown in grey. The amino acyl- and 
peptidyl- tRNAs are represented as copper or dark grey spheres respectively. A surface representation of the 
peptide exit tunnel is shown, yellow surface represents the outside of the tunnel and blue surface represents the 
tunnel interior. Ribosomal proteins L4 and L22, which contact the wall of the tunnel, forming a constriction, are 
shown as green ribbons. Figure adapted from (Jenni and Ban, 2003). 
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Figure 1.4. Chemical structures of representative members of clinically used antibiotics that target the 
ribosome. (A) Classes targeting the 50S subunit; phenicols (chloramphenicol), lincosamides (clindamycin), 
macrolides (erythromycin), oxazolidinones (linezolid), pleuromutilins (retapamulin), type A streptogramins 
(virginiamycin M1), and type B streptogramins (virginiamycin S1). (B) Classes targeting the 30S subunit; 
aminoglycosides (kanamycin) and tetracyclines (tetracycline). 
. 
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1.3 Mechanisms of resistance to ribosomal antibiotics 
Ribosomally active antibiotics play important roles in clinical and veterinary medicine. Of the 
30S targeted antibiotic classes, aminoglycosides and tetracyclines are important agents for 
the treatment of both Gram-positive and Gram-negative infections. Of the antibiotic classes 
that bind the 50S subunit in the vicinity of the PTC, seven are used in clinical and veterinary 
medicine for the treatment of primarily Gram-positive infections, namely the amphenicols, 
lincosamides, macrolides, oxazolidinones, pleuromutilins, and type A and B streptogramins. 
Although all of these antibiotics have potent antibacterial effects and form a large proportion 
of the antibiotic armamentarium, the development of resistance poses a threat to their 
continued efficacy. 
Most Gram-negative bacteria are intrinsically resistant to 50S targeted antibiotics due to the 
inability of these predominantly hydrophobic drugs to penetrate the Gram-negative outer 
membrane (Wilson, 2014). By contrast, the mechanisms by which Gram-positive and 
sensitive Gram-negative bacteria resist the action of ribosomal antibiotics can be separated 
into three groups; alteration of the target, through modification and dissociation; alteration 
of the drug, through modification or destruction; and decreased accumulation, through 
efflux. Examples of each mechanism are described below. 
1.3.1 Resistance through antibiotic modification and degradation 
A number of plasmid-borne enzymes have been identified that mediate drug inactivation 
through destruction or degradation of aminoglycosides, amphenicols, lincosamides, 
macrolides, both type A and B streptogramins, and tetracyclines. However, to date, no 
resistance genes encoding enzymes that modify or destroy antibiotics belonging to either 
the pleuromutilin or oxazolidinone class have been identified. Drug modification generally 
acts through the addition of functional groups which prevent the antibiotic from binding to 
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its target site, whereas drug degradation relies on cleavage of chemical bonds that are 
integral to the compounds activity. 
1.3.1.1 Inactivation of aminoglycosides 
Resistance to the aminoglycoside antibiotics in both Gram-positive and Gram-negative 
pathogens is predominantly mediated by modification of the drug through N-acetylation, 
O-adenylation or O-phosphorylation. Addition of these bulky chemical groups to any one of 
a number of OH or NH2 groups on the aminoglycoside molecule disrupts the interaction of 
the drug with its target, the ribosomal RNA. Over 100 aminoglycoside modifying enzymes 
(AMEs) catalysing such reactions have been identified, and they are grouped into three 
classes according to the type of chemical modification catalysed: aminoglycoside 
acetyltransferases (AACs), aminoglycoside nucleotidyltransferases (ANTs) and 
aminoglycoside phosphotransferases (APHs) (Ramirez and Tolmasky, 2010).  
Some AMEs are bifunctional enzymes, possessing the ability either to perform more than 
one type of chemical modification, or to modify more than one type of substrate. The 
enzyme AAC (6’)-APH(2”) is one such bifunctional AME, and is one of the most common 
mediators of aminoglycoside resistance in S. aureus. The N-terminal portion of this enzyme 
possesses AAC activity, whilst the C-terminal domain has APH activity. The dual catalytic 
activity of this enzyme appears to have arisen as a consequence of fusion of two ancestral 
genes to yield a single, bifunctional enzyme possessing a broad substrate profile that 
encompasses nearly all the members of the aminoglycoside class (with the exception of 
streptomycin and spectinomycin) (Zhang et al., 2009). 
1.3.1.2 Inactivation of amphenicols 
The most frequently encountered inactivating modification of chloramphenicol is acetylation 
of the drug via chloramphenicol acetyltransferases (CATs). CATs can be classified into two 
groups based on differences in their structure: class A and class B (also known as xenobiotic 
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CATs). Both groups of enzyme act by catalysing O-acetylation of the 3-hydroxyl group of 
chloramphenicol. The synthetic chloramphenicol analogue florfenicol is refractory to the 
action of CATs due to the replacement of the hydroxyl group at C-3 by a fluorine moiety. 
(Schwarz et al., 2004).  
1.3.1.3 Inactivation of macrolides 
Erythromycin is the target of esterases that render the compound inactive through hydrolysis 
of its macrolactone ring. The genes encoding these enzymes were originally identified in E. 
coli and have been designated ere(A) and ere(B) (Ounissi and Courvalin, 1985, Arthur et al., 
1986). Although ere mediated degradation is not a common resistance mechanism, ere 
genes confer a very high-level of resistance (≥1600 µg / ml in E. coli) (Nakamura et al., 2000) 
and have been found on mobile genetic elements [that provide a means of dissemination 
(Biskri and Mazel, 2003, Plante et al., 2003). It is of note that an erythromycin esterase has 
also been identified in a clinical strain of S. aureus (Wondrack et al., 1996).  
A second enzymatic mechanism for inactivation of macrolides is phosphorylation. Three 
genes encoding macrolide kinases have been identified; two in E.coli, [mph(A) and mph(B)], 
and one in S. aureus; [mph(C)]. Genes encoding macrolide kinases are not currently 
widespread, but confer high-level (>2 mg/ml) resistance to 14- and 16- member macrolides 
and ketolides (Matsuoka and Sasaki, 2004, Wright, 2005). 
1.3.1.4 Inactivation of lincosamides 
Lincomycin nucleotidyltransferases catalyse inactivation of lincomycin and clindamycin 
through adenylation. To date, seven distinct lincomycin nucleotidyltransferases have been 
identified and designated lnu(A) to (F) (http://faculty.washington.edu/marilynr/ermwe
bA.pdf, last accessed 28th September 2015). Although the majority of these genes are 
confined to Gram-positive bacteria, lnu(F) was identified in E. coli (Zhao et al., 2014).  
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1.3.1.5 Inactivation of streptogramins 
The vat genes encode enzymes that inactivate type A streptogramins through acetylation 
(Wright, 2005). Whereas the vgb genes encode lyases that degrade type B streptogramins 
(Allignet et al., 1988). Type A and B streptogramins are usually co-administered, as binding 
of a streptogramin A antibiotic to the ribosome increases the affinity of the streptogramin B 
binding site, resulting in synergy between the two compounds (Harms et al., 2004). 
Inactivation of one of the two compounds results in a small decrease in susceptibility to the 
synergistic mixture. However, plasmids encoding both vgb and vat genes have been shown 
to confer full resistance to synergistic streptogramin combinations (Allignet et al., 1998, 
Allignet and El Solh, 1999).  
1.3.2 Resistance through target site modification 
Modification of the binding sites of antibiotics that target the PTC and peptide exit tunnel 
decreases the affinity of the drugs for their target. These alterations can occur through post-
transcriptional modification of 23S rRNA, via mutations in genes encoding rRNA and proteins, 
or through a direct interaction of a protein or peptide with the ribosome. 
1.3.3.1 Mutations in rRNA and ribosomal proteins 
The majority of ribosome targeting antibiotics interact exclusively with rRNA (Wilson, 2009, 
Wilson, 2014). Thus, mutations to rRNA genes can result in modification of the conformation 
of antibiotic binding sites and thereby lead to decreased affinity of the drug. Most bacterial 
pathogens possess multiple alleles of rRNA genes organised into operons, with the notable 
exceptions of Helicobacter pylori (Versalovic et al., 1996), Mycobacterium spp. (Menendez 
et al., 2002) and select propionibacteria, which have only one or two rRNA operons [(Ross et 
al., 1997)]. Thus the effects of resistance conferring mutations in a single rRNA gene are 
frequently masked by the multiple copies of wild-type drug susceptible rRNA being 
simultaneously expressed. In Gram-positive pathogens such as Staphylococcus and 
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Streptococcus spp., which possess six and four rRNA operons respectively, mutation of the 
majority of rRNA alleles is generally required for resistance. For example, the MICs of 
macrolide and oxazolidinone antibiotics have been shown to increase in parallel with the 
number of mutated rRNA operons (Prunier et al., 2003, Besier et al., 2008, Marshall et al., 
2002). 
However, mutations do not always have to arise independently; the processes of mutation 
and recombination may also act together to evolve an antibiotic-susceptible 23S rRNA to a 
more resistant form.  This is exemplified by mutational resistance to linezolid that has 
emerged in bacterial genera harbouring four to six copies of the 23S rRNA gene (Eliopoulos 
et al., 2004). Such linezolid-resistant isolates carry resistance mutations in domain V of the 
23S23S rRNA, and the mutations are usually found in two to five of the alleles encoding the 
23S rRNA. These multiple resistance alleles are not the result of independent mutational 
events, but are instead the consequence of ‘gene conversion’; following emergence of a 
resistance mutation in a single 23S rRNA allele, this mutation is then introduced to one or 
more of the ‘susceptible’ alleles by homologous recombination within the cell, thereby 
converting them to the resistant form (Lobritz et al., 2003). 
Although ribosomal proteins do not normally interact directly with ribosome targeted 
antibiotics, mutations to genes encoding ribosome proteins, which are normally present as 
a single copy, can in some instances result in resistance. This appears to arise indirectly, 
through changes in protein structure inducing conformational changes in rRNA. For example, 
mutations in in rplD and rplV, which encode ribosomal proteins L4 and L22, have been shown 
to confer macrolide resistance in clinical strains of Streptococcus pneumoniae, Haemophilus 
influenzae, and Staphylococcus aureus (Peric et al., 2003, Prunier et al., 2005, Franceschi et 
al., 2004). The L4 and L22 proteins converge to form a narrowing in the peptide exit tunnel 
adjacent to the macrolide-binding site (Figure 1.3, Page 10) and mutations in these proteins 
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result in distortions to the erythromycin-binding pocket and decreased affinity of the 
ribosome for the drug (Lovmar et al., 2009a). 
1.3.3.2 Modification of rRNA 
Modification of single nucleotides within the 23S rRNA in the vicinity of the PTC by mono or 
dimethylation can prevent a range of antibiotics from binding their target sites. 
Methyltransferase enzymes of the erythromycin rRNA methylase (Erm) family mediate 
resistance to macrolide, lincosamide and streptogramin B antibiotics (MLSB phenotype) via 
methylation of a single adenine of the 23S rRNA (nucleotide position 2058 in E. coli). The Erm 
family represent the most widespread mechanism of resistance to macrolides and 
lincosamides in pathogenic bacteria, and to date over 30 different members of this family 
have been identified (Roberts, 2008). Another methylase, termed Cfr (for 
chloramphenicol/florfenicol resistance), methylates nucleotide A2053 (E. coli numbering) in 
the 23S rRNA. The cfr gene was originally identified as a plasmid-borne amphenicol 
resistance determinant in Staphylococcus sciuri, however, further analysis of the cfr 
phenotype showed that the methylase also mediates resistance to lincosamides, 
oxazolidinones, pleuromutilins and streptogramin As (PhLOPSA phenotype), providing the 
first example of horizontally-acquired resistance to the oxazolidinone linezolid (Long et al., 
2006). Recently, a Cfr homologue, Cfr(B), was identified in two clinical isolates of 
Enterococcus faecium (75% amino acid identity to Cfr). As with cfr, cfr(B), was found on a 
mobile genetic element and when expressed in S. aureus also conferred the PHLOPSA 
phenotype (Deshpande et al., 2015). Although linezolid resistance is currently rare amongst 
clinical strains (Mendes et al., 2014) the potential for wide spread dissemination of cfr genes 
has necessitated the development of second generation oxazolidinones, such as tedizolid 
and radezolid, which are refractory to Cfr-mediated resistance (Shaw and Barbachyn, 2011, 
Mendes et al., 2014).  
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The detection of cfr organised into an operon also encoding erm(B) (termed the mlr operon) 
in the clinical methicillin-resistant Staphylococcus aureus strain CM05 is a particularly 
worrying development (Locke et al., 2012, Smith and Mankin, 2008). The mlr operon 
mediates resistance to members of all seven clinically used antibiotic classes that bind in the 
vicinity of the PTC and is present in a in a highly mobile region of the chromosome, providing 
potential for further dissemination (Locke et al., 2012). 
Methylation of the 16S rRNA can also lead to antibiotic resistance. This mechanism is of 
particular importance for self-protection in aminoglycoside producing Streptomyces spp. 
and Micromonospora spp. (Cundliffe, 1989). These organisms possess chromosomally 
encoded 16S methyltransferases (16S-RMTases) that methylate rRNA at numerous different 
positions (Wachino and Arakawa, 2012). At present, this resistance mechanism is not 
frequently found in pathogenic bacteria, however, clinical isolates of Acinetobacter 
baumannii, Klebsiella pneumoniae and Pseudomonas aeruginosa showing high-level 
aminoglycoside resistance, due to horizontally acquired 16S-RMTases, have been identified 
(Galimand et al., 2003, Yokoyama et al., 2003, Tada et al., 2014). 
1.3.3.3 Dissociation of drugs from the ribosome 
Protein mediated dissociation of antibiotics from their ribosomal binding site represents an 
important mechanism of resistance to the tetracyclines. A family of determinants termed 
the ribosomal protection proteins (RPPs) mediate resistance to tetracyclines in both Gram-
positive and Gram-negative bacteria (Connell et al., 2003a). To date, more than ten RPPs 
have been identified (http://faculty.washington.edu/marilynr/tetweb1.pdf last accessed 
28th September 2015), and detailed study of the two most prevalent RPPs [Tet(M) and 
Tet(O)] has provided much of our understanding of this family of resistance proteins 
(Dönhöfer et al., 2012, Spahn et al., 2001). RPPs exhibit homology to bacterial house-keeping 
G-proteins that participate in protein synthesis, particularly the enzyme elongation factor-G 
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(EF-G) that associates transiently with the ribosome to bring about translocation, and their 
site and mode of binding to the ribosome appear to closely mimic that of EF-G. However, 
whilst domain IV of the EF-G protein acts to reach into the decoding site of the ribosome 
where it prompts translocation by driving the movement of A-site tRNA to the P-site, the 
equivalent domain of the RPPs directly interacts with the binding site of tetracycline, thereby 
acting to displace the drug from the ribosome (Dönhöfer et al., 2012, Spahn et al., 2001). 
Resistance to antibiotics of the macrolide class can be mediated by the expression of short 
peptides of four to six amino acids (Tenson et al., 1996, Tenson et al., 1997, Tenson and 
Mankin, 2001, Verdier et al., 2002, Vimberg et al., 2004, Lovmar et al., 2006, Lovmar et al., 
2009b). This resistance mechanism was discovered when a pentapeptide encoding open 
reading frame (ORF) within the gene encoding E. coli 23S rRNA was shown to confer low-
level erythromycin resistance (Tenson et al., 1996). Subsequently, characterisation of 
random pentapeptide libraries has identified several alternative peptides capable of 
mediating resistance to different drugs within the macrolide class (Tenson et al., 1997). 
These peptides are thought to act in cis, directly upon the ribosomes from which they are 
translated, to mediate displacement of macrolide antibiotics from their binding sites (Tenson 
and Mankin, 2001, Verdier et al., 2002, Vimberg et al., 2004). The expression of macrolide 
resistance peptides could therefore increase the amount of drug-free ribosomes within the 
cell, permitting continued protein synthesis in the presence of macrolide antibiotics (Tenson 
and Mankin, 2001, Verdier et al., 2002, Vimberg et al., 2004). It is currently unclear whether 
this erythromycin resistance mechanism is physiologically important, as due to the 
association of 23S rRNA with ribosomal proteins and sequestration of the Shine-Dalgarno 
region of the ORF within the secondary structure of 23S rRNA, the pentapeptide encoding 
mini-gene is not expressed unless the 23S rRNA gene is subjected to mutation or 
fragmentation (Tenson and Mankin, 2001). No peptides that confer resistance to any other 
PTC-targeted drugs have been identified to date (Vimberg et al., 2004).  
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1.3.3 Resistance through active efflux 
By restricting the accumulation of an antibiotic inside the cell, a bacterium may experience 
only low (sub-inhibitory) antibiotic concentrations at the drug target, even under conditions 
where extracellular concentrations of antibiotic are high. Bacteria have evolved an array of 
membrane-located proteins capable of actively transporting intracellular molecules across 
the membrane(s) and out of the cell. A subset of these efflux transporters includes within 
their substrate profile one or more antibiotic classes, and can therefore act to reduce the 
intracellular accumulation of antibacterial drugs. The transporter proteins involved in 
antibiotic resistance are distributed across five protein families; the major facilitator 
superfamily (MFS), small multidrug resistance (SMR) family, resistance-nodulation-cell 
division (RND) family, multidrug and toxin extrusion (MATE) family, and ABC family (Piddock, 
2006, Li and Nikaido, 2009). To achieve active transport of antibiotics against a concentration 
gradient, these transporters require a source of energy; efflux proteins belonging to the SMR, 
MFS, MATE and RND families all utilise the proton-motive force generated by cellular 
metabolism to drive transport, whilst transporters of the ABC family derive the necessary 
energy from the hydrolysis of ATP.  
In Gram-positive bacteria, resistance to targets that bind the ribosome at the PTC is mediated 
by MFS and ABC efflux systems, some of which are specific for one antibiotic class, whilst 
others are capable of recognising and exporting a wide range of structurally-diverse 
molecules.  
1.3.2.1 Efflux of PTC-targeted antibiotics by MFS proteins 
The MFS efflux proteins found in Gram-positive bacteria can be split into two groups, those 
that confer multidrug resistance (MDR) and those specific to a single antibiotic class. 
Examples of MDR MFS systems include the chromosomally encoded S. aureus proteins LmrS 
and MdeA. Expression of LmrS in an antibiotic-hypersensitive strain of E. coli has been shown 
to confer resistance to amphenicols, lincosamides, macrolides, and oxazolidinones, in 
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addition to a broad range of antibiotics and antibacterial compounds (Floyd et al., 2010). 
Similarly, overexpression of MdeA in S. aureus has been shown to result in resistance to 
streptogramins, as well as numerous non-ribosomal antibiotics (Huang et al., 2004). 
Although these MDR MFS proteins have shown to confer resistance in vitro, they have not 
yet been associated with antibiotic resistance in clinical strains of S. aureus. 
In contrast, the tetracycline-specific Tet efflux proteins are the predominant mechanism of 
tetracycline resistance in Gram-negative bacteria and are also found in Gram-positive 
organisms. Tetracycline was the first antibiotic for which efflux was identified as a 
mechanism of resistance (McMurry et al., 1980). Since that time, over 20 different 
tetracycline efflux proteins have been described, and all are members of the MFS transporter 
family (http://faculty.washington.edu/marilynr/tetweb1.pdf, last accessed 28th 
September 2015). The widespread emergence of resistance to first and second generation 
tetracyclines, through efflux and ribosomal protection, led to a systematic search for a new 
generation of tetracycline analogues. The result was the glycylcyclines, of which the best 
known is tigecycline; these antibiotics are not susceptible to current efflux mechanisms. 
However, it has been demonstrated in vitro that mutations to pre-existing Tet efflux pumps 
can elicit resistance to glycylcyclines, suggesting a route by which resistance to these drugs 
may develop with sustained clinical use (Guay et al., 1994, Chopra and Roberts, 2001).  
A second example group of drug specific MFS proteins with an important role in clinical 
antibiotic resistance can be found in the Mef proteins. These proteins mediate resistance to 
14- and 15- membered macrolides, but not to 16- membered macrolides, type B 
streptogramins or lincosamides. This resistance profile is frequently observed in clinical 
strains of streptococci and is designated the M-phenotype (Sutcliffe et al., 1996). The 
resistance genes that underpin this resistance mechanism, mef(A) and mef(E) were originally 
identified in Streptococcus pyogenes (Clancy et al., 1996) and Streptococcus pneumoniae  
respectively (Tait-Kamradt et al., 1997).  
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1.3.2.2 Efflux of ribosomal antibiotics by ABC proteins 
The first MDR ABC transporter to be characterised in bacteria was the LmrA protein of 
Lactococcus lactis (van Veen et al., 1998). Due the homology exhibited by LmrA to an ABC 
transporter frequently found to be upregulated in mammalian tumour cells (MDR1), LmrA 
has been the subject of multiple functional and structural studies (Poelarends et al., 2002, 
Federici et al., 2007). When expressed in an antibiotic-hypersensitive strain of E. coli LmrA 
confers resistance to a broad range of structurally dissimilar compounds, including multiple 
antibiotics, several of which target the PTC (Poelarends et al., 2002). However, the 
physiological function of this protein in its natural host is unclear (van den Berg van Saparoea 
et al., 2005), and, although a homologue has been identified in S. aureus (van Veen and 
Konings, 1998), LmrA mediated MDR is not currently common in pathogenic bacteria.  
Members of a large subgroup of ABC proteins, termed the ABC-F or type II ABC subfamily, 
confer resistance to several structurally diverse classes of antibiotic that target the PTC and 
exit tunnel of the 50S ribosomal subunit (Kerr et al., 2005, Reynolds et al., 2003). Although 
frequently cited as mediators of efflux, a long standing controversy exists regarding the 
mechanism by which ABC-F proteins confer antibiotic resistance. Due to the lack of a 
definitive explanation for their mechanism of action, this subgroup of ABC proteins was 
chosen as the subject of this thesis and is discussed in more detail below. 
1.4 The ABC-F sub-family of ABC proteins mediates resistance to ribosomally 
active antibiotics 
Members of the ABC-F subgroup of ABC superfamily proteins specifically mediate resistance 
to PTC-targeted antibiotics through a poorly characterised mechanism and, for that reason, 
are the subject of this study. The classification of ABC-F proteins within the context of the 
ABC superfamily is discussed below (Section 1.4.2). Additionally the phylogeny, phenotype, 
and potential mechanism of ABC-F proteins involved in antibiotic resistance are outlined. 
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1.4.1 The ABC domain 
Proteins of the ABC superfamily are universally distributed across all three domains of life 
(Dassa and Bouige, 2001). These proteins are named for their stereotypical ABC domains 
(also known as the nucleotide binding domain, NBD) that permit binding and hydrolysis of 
ATP, releasing energy to drive a wide variety of biological processes (Davidson et al., 2008, 
Dorrian, 2009). ABC domains, each around 200 amino acids in length, are characterized by 
five unequivocally conserved short sequence motifs, which should be present in the 
following order to qualify as an ABC ATPase: the Walker A motif, a highly conserved 
glutamine residue in the Q-loop, the signature motif which is characteristic of ABC ATPases, 
the Walker B motif and finally, a highly conserved histidine residue within the H-loop or 
Switch region (Davidson et al., 2008, Dorrian, 2009, Dassa, 2011) (Figure 1.5 A).  
A single ABC domain is composed of two structurally distinct sub-domains: A RecA-like 
domain, which contains the Walker A and B motifs, and a helical domain that is unique to 
ABC ATPases and includes the signature motif (Figure 1.5 B) (Davidson et al., 2008, Dorrian, 
2009, Dassa, 2011). The two domains are joined by two loops, one of which is the Q-loop 
(Davidson et al., 2008, Dorrian, 2009, Dassa, 2011) and is important for interactions of the 
ABC domain with other cellular proteins (Davidson et al., 2008, Chen et al., 2014). Crystal 
structures of ABCs bound to ATP have shown that ATP co-ordination requires formation of a 
“nucleotide-sandwich dimer” containing two ABC domains (Jones and George, 1999, 
Hopfner et al., 2000, Smith et al., 2002). The two monomers in the complex align in a “head 
to tail” orientation, resulting in the formation of two ATP binding pockets in which the Walker 
A and B motifs of one monomer act in concert with the signature motif of the other monomer 
to bind the nucleotide (Jones and George, 1999, Hopfner et al., 2000, Smith et al., 2002). 
Thus the binding and hydrolysis of ATP results in conformational changes throughout the 
complex that are used to elicit biological effects. 
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Figure 1.5. The motifs and domain architecture characteristic of ATP binding cassette proteins. (A) A linear 
representation of the five unequivocally conserved motifs characteristic of ABC ATPases. The Walker A motif and 
the Walker B motif, shown as large polygons, form the nucleotide-binding fold of the P-loop ATPase family. The 
signature motif is unique to ABC proteins and also interacts with ATP. The Q-loop and H-loop, represented as 
triangles, contain single covered residues. These residues make contacts with the γ-phosphate of ATP and the Q-
loop is also involved in interactions with other cellular proteins. The consensus sequence of each motif is shown 
using the single-letter amino acid code, where x and h stand for any and hydrophobic amino acids respectively. 
(B) Localization of conserved motifs within the structure of an ABC monomer (HisP of Salmonella typhimurium, 
PDB: 1B0U (Hung et al., 1998)). The same colour code as for the linear representation is used. The RecA-like 
domain is shown in purple, the helical domain in cyan. Figure adapted from Dassa (2011). 
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1.4.2 Classification of ABC proteins 
ABC transporters represent the architecture most frequently associated with ABCs. Here, 
two cytoplasmic, hydrophilic ABC domains associate with two hydrophobic trans-membrane 
domains (TMDs). The four domains may be expressed as separate polypeptides or as various 
configurations of domain fusions (Davidson et al., 2008, Dassa, 2011). The resulting 
functional complex uses the energy derived from ATP-hydrolysis to drive conformational 
changes that result in the cellular import or export of a wide variety of substrates (Jones and 
George, 1999). However, it has become increasingly evident that ABCs also participate in 
cellular processes other than transport (Dassa and Bouige, 2001).  
Classification by Dean et al. (Dean et al., 2003) of ABC systems in accordance with sequence 
homology in eukaryotic ABC proteins has divided the ABC superfamily into seven sub-
families, designated ABC-A to ABC-G (Dean et al., 2003, Kerr, 2004). The majority of these 
groups constitute ABC transport systems. However, two groups, ABC-E and ABC-F, are 
composed of proteins that possess tandemly repeated ABC domains and lack TMDs. ABC-E 
and ABC-F proteins have been shown to play non-transport roles in all three domains of life 
(Kerr, 2004). 
More recently, an alternative system for classification of ABC proteins was proposed by Elie 
Dassa (Dassa, 2011) in which proteins are grouped based on sequence homology and 
function. This analysis includes sequences from all three domains of life, and separates ABC 
proteins into three major classes and multiple further sub-classes. The three classes appear 
to correlate to architecture and function of ABC proteins; class 1 is made up of the majority 
of ABC exporters, class 2 comprises soluble proteins with two tandemly repeated ABC 
modules and no recognised TMDs, and class 3 is predominantly composed of bacterial 
importers that require an extracellular or periplasmic substrate binding domain for their 
function (Figure 1.6). 
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The large subgroup of ABC proteins that specifically mediate resistance to PTC-targeted 
antibiotics are found within the ABC-F and class 2 groups of the Dean and Dassa classification 
schemes respectively. In accordance with the most current literature (Boel et al., 2014, Chen 
et al., 2014, Lenart et al., 2015), these proteins are referred to throughout this study as 
antibiotic resistance (ARE) ABC-F proteins. 
 
 
 
Figure 1.6. Classification of ABC proteins. The Dassa scheme of classification separates the ABC superfamily into 
three major classes. Class 1 and class 3 are canonical ABC transport proteins, comprising a functional complex of 
two hydrophobic TMDs and two hydrophilic intracellular ABC domains, class 3 proteins are frequently also 
associated with an extracellular or periplasmic SBD. In contrast, class 2 proteins, which comprise two tandemly 
repeated ABC domains, lack recognised TMDs. These Dassa classes broadly correlate with the function of their 
members, class 1 are primarily export proteins, whereas class 3 proteins are primarily involved with import within 
bacteria. Class 2 appear to play predominantly non-transport roles, although the mechanism of antibiotic 
resistance proteins within this class is unknown. Within the dean classification scheme, ABC proteins with 
tandemly repeated NBDs and no associated TMDs fall within the ABC-E and ABC-F sub-families, which correlate 
to class 2 in the Dassa system (Dean et al., 2003, Kerr, 2004, Dassa, 2011).
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1.4.3 The ARE ABC-F proteins mediate resistance to ribosomally active antibiotics 
In Gram-positive bacteria, a sub-group of ABC-F proteins mediates resistance to antibiotics 
that exert their action on the ribosome. These proteins are found in both antibiotic-
producing bacteria (e.g. the streptomycetes), and in pathogenic bacteria that include the 
staphylococci, streptococci, enterococci, and, in one instance, the Gram-negative zoonotic 
pathogen Pasteurella multocida.  (Figure 1.7). Collectively, the ARE ABC-F family of proteins 
mediates resistance to the majority of antibiotic classes that bind to either the PTC or peptide 
exit tunnel of the ribosome, including the ketolides (Reynolds and Cove, 2005), lincosamides 
(Novotna and Janata, 2006, Singh et al., 2002), macrolides (Ross et al., 1990), oxazolidinones 
(Wang et al., 2015), phenicols (Wang et al., 2015), pleuromutilins (Gentry et al., 2008), 
streptogramin As (Allignet et al., 1992, Singh et al., 2002), and streptogramin Bs (Ross et al., 
1990) (Figure 1.7). However, no single ARE ABC-F determinant confers resistance to every 
listed class, and three phenotypic resistance profiles are distinguished in clinical isolates. 
Combined lincosamide, streptogramin A (and sometimes pleuromutilin) resistance, referred 
to as the LSA (or LSAP) phenotype is conferred by vga-, lsa- and sal- type genes (Tesse et al., 
2013, Singh et al., 2002, Hot et al., 2014), concurrent resistance to macrolides, streptogramin 
Bs (and sometimes ketolides) (MSB phenotype) by the msr-type determinants (Ross et al., 
1990, Reynolds and Cove, 2005), and resistance to phenicols and oxazolidinones by the 
recently identified optrA gene (Wang et al., 2015) (Figure 1.7). 
In antibiotic-producing bacteria, ARE ABC-F mediated resistance appears to be specific to the 
particular antibiotic produced by each species. However, as levels of resistance to other PTC-
targeted antibiotics have predominantly not yet been determined, it is unclear whether 
these proteins mediate any further cross resistance. It is of note that the lincomycin-
resistance determinant lmr(C) from Streptomyces lincolnensis has been shown to 
additionally confer low-level erythomycin resistance (Peschke et al., 1995), suggesting that 
ARE ABC-F proteins from antibiotic-producing bacteria may show similar resistance spectra 
to those found in bacterial pathogens.  
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Figure 1.7. Phylogenetic tree and antibiotic resistance profiles of the ARE ABC-F proteins found in Gram-positive pathogens and producer organisms. An overview of the resistance phenotypes 
conferred by the different subgroups of determinant are shown at the right of the figure (although variations in individual resistance phenotypes within each subgroup are not). Alignments 
were performed using the  MUSCLE alignment program (Edgar, 2004) and the phylogenetic tree was generated using the maximum likelihood method. Analysis was performed using the MEGA 
6.0.6 software package (Tempe, AZ, USA). 
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1.4.4 Domain architecture of ARE ABC-F proteins 
As with all members of the ABC-F sub-family, ARE ABC-F proteins comprise a single 
polypeptide containing two ABC domains separated by an inter-domain linker of ~80 amino 
acids and do not include any predicted membrane-spanning domains. Equally, genes 
encoding ARE ABC-F proteins are not linked in operons with any identified genes encoding 
TMDs. Within ABC-F proteins of Gram-positive pathogens, Pfam (Marchler-Bauer et al., 
2015) identifies a conserved domain separate from the two ABC domains within the linker 
region (PF12848 or ABC_tran_2); however, this domain is not recognised in ARE ABC-F 
proteins of antibiotic-producing bacteria (Figure 1.8). The linker region of msr-type ARE ABC-
F proteins is additionally identified as a Q-linker (Wootton and Drummond, 1989). Q-linkers 
comprise a class of interdomain sequences that are typically rich in glutamine and other 
hydrophilic amino acids and have a characteristic spacing of hydrophobic amino acids. 
Amongst ARE ABC-F proteins, the Q-linker appears to be confined to msr-type determinants 
as the inter-domain linkers of OptrA and Vga- or Lsa- type proteins do not meet these criteria. 
Studies of Vga(A) have shown the amino acid composition of sequence of the linker to 
influence the spectrum of resistance mediated by the protein. Initially, a Vga(A) variant, 
Vga(A)LC, that conferred enhanced levels of resistance to lincosamide antibiotics in 
comparison to Vga(A), was identified in several clinical isolates of Staphylococcus 
haemolyticus. Sequence analysis showed the Vga(A)LC protein to differ from Vga(A) by seven 
amino acid substitutions, four of which were shown to influence the resistance phenotype 
and were clustered within an 18 amino acid region of the linker. Subsequently, a detailed 
mutational analysis of the Vga(A) interdomain linker found that the sequence of an eight 
amino acid stretch (amino acids 212 to 220) was responsible for determining different levels 
of resistance to streptogramin As, lincosamides and pleuromutilins. With one amino acid 
substitution (K219T) conferring high levels of resistance to antibiotics of all three classes. 
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Both OptrA and Vga-type proteins possess a C-terminal extension of ~40 and ~110 amino 
acids respectively. Deletion of the final 18 amino acids of this extension in Vga(A) resulted in 
a four-fold reduction in the level of resistance conferred to a streptogramin A antibiotic, 
suggesting that the C-terminal extension of both proteins may be of functional importance 
(Jacquet et al., 2008), although no corresponding modification of OptrA has been performed. 
 
 
 
Figure 1.8. Predicted domains of representative members of five ARE ABC-F subgroups. Domains were 
assigned using the CDD: NCBI's conserved domain database (Marchler-Bauer et al., 2015).  
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1.5 Genetic environment and clinical prevalence of ARE ABC-F resistance 
determinants 
Several studies have attempted to document the genetic environment of ARE ABC-F genes 
in clinical strains of staphylococci and enterococci. From the resulting data, it is clear that 
ARE ABC-F determinants are found in a diverse array of genetic environments; with optrA, 
vga-, lsa- and msr-type genes frequently located within mobile genetic elements, such as 
plasmids and transposons, or integrated into the chromosome where they may be coupled 
with factors to facilitate their mobilisation (Ross et al., 1990, Singh et al., 2002, Novotna and 
Janata, 2006, Gentry et al., 2008, Schwendener and Perreten, 2011, Hauschild et al., 2012, 
Tesse et al., 2013, Hot et al., 2014, Wang et al., 2015, Li et al. 2016). Although the majority 
of ARE ABC-F determinants found in Gram-positive pathogens confer acquired resistance, 
three genes, lsa(A), msr(C) and sal(A), are chromosomally encoded and thought to be 
intrinsic resistance determinants of E.  faecalis, E. faecium and Staphylococcus sciuri 
respectively (Singh, Weinstock and Murray 2002; Hot, Berthet and Chesneau 2014; Singh, 
Malathum and Murray 2001). As such, lsa(A) is responsible for the innate resistance of 
E. faecalis to antibiotics of the lincosamide and streptogramin A classes, sal(A) confers the 
same resistance phenotype in S. sciuri, and msr(C) confers macrolide and streptogramin B 
resistance in E. faecium, although there is some debate as to whether the gene an intrinsic 
to all E. faecium isolates (Werner, Hildebrandt and Witte 2001).  
The prevalence of ARE ABC-F determinants in clinical strains of staphylococci and enterococci 
exhibiting resistance to antibiotics targeting the large ribosomal subunit has been 
documented in several reports. For macrolide and streptogramin B antibiotics, it is evident 
that although ribosomal methylation is the predominant mechanism of resistance to these 
drugs, msr-type determinants, particularly msr(A), can also be contributing factors 
(Gatermann, Koschinski and Friedrich 2007). The frequency at which msr(A) is found as the  
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sole resistance determinant in strains exhibiting the MSB phenotype varies between <10% 
(Nawaz et al. 2000) to 100% (Eady et al. 1993) amongst different hospitals and geographical 
areas . However, from the available data, it can be roughly estimated that msr(A) is the sole 
determinant underlying around a tenth of strains exhibiting the MSB phenotype (Martineau 
et al. 2000; Szczuka et al. 2016; Aktas et al. 2007; Gatermann, Koschinski and Friedrich 2007; 
Eady et al. 1993). Equivalent information regarding the clinical prevalence of vga-type 
determinants is lacking, however a study in which a large staphylococcal strain collection 
(5,676 strains) was screened for retapamulin resistance found that although the incidence of 
resistance was low (~1%), the vga(A) and vga(A)v genes were the sole resistance genes 
associated with this phenotype (Gentry et al. 2008). Similarly, as the optrA gene has only 
been recently identified, only one study has investigated its prevalence in human clinical 
isolates. This screen of 595 clinical enterococcal isolates from a Chinese hospital detected 
optrA in 2% of strains (Wang et al. 2015). A concurrent screen of 290 enterococcal strains 
isolated from animals in a variety of locations within China found optrA to be present in 
15.9% of strains (Wang et al. 2015). It is also of note that optrA has been found co-resident 
with the ribosomal methylase cfr on a plasmid isolated from Staphylococcus sciuri; a 
particularly worrying development given that optrA confers resistance to tedezolid, the 
second commercially available oxazolidinone, which ordinarily shows activity against 
staphylococcal strains expressing cfr (Li et al. 2016).  
1.6 The mechanism of ARE ABC-F mediated resistance 
The mechanism by which the ARE ABC-F proteins mediate antibiotic resistance has been a 
subject of long-standing controversy, with two competing hypotheses having each attracted 
considerable support; antibiotic efflux and ribosomal protection (Ross et al., 1990, Reynolds 
et al., 2003, Kerr et al., 2005, Chesneau et al., 2005, Kerr, 2004, Nunez-Samudio and 
Chesneau, 2013, Lenart et al., 2015). The efflux hypothesis posits that ARE ABC-F proteins 
associate with as-yet-unidentified TMDs to form a functional efflux complex capable of 
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exporting antibiotics out of the cell, whilst the ribosomal protection hypothesis suggests that 
these resistance proteins act instead to reduce the accessibility or affinity of the antibiotic 
binding sites in the 50S subunit, thereby directly protecting the translational machinery from 
antibiotic-mediated inhibition (Reynolds et al., 2003, Kerr et al., 2005, Reynolds, 2005, 
Dorrian, 2009) (Figure 1.9). Evidence in support of each hypothesis is discussed below. 
 
 
 
 
 
Figure 1.9. Potential mechanisms of ARE ABC-F mediated resistance. In the absence of the resistance 
determinant translation is inhibited by the antibiotic, arresting growth of the bacterial cell. ARE ABC-F proteins 
(green) are proposed to rescue translation from inhibition either by recruiting an unknown membrane-spanning 
protein to promote active efflux of the antibiotic (left), or, by displacing the antibiotic from its ribosomal binding 
site (right). Figure adapted from (Kerr et al., 2005). 
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1.6.1 Evidence in support of a mechanism of ARE ABC-F mediated resistance driven by 
efflux 
Early studies of the first ARE ABC-F resistance determinant to be characterised, msr(A), 
showed that expression of the msr(A) gene was associated with reduced intracellular 
accumulation of radiolabelled erythromycin in S. aureus (Ross et al., 1990) and was not 
associated with any erythromycin inactivating enzyme activity (Ross et al., 1989). 
Erythromycin accumulation experiments showed an initial uptake phase, followed by a 
decrease in the level of intracellular drug, which was abolished by addition of arsenate and 
strongly inhibited by dinitrophenol, leading to the hypothesis that Msr(A) functions in 
tandem with unidentified TMDs to drive ATP-dependent drug efflux. Subsequently, a similar 
study was conducted using the vga(A) variant vga(A)LC, which like msr(A) was shown to 
mediate ATP-dependent reduced accumulation of its target antibiotic, radio-labelled 
lincomycin, when expressed in S. haemolyticus (Novotna and Janata, 2006).  
Interpretation of the data generated by these accumulation studies is complicated by the 
observation that decreased accumulation of ribosomally active antibiotics can also result 
from protection of their target site. Addition of an excess of unlabelled erythromycin, or a 
streptogramin B antibiotic (which has an overlapping binding site to erythromycin), has been 
shown to result in decreased accumulation of radiolabelled erythromycin in S. aureus 
(Reynolds et al., 2003, Barre et al., 1986). Furthermore, the presence of the erm(B) ribosomal 
methylase has been shown to confer decreased erythromycin accumulation in S. pyogenes 
(Canton et al., 2005). This phenomenon is thought to occur due to the fact that erythromycin 
passes through the cell membrane by passive diffusion and accumulates in cells because it 
bind to ribosomes, which act as a “sink” and thereby maintain the concentration gradient 
(Barre et al., 1986, Capobianco and Goldman, 1990). Protection of the erythromycin 
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ribosomal binding site by a competing antibiotic or through methylation would abolish this 
gradient and thereby negate the driving force for import (Kerr et al., 2005).  
A further observation that has been proposed as evidence for efflux can be found is studies 
of the sub-cellular localisation of ARE ABC-F proteins. Investigation of Vga(A) localisation 
though western blotting of cell fractions generated by centrifugation has shown that in 
clinical strains of Staphylococcus epidermidis the protein is solely present in the membrane 
fraction (Chesneau et al., 2005). Similarly, expression of vga(A) from the vegII promoter in a 
laboratory strain of S. epidermidis primarily resulted in membrane localisation of Vga(A), with 
around 20% of the protein present in the cytosol (Chesneau et al., 2005). A similar analysis 
of the cellular localisation of a maltose-binding protein tagged fusion of the N-terminal 
domain of Ole(B), an ARE ABC-F protein that mediates self-protection in the oleandomycin 
producer Streptomyces anitbioticus, showed the protein to be present in both the membrane 
and cytosolic fractions (Olano et al., 1995). Membrane localisation of multiple ARE ABC-F 
proteins appears to support the efflux hypothesis. 
In order for ARE ABC-F proteins function to drive efflux they must co-opt TMDs. In classical 
ABC-transport proteins it is the TMDs that confer substrate specificity (Dassa and Bouige, 
2001). However, if ARE ABC-F proteins are “hijacking” existing TMDs then a requirement is 
that they either confers substrate specificity themselves or alter the specificity of pre-existing 
TMDs. Work by Jacquet et al. investigated the ATPase activity of Vga(A) and, after 
demonstrating that ATPase activity was essential for biological function, found that 
pristinamycin IIA inhibited ATPase activity in a non-competitive manner, suggesting a direct 
interaction between the protein and antibiotic (Jacquet et al., 2008). 
More recently, an investigation into the cellular localisation of msr(D), a streptococcal 
macrolide resistance determinant, was proposed to provide the first example of an ARE ABC-
F protein working in tandem with an efflux transporter. In streptococci, the msr(D) gene is 
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co-transcribed with the mef(E) MFS macrolide efflux transporter from a conserved operon 
found within large chromosomal elements that resemble defective transposons (Santagati 
et al., 2000, Gay and Stephens, 2001, Del Grosso et al., 2002). Through the use of E. coli 
strains expressing GFP-tagged Msr(D) and Mef(E) the sub-cellular localisation of each protein 
was investigated. Expression of GFP-tagged Msr(D) alone showed the protein was 
homogeneously distributed throughout the cytoplasm and expression of GFP-tagged Mef(E) 
alone showed several fluorescence spots throughout the bacterium. However, co-expression 
of both resistance determinants resulted in localisation of Mef(E) at the poles of the cell. Pull 
down assays were subsequently used to show an interaction of Msr(D) and Mef(E), leading 
to the conclusion that Msr(D) might act as an enhancer of macrolide efflux mediated by the 
MFS Mef(E) (Nunez-Samudio and Chesneau, 2013).  
1.6.2 Evidence in support of a mechanism of ARE ABC-F mediated resistance through 
ribosomal protection 
There is currently a lack of direct experimental evidence in support of ARE ABC-F mediated 
ribosomal protection. However, indirect evidence in support of this hypothesis can be found 
in the apparent correlation between resistance phenotypes of ARE ABC-F proteins and the 
binding sites of their target antibiotics within the 50S subunit. For example, the msr-type 
determinants mediate resistance to macrolide and streptogramin B antibiotics, which bind 
close to the peptide exit tunnel within the 50S subunit (Hansen et al., 2002, Tu et al., 2005). 
Whereas vga- and lsa- type determinants give resistance to streptogramin A, lincosamide, 
and pleuromutilin drugs, which bind to overlapping sites within the PTC (Harms et al., 2004, 
Tu et al., 2005, Davidovich et al., 2007). The apparent requirement of ARE ABC-F resistance 
phenotypes for an overlap in ribosomal binding site, rather than common chemical 
composition of their target drugs, suggests that these proteins mediate their effects while 
their target drugs are ribosomally associated. 
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Further indirect support for ribosomal protection can be found through analysis of the 
functions of members of the ABC-F sub-family not involved in antibiotic resistance. These 
proteins have been shown to function in non-transport processes, including regulation of 
translation. Three of these translational regulators have been shown to be associated with 
ribosomes. In fungi, the highly conserved ABC-F protein eEF3 binds to the ribosome and 
promotes release of tRNA from the E site. In eukaryotes and archaea the ABC-F protein 
ABCE1 acts in concert with both initiation factors and release factors to facilitate recycling of 
ribosomes, rescue of stalled ribosomes and subsequent promotion of initiation. In bacteria, 
the ABC-F protein EttA preferentially binds to the 70S ribosome with fMet-tRNA at the P-site 
and regulates translation in response to changes in the cellular ATP: ADP ratio. Thus, ABC-F 
proteins from all domains of life have been shown to interact with the ribosome and 
influence translation. 
1.7 Objectives 
This study was undertaken due to the lack of a coherent explanation for the mechanism 
governing antibiotic resistance mediated by ABC-F proteins. The primary objective of this 
work was therefore to provide a definitive answer to the efflux vs protection question, or to 
identify any other plausible mechanistic explanations. In order to achieve this goal, studies 
of ARE ABC-F proteins were required. The first step in this process was the optimisation of 
conditions for the heterologous expression and subsequent purification of members of the 
ARE ABC-F subfamily. Secondly, appropriate assays were established with which to 
distinguish between efflux and ribosomal protection and screening for conditions to 
promote crystallisation of ARE ABC-F proteins was performed. In tandem with biochemical 
approaches using purified protein, complimentary methods using DNA manipulation and 
bacteriology were used to further investigate ARE ABC-F resistance phenotypes. Finally, the 
data derived from this study was assessed in the context of the wider scientific literature to 
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re-evaluate the hypotheses for the ARE ABC-F resistance mechanism and an appropriate 
model has been proposed. 
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2. Materials and Methods 
2.1 Materials 
2.1.1 Bacterial strains, plasmids, and growth media 
Strains of bacteria used in this study are listed in Table 2.1. Plasmids used during this study 
are listed in Table 2.2. Routine culture of E. coli strains used Luria-Bertrani (LBB) broth and 
(LBA) agar (Sigma-Aldrich, Poole, UK). S. aureus and E. faecalis strains were propagated using 
Mueller-Hinton broth (MHB) and agar (MHA) (Oxoid, Basingstoke, UK) unless otherwise 
stated. For long-term maintenance bacterial strains were stored as saturated cultures 
supplemented with 16% (v/v) glycerol at -80°C. Purified plasmid DNA was stored at -20°C. 
2.1.2 Chemicals and antibiotics 
Unless otherwise stated, all chemicals were purchased from Sigma-Aldrich. All solutions 
were prepared using deionised water, and either heat-sterilised (121°C for 20 min) or filter-
sterilised (0.22 μm filters Merck Millipore, Darmstadt, Germany). Antibiotics used in this 
study are listed in Table 2.3, along with related solvents and suppliers. Radiolabelled 3H-
lincomycin was from Quotient Bio Research (Nottingham, UK).  
 
40 
 
 
Table 2.1. Bacterial strains used in this study 
Organism Strain Comments Reference / Source 
Enterococcus 
faecalis 
ATCC 29212 Source of lsa(A) gene Kim et al., (2012) 
ATCC 
Enterococcus 
faecium 
E1679 Source of msr(C) gene Gift from W. Schaik 
(Department of 
Medical 
Microbiology, 
University Medical 
Center Utrecht). 
Staphylococcus 
aureus 
RN4220 Restriction deficient derivative of 
S. aureus 8325-4. Used for routine 
cloning and antibiotic susceptibility 
testing. 
Fairweather et al., 
(1983) 
 CYL557 RN4220 containing the accessory 
plasmid pLL2787 encoding the ϕ11 int 
gene. 
Luong and Lee, (2007) 
Escherichia coli DH5α For routine cloning procedures. 
Genotype: fhuA2 lac(del)U169 phoA 
glnV44 Φ80' lacZ(del)M15 gyrA96 
recA1 relA1 endA1 thi-1 hsdR17 
Invitrogen (Paisley, 
UK) 
 XL10-Gold For use during site directed 
mutagenesis. 
Genotype: endA1 glnV44 recA1 thi-1 
gyrA96 relA1 lac Hte Δ(mcrA)183 
Δ(mcrCB-hsdSMR-mrr)173 tetR 
F'[proAB lacIqZΔM15 Tn10(TetR Amy 
CmR)] 
Agilent Technologies 
(Cheshire, UK) 
 BL21 (λDE3) 
Gold 
For expression of genes from the T7 
promoter. 
Genotype: F-ompT gal dcm lon 
hsdSB(rB- mB-) λ(DE3 [lacI lacUV5-T7 
gene 1 ind1 sam7 nin5]) 
Agilent Technologies  
 BL21-CodonPlus 
(λDE3) RIL 
For expression of genes from the T7 
promoter. Designed to enhance 
expression of genes with a high AT-
content. 
Genotype: B F- ompT hsdS(rB- mB-) 
dcm+ Tetr gal λ(DE3) endA Hte [argU 
ileY leuW Camr] 
Agilent Technologies  
 CopyCutter 
EPI400 
Used to maintain plasmid pC19Saluc 
at low-copy number, can be induced 
to higher copy number for improved 
plasmid yield. 
Genotype: F-mcrA∆(mrr-hsdRMS-
mcrBC) φ80dlacZ∆M15 ∆lacX74 recA1 
endA1 araD139 ∆(ara,leu)7697 galU 
galK λ– rpsL nupG tonA ∆pcnB dhfr. 
Epicentre (Madison, 
WI, USA) 
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Table 2.2. Plasmids used during this study. 
Vector Comments Reference / Source 
pEPSA5 S. aureus / E. coli shuttle vector. For expression of genes in S. 
aureus from pT5X xylose-inducible promoter. ampicillinER, 
chloramphenicolSR 
Forsyth et al., (2002)  
Elitra Pharmaceuticals, 
(San Diego, CA, USA) 
pLL39 Single copy integration vector for integration at the L54a 
attP or ϕ11 attP sites on the S. aureus chromosome. 
spectinomycinlER, tetracyclineSR  
Luong and Lee, (2007) 
Gift from C.Y. Lee 
(University of 
Arkansas for Medical 
Sciences, USA) 
pIVEX2.3d Optimised for expression in in vitro T7 T/T systems, also used 
for expression in E. coli. Encodes a non-cleavable C-terminal 
6-His tag. ampicillinER 
Roge and Betton, 
(2005) 5 PRIME 
(Düsseldorf , 
Germany) 
pDIA17 Encodes lacI gene. Co-transformed with pIVEX2.3d to 
improve transformation efficiency. chloramphenicolER 
Roge and Betton, 
(2005) Gift from J.M. 
Betton (Inst Pasteur, 
Paris, France) 
pET28a-Tev Modified pET28a expression vector encoding an N-Terminal 
10xHis-tag followed by a Tobacco Etch Virus (TEV) protease 
recognition site. Vector used to allow affinity purification. 
kanamycinER  
Novagen  
pET28a-SUMO Modified pET28a expression vector encoding N-Terminal 
6xHis  and SUMO (type 3) tags followed by a recognition site 
for U1p protease. Vector used to improve protein solubility 
allow affinity purification. kanamycinER 
Novagen  
pET28a-MAL Modified pET28a expression vector encoding an N-Terminal 
6xHis and maltose binding protein (MBP) tags followed by a 
PreScission protease cleavage site. Vector used to improve 
protein solubility allow affinity purification. kanamycinER 
Novagen  
pET28a-GST Modified pET28a expression vector encoding  N-Terminal 
6xHis and Glutathione S-transferase (GST) tags followed by a 
PreScission protease cleavage site. Vector used to improve 
protein solubility and allow affinity purification. kanamycinER 
Novagen  
pBEST Contains firefly luciferase (luc) gene under the control of the 
E. coli tac promoter. ampicillinER  
Promega (Madison, 
WI, USA) 
pBEST19Saluc Contains luc gene under the control of the strong 
staphylococcal Cap1A promoter and a staphylococcal origin 
of replication. ampicillinER, chloramphenicolSR 
Acquired from J.K. 
Hobbs (University of 
Leeds, unpublished 
work) 
pBSSC12 Source for vga(E) Schwendener and 
Perreten, (2011) Gift 
from V. Perreten 
(University of Berne, 
Switzerland) 
* ER denotes resistance phenotype in E. coli. SR denotes resistance phenotype in S. aureus   
42 
 
 
Table 2.3.  Antibiotics used in this study 
Compound Solvent Source 
Ampicillin Water Sigma-Aldrich (Poole, UK) 
Blasticidin S Water Merck Chemicals (Nottingham, UK) 
Chloramphenicol 50% (v/v)Ethanol Sigma-Aldrich  
Erythromycin 50% (v/v) Ethanol Sigma-Aldrich  
Fluorphenicol 50% (v/v) Ethanol Sigma-Aldrich  
Kanamycin Water Sigma-Aldrich  
Leucomycin DMSO Santa Cruz Biotechnology (Dallas, TX, 
USA) 
Lincomycin Water Sigma-Aldrich  
Linezolid DMSO Sigma-Aldrich  
Puromycin Water Sigma-Aldrich  
Retapamulin DMSO Gift from GlaxoSmithKline 
(Brentford, UK) 
Sparsomycin DMSO Gift from E. Cundliffe (University of 
Leicester, UK) 
Spiramycin DMSO Santa Cruz Biotechnology  
Tetracycline Water Sigma-Aldrich  
Tiamulin DMSO Sigma-Aldrich  
Tylosin Water Santa Cruz Biotechnology  
Virginiamycin M DMSO Sigma-Aldrich  
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2.2 Molecular biology techniques 
2.2.1 Determination of DNA concentration 
DNA was quantified spectrophotometrically by reading absorbance at 260 nm using a P300 
nanophotometer (Implem, Munich, Germany). The purity of DNA samples was assessed by 
determining the ratios of absorbance at 260 nm / 280 nm and 260 nm / 230 nm (Sambrook 
et al., 2001). 
2.2.2 Isolation of plasmid DNA 
Plasmid DNA was isolated from E. coli DH5α and BL21 strains using the QIAprep Spin 
Miniprep Kit (Qiagen, Venlo, Limburg, Netherlands) according to manufacturer’s 
instructions. The same kit was also used for extracting plasmid DNA from S. aureus. However, 
in order to degrade staphylococcal cell walls buffer P1 was supplemented with 100 μg/ml 
recombinant lysostaphin (affinity purified in our laboratory) and the P1-cell suspension was 
incubated at 37°C for 10 min before proceeding to alkaline lysis.  
In order to isolate large quantities of plasmid pC19SA5 for use in in vitro T/T assays (2.5.2) 
100 ml of LBB containing 100 μg/ml ampicillin was inoculated with a single colony of E. coli 
CopyCutter EPI400 carrying the pC19SA5 plasmid and grown overnight at 37°C with vigorous 
aeration. The following day, 500 ml of LBB containing 100 μg/ml ampicillin and 500 μl 
CopyCutter Induction Solution (Epicentre, Madison, WI, USA) was inoculated with 56 ml of 
saturated overnight culture and grown for 4 h. Cells were harvested by centrifugation (5000 
x g, 15 min) and then processed using a HiSpeed Plasmid Maxi Kit (Qiagen) according to 
manufacturer’s instructions.  
2.2.3 Isolation of genomic DNA 
The PurElute Bacterial Genomic Kit (Edge BioSystems, Gaithersburg, MD, USA) was used to 
isolate chromosomal DNA from E. faecalis and E. faecium according to manufacturer’s 
instructions. This kit was also used to isolate chromosomal DNA from S. aureus; however, 
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prior to the initial cell lysis step, spheroplast buffer was supplemented with lysostaphin and 
incubated as detailed in Section 2.2.2. 
2.2.4 Concentration of DNA 
DNA was concentrated by ethanol precipitation. Briefly, a 1/10 volume of 3M sodium acetate 
(pH 5.2) was added to one volume of DNA before addition of 2-3 volumes of 100% (v/v) 
ethanol. The resulting suspension was placed at -80°C for 1 h and subsequently centrifuged 
at 30 000 x g for 30 min at 4°C. Supernatant was carefully removed from the resultant DNA 
pellet. The pellet was washed in 2-3 volumes of 70% (v/v)  ethanol and centrifuged at 30 000 
x g for 10 min at 4°C. Finally, the supernatant was carefully removed and the DNA pellet was 
air-dried for 5 min and resuspended in an appropriate volume of 10 mM Tris-Cl (pH 8.5). 
2.2.5 Polymerase chain reaction 
Oligonucleotide primers were obtained from Eurofins MWG operon (Ebersberg, Germany), 
diluted to 100 pmol/μl in 10 mM Tris-Cl (pH 8.5), and stored at -20°C. Nucleotides were from 
Promega (Madison, WI, USA). PCRs were performed in a Techne TC-3000 thermal cycler 
(Bibby Scientific, Staffordshire, UK) using Q5 High-Fidelity DNA Polymerase (New England 
Biolabs [NEB], Ipswich, Massachusetts, USA). Q5 High-Fidelity DNA Polymerase catalysed 
PCRs were carried out according to manufacturer’s instructions and reaction conditions were 
optimised where appropriate. Primer melting temperatures and corresponding PCR 
annealing temperatures were calculated using the “NEB-Tm calculator” at 
http://tmcalculator.neb.com/ (last accessed 27-07-2015). Oligonucleotide primers used for 
PCR during this study are listed in Table 2.4. 
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Table 2.4. Oligonucleotide primers used in this study. Restriction sites and sequences complementary to the 
pLL39 vector used for Gibson assembly are italicised and lower case, codons targeted for mutagenesis are 
underlined, and expression signals (promoters and ribosome binding sites) are shown in bold. 
Designation Description Sequence (5’-3’) 
VgaA_E105Q_fwd 
For mutagenesis of catalytic 
glutamine in N-terminal ABC 
AAAAATCCAGAACTGCTATTAGCAGATCAGC
CAACAACTAACTTAGATAATAAC 
VgaA_E105Q_rev 
GTTATTATCTAAGTTAGTTGTTGGCTGATCT
GCTAATAGCAGTTCTGGATTTTT 
VgaA_K219T_fwd 
For mutagenesis of the vgaA 
interdomain linker  
AAGTATGGCTTTGCTCCCGTTATTTTGCCTTC
AGATAAACTTAAGTTTTTCG 
VgaA_K219T_rev 
CGAAAAACTTAAGTTTATCTGAAGGCAAAAT
AACGGGAGCAAAGCCATACTT 
VgaA_cap1a39_fwd 
For introduction of vga(A) 
into plasmid pLL39 under 
control of the cap1A 
promoter 
agcttagatctaatcgaattcgagctcggtaccCAGA
GTTTGCAAAATATACAGGGGATTATATATA
ATGGAAAACAAGAAAGGAAAATAGGAGGT
TTATATGGCAAAAATAATGTTAGA 
VgaA_cap1a39_rev 
tgtaggtaataaaaaagcttgcatgcctgcaggtcgac
tctagaggatTTATTTATCCAAATTTCTTTTTTC
A 
VgaA_pEPSA5_fwd 
For introduction of vga(A) 
into plasmid pEPSA5 
 
GCTAgagctcATAAGAGGATGAGAAAATATG
GCAAAAATAATGTTAGAGGGACT 
VgaA_pEPSA5_rev 
GACTCggatccTTATTTATCCAAATTTCTTTTTT
CAT 
Cfr_pEPSA5_fwd 
For introduction of cfr into 
plasmid pEPSA5 
GCAACgagctcATAGGAGGATCAGAAAATAT
GAACTTTAACAACAAAACGAAATATGG 
Cfr_pEPSA5_rev 
GCAACggatccTTACTGGGAGTTCTGATAGTT
ACC 
VgaA_pIVEX_fwd For introduction of vgaA into 
plasmid piVEX2.3d 
CTccatggCAAAAATAATAGAGGGAC 
VgaA_pIVEX_rev CTgggcccTTTATCCAAATTTCTTTTTTC 
VgaA_28a_fwd 
For introduction of vga(A) 
into pET28a based vectors 
GCGCTAGGATCCATGGCAAAAATAATGTTA
GAGG 
VgaA_28a_rev 
CGACTAAAGCTTTTATTTATCCAAATTTCTTT
TTTCAT 
VgaAv_28a_fwd 
For introduction of vga(A)v 
into pET28a based vectors 
GCGCTAggatccATGAAAATATTGTTAGAGGC
TCTTC 
VgaAv_28a_rev 
CGACTActcgagTCAATTATCTAAATTTCTTTT
CTCGT 
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Table 2.4 continued. Oligonucleotide primers used in this study. 
VgaC_28a_fwd 
For introduction of vga(C) into 
pET28a based vectors 
GCGCTAggatccATGGTTTTACTAGAGGC 
VgaC_28a_rev 
CGACTAaagcttTTACTCCTTTAACTTACTTTTT
T 
VgaE_28a_fwd 
For introduction of vga(E) into 
pET28a based vectors 
GCGCTAggatcc 
ATGTTATTATTTGAAGGTACAT 
VgaE_28a_rev 
CGACTAaagcttTTATAGTTTTTTAGTCAGTTC
TT 
MsrA_28a_fwd For introduction of msr(A) 
into pET28a based vectors 
 
GCGCTAggatccATGGAACAATACACCATCAA
AT 
MsrA_28a_rev CGACTAaagcttTTAGGTGATGTCGTGCAG 
MsrC_28a_fwd 
For introduction of msr(C) 
into pET28a based vectors 
 
gcgctaggatccATGGAAAATTTAGCAGTAAAT
ATAAC 
MsrC_28a_rev 
CGACTAgagctcTTAAAAATTTCTCGTAAGTA
CTTTTTTTA 
LsaA_28a_fwd 
For introduction of lsa(A) into 
pET28a based vectors 
 
GCGCTAggatccATGTCGAAAATTGAACTAAA
ACAAC 
LsaA_28a_rev 
CGACTAaagcttTTATGATTTCAAGACAATTTT
TTTATCTGT 
  
2.2.6 Colony PCR 
Colony PCR was performed using GoTaq Green Master Mix (Promega). A colony PCR primer 
stock was prepared by diluting forward and reverse primers to 2.5 pmol/μl in a volume of 
200 μl. Single colonies were suspended in 20 μl phosphate buffered saline (PBS). Reactions 
were composed of 12 μl GoTaq Green Master Mix, 10 μl colony PCR primer stock (1 μM) and 
2 μl PBS-colony suspension. Reactions underwent an initial denaturation at 95°C for 10 min, 
followed by 18 cycles of 30 s denaturation at 95°C, 30 s annealing at 50°C and 1 min/kb 
extension at 72°C. Reactions were held at 4°C before analysis by agarose gel electrophoresis 
(Section 2.2.8). 
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2.2.7 Site-directed mutagenesis 
The Agilent Technologies Quick Change Lightning site-directed mutagenesis kit was used 
according to manufacturer’s guidelines. Mutagenised plasmids were transformed into ultra-
competent cloning strain E. coli XL1-Gold (Table 2.1). The plasmid DNA of putative mutants 
was extracted (Section 2.2.2) and mutations were confirmed by DNA sequencing (Section 
2.2.14). 
2.2.8 Agarose gel electrophoresis 
Agarose gels (30 ml) were composed of between 0.5% and 1.2% (w/v) agarose in TAE buffer 
containing 3 μl 10 000X SYBR Safe DNA stain (Life technologies, Carlsbad, CA, USA). Agarose 
content was tailored to give optimum resolution for the DNA fragments undergoing analysis. 
DNA samples were mixed with 6x loading dye (Promega) in a 6:1 ratio and loaded into the 
gel. Electrophoresis was typically performed at 90 V for 28 min in TAE buffer. For 
quantification of purified ribosomal RNA, denaturing agarose gels were composed of 1% 
agarose (w/v) in TBE buffer containing 1M urea and SYBR-Gold DNA stain (Life Technologies). 
Electrophoresis of rRNA was performed at 90 V for 60 min in TBE buffer. 
2.2.9 Restriction digests 
Restriction enzymes and appropriate buffers were from NEB. Preparative digests of PCR 
products and plasmids were performed in a reaction volume of 50 μl. Typically, DNA was 
digested simultaneously with two restriction enzymes in reactions comprising 5 μl CutSmart 
buffer, 2 μg DNA and 800 units of each restriction enzyme. Reactions were incubated at 37°C 
for 3 h and digested DNA was gel or column purified (Section 2.2.10). 
2.2.10 Purification of DNA  
DNA amplified by PCR reactions was purified using the QIAquick PCR Purification Kit (Qiagen).  
In order to remove enzymes and exchange buffers following restriction digests, digested and 
undigested DNA was separated by electrophoresis (Section 2.2.8), the relevant band was 
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excised from the agarose gel and DNA was extracted from the gel using the QIAquick Gel 
Extraction Kit according to manufacturer’s instructions (Qiagen).   
2.2.11 DNA Ligation 
DNA ligations were performed using the NEB Quick Ligation Kit according to manufacturer’s 
guidelines. Reactions typically contained 50 ng of digested plasmid and a 3 molar excess of 
digested insert. Ligation reactions were incubated at 25°C for 10 min. 
2.2.12 Transformation of E. coli strains 
Chemically competent E. coli strains were prepared according to the Inoue method 
(Sambrook et al., 1989). For transformation, cells were thawed on ice and 1-10ng of DNA 
was added. The cell-DNA suspension was incubated on ice for 30 min, heat-shocked at 42°C 
for 30 s and allowed to recover on ice for 2 min. SOC media (Hanahan, 1983) was added to a 
final volume of 1 ml and the resulting culture was grown at 37°C for 1 h with vigorous 
aeration. Finally, volumes of culture were plated onto LBA containing appropriate antibiotics 
for selection and incubated at 37°C overnight. If the cells were transformed with a ligation 
reaction, resulting colonies were screened for the presence and correct orientation of a 
ligated insert by colony PCR (Section 2.2.6). 
2.2.13 Transformation of S. aureus strains 
Electrocompetent strains of S. aureus were prepared according to a method previously 
defined by Monk et al. (Monk et al., 2012).  For electroporation, cells were thawed on ice for 
5 min before being centrifuged (10 000 × g for 1 min) and resuspended in 50 µl of 10% 
glycerol (v/v) and 500 mM sucrose (filter sterilized). Plasmid DNA (1-50 ng for pEPSA5, 1-5 
μg for pLL39) was added to the cells, the DNA-cell suspension was transferred to a 1-mm 
electroporation cuvette (Geneflow, Elmhurst, UK), and pulsed at 21 kV/cm, 100 Ω, and 25 
µF. TSB supplemented with 500 mM sucrose (filter sterilized) was immediately added to a 
final volume of 1 ml and the resulting culture was incubated at 37°C for 1 h before plating 
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onto MHA containing appropriate antibiotics for selection. Plates were incubated at 37°C 
overnight. 
2.2.14 DNA sequencing 
DNA sequencing was used to confirm the correct orientation and sequence of cloned inserts 
following ligation (Section 2.2.11), and the introduction of point mutations following site 
directed mutagenesis (Section 2.2.7). Sequencing was performed by Beckman-Coulter 
Genomics (MA, USA) by Sanger sequencing (Sanger et al., 1977). 
2.3 Determination of susceptibilities to antibacterial agents 
2.3.1 Standardised susceptibility testing 
MICs of antibacterial agents against various S. aureus strains were determined according to 
Clinical and Laboratory Standards Institute (CLSI) guidelines (Cockerill et al., 2012), by 
exposing bacteria to serial two-fold dilutions of antibiotic agents in MHB. S. aureus strains 
carrying the pEPSA5 plasmid (Table 2.2) used MHB supplemented with 2% (w/v) d-xylose to 
induce expression of resistance genes from the pT5Xpromoter.  
2.3 Expression of recombinant proteins 
2.3.1 Auto-induction media 
Media for the production of proteins using the auto-induction method was prepared as 
previously described (Studier, 2005).  
2.3.2 Small-scale expression trials 
Prior to large scale production of proteins, expression levels of recombinant ARE ABC-F genes 
were assessed in 10 ml cultures. A single-colony from a freshly transformed E. coli 
BL21(DE3λ) strain was used to inoculate 10 ml of auto-induction media in a 50 ml sterile 
Falcon tube. This culture was grown at 25°C with vigorous aeration for 1-2 d. An aliquot of 1 
ml was removed and centrifuged at 10 000 x g 2 min to harvest cells. The resultant pellet was 
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resuspended in 200 μl lysis buffer (see Table 2.4, Page 52 for buffer composition) and 
subjected to three cycles of rapid freezing at -80°C followed by thawing at 4°C. In order to 
separate the insoluble and soluble fractions, lysate was centrifuged at 30 000 x g at 4°C for 
10 min. The supernatant corresponding to the soluble fraction was added in a 1:1 ratio to 2x 
sodium dodecyl sulphate (SDS) loading buffer (Sambrook et al., 2001). The pellet, 
corresponding to the insoluble fraction, was dissolved in 300 μl 8M urea solution and added 
in a 1:1 ratio to 2x SDS loading buffer. Samples were analysed by SDS-PAGE (Section 2.3.4).  
2.3.3 Preparative scale expression of recombinant proteins 
FusB was expressed as previously described (Cox et al., 2012). For large-scale expression of 
Vga(A) and Lsa(A), a single colony of BL21 (DE3) Gold containing pIVEX2.3d-vga(A) or 
BL21 (DE3) CodonPlus RIL containing pET28aSUMO-lsa(A) was used to inoculate 400 ml of 
sterile auto-induction media in 2 L baffled flasks. The cultures were incubated at 25°C (for 
vgaA expression) or 18°C (for lsaA expression) for 3 (vgaA) or 4 (lsaA) d with vigorous 
aeration. Cells were harvested by centrifugation (6 000 x g, 20 min), washed with PBS, 
weighed, and stored as pellets at -80°C. 
2.3.4 SDS-PAGE 
Protein samples containing SDS-PAGE loading buffer (4% (w/v) SDS, 20% (v/v) glycerol, 
0.004% (w/v) bromophenol blue, 200 mM DTT and 0.125 M TrisHCl [pH6.8]) (Sambrook et 
al., 2001) were denatured by heating to 95°C for 5 min prior to separation by SDS-PAGE. 
Electrophoresis using pre-cast 4-20% (w/v) gradient polyacrylamide gels (Expedeon, 
Cambridge, UK) in TEO-Tricine buffer was performed at 175 V for 35 min. When improved 
resolution was required, acrylamide gels were cast with stacking and resolving layers of 4% 
(w/v) and 14% (w/v) acrylamide/bis-acrylamide (Severn Biotech, Kidderminster, UK) 
respectively and run in electrophoresis buffer (0.1% (w/v) SDS, 25 mM Tris base, 192 mM 
glycine) at 12 W for 3-4 h. Gels were stained by soaking in Coomassie stain: Coomassie 
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Brilliant Blue R-250 (150 mg/l), in 25 % (v/v) methanol, 10% (v/v) acetic acid and de-stained 
by soaking in de-stain solution: 40% (v/v) methanol, 10% (v/v) acetic acid. Alternatively, if 
SDS-PAGE results were required quickly, cells were stained with InstantBlue (Expedeon). 
2.4 Purification of recombinant proteins 
2.4.1 Preparation of buffer solutions 
Buffers were prepared as detailed in Table 2.4. All buffers to be used with the ÄKTA purifier 
system (GE Healthcare, Buckinghamshire, UK) were degassed and filtered (0.22 μM filters, 
Merck Millipore) prior to use.  
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Table 2.4. Buffers used during purification of Vga(A) and Lsa(A) 
Buffer Composition 
Lysis  50 mM NaH2PO4, pH 8.0; 300 mM NaCl, 10 mM 
imidazole, 1 mM MgCl2 
VgaA-IMAC-W 50 mM NaH2PO4, pH 8.0; 2 M NaCl, 20 mM imidazole, 
10% (v /v) glycerol, 1 mM MgCl2 
VgaA-IMAC-E 50 mM NaH2PO4 pH 8.0, 2 M NaCl, 250 mM imidazole, 
10% (v/v) glycerol, 1 mM MgCl2 
VgaA-GF 50mM HEPES, pH 7.4; 2M NaCl, 1mM DTT, 1 mM MgCl2 
VgaA-IEX 50 mM HEPES, pH 7.4; 50 mM NaCl, 1 mM DTT 
LsaA-IMAC-W 50 mM NaH2PO4, pH 8.0; 300 mM NaCl, 20 mM 
imidazole, 10% (v/v) glycerol  
LsaA-IMAC-E 50 mM NaH2PO4, pH 8.0; 300 mM NaCl, 
250 mMimidazole, 10% (v/v)  glycerol  
LsaA-IMAC-S 50 mM NaH2PO4, pH 8.0; 300 mM NaCl, 40 mM 
imidazole, 10% (v/v) glycerol  
Storage buffer* 50 mM HEPES, pH 7.4; 300 mM NaCl, 1 mM DTT 
 * Additionally used for LsaA gel filtration 
2.4.2 Preparative scale lysis of E. coli cells 
Cell pellets were thawed on ice and resuspended in 3 ml Lysis buffer (Table 2.4) per-g wet-cell weight. 
Cell suspensions were incubated with 7000 U chicken egg-white lysozyme (7000 U/ mg, Sigma-
Aldrich), one EDTA-free protease inhibitor tablet / cell pellet (Roche, Basel, Switzerland) and 17 units 
Basemuncher endonuclease/ ml of suspension  (Expedeon) at 4°C for 30 min and lysed by sonication 
(20s on / 40s off, 50% amplitude, large probe). During sonication samples were packed with ice and 
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checked regularly to prevent heating. Lysates were clarified by centrifugation (30,000 x g, 20 min) and 
kept on ice for all subsequent purification steps.  
2.4.3 Purification of Vga(A) 
Purification of Vga(A) was optimised as described in Chapter 3. The optimised protocol for Vga(A) 
purification using  immobilized metal ion affinity chromatography (IMAC), gel filtration (GF) and ion 
exchange (IEX) is detailed below.  
Cleared lysate was equilibrated with 3 mL Ni-NTA agarose (Expedeon) for 15 min and subsequently 
loaded into a 25-mL free-flow gravity column (GeneFlow). Unbound protein was allowed to flow 
through the column before washing with 10-column volumes of Vga-IMAC-W buffer (Table 2.4). 
Bound protein was eluted with 5 ml VgaA-IMAC-E buffer (Table 2.4) and dialysed overnight into 
Vga-GF buffer (Table 2.4) using SnakeSkin Dialysis Tubing (Life Technologies, 10 kDa MWCO). Dialysed 
protein was loaded onto a Superdex 200 (16/60) column (GE Healthcare) pre-equilibrated with VgaA-
GF buffer. Fractions corresponding to Vga(A) were collected and concentrated to a volume <5 ml with 
Pierce Protein Concentrators (Life technologies). Once concentrated, Vga(A) was exchanged into 
VgaA-IEX buffer (Table 2.4) using five HiTrap Desalting columns (GE Healthcare) connected in series 
and subsequently loaded onto a 6 ml resource S column (GE Healthcare) for purification by cation-
exchange. The resource S column was eluted with a 50 mM-1M NaCl linear gradient. Fractions 
corresponding to Vga(A) were collected, concentrated, exchanged into Storage buffer, and stored at -
80 oC.  
2.4.4 Purification of Lsa(A) 
Purification of Lsa(A) by IMAC was performed as detailed in Section 2.4.3 with the following buffer 
substitutions (Table 2.4); LsaA-IMAC-W for VgaA-IMAC-W; LsaA-IMAC-E for VgaA-IMAC-E. Following 
IMAC, the eluate was dialysed (Section 2.4.3) against LsaA-IMAC-S buffer (Table 2.4) in the presence 
of U1p SUMO protease. After dialysis, the sample was re-applied to the Ni-TNA column in order to 
separate the cleaved 6-His-SUMO tag, which bound the column, from Lsa(A), which was eluted in the 
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flow through. Once the flow-through had been collected, it was concentrated to a volume < 5ml 
(Section 2.4.3) and loaded onto a Superdex 200 (16/60) column (GE Healthcare) pre-equilibrated with 
Storage buffer. Fractions corresponding to Lsa(A) were collected, concentrated, and stored at ‒80°C. 
2.4.5 Purification of FusB 
FusB was purified by IMAC and gel filtration as previously described (Cox et al., 2012). 
2.4.6 Determination of protein concentration 
Recombinant protein concentration was determined by measurement of UV absorbance at 280 nm 
using a P300 nanophotometer (Implem). Levels of contamination of protein samples with nucleic acid 
were assessed using the same instrument to measure absorbance at 260 nm and calculating the 
260/280 ratio. Extinction coefficients were derived using the ProtParam tool on the ExPASy 
proteomics server at http://web.expasy.org/protparam/ (last accessed 27-07-2015).  
The Bradford assay (Bradford, 1976) was used to determine the concentration of protein present in 
S30 fractions (Section 2.5.1). Sample concentrations were determined relative to a bovine γ-globulin 
standard curve. Bradford reagent was from Bio-Rad (Hercules, CA, USA). 
2.5 In vitro transcription-translation assays 
2.5.1 Preparation of S30 extracts 
Staphylococcal S30 extract was prepared from S. aureus RN4220 in accordance with the protocol of 
Murray et al. (Murray et al., 2001) with limited modifications, as detailed below.  
Cells were grown in Brain-Heart Infusion (BHI) broth to saturation, harvested by centrifugation (6000 
x g, 20 min, 4°C), and washed successively in ice-cold buffer A (10 mM Tris-acetate pH8, 14 mM 
magnesium acetate, 1 mM DTT) containing 1 M KCl and cold buffer A containing 50 mM KCl. Cell pellets 
were weighed and frozen at -80°C. Subsequent steps were undertaken within 3 d, performed at 4°C 
unless otherwise stated, and kept strictly RNase free. Cell pellets were thawed on ice and resuspended 
in 2 ml buffer B (10 mM Tris-acetate pH8, 20 mM magnesium acetate, 50 mM KCl, 1 mM DTT) / g wet-
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cell weight plus 15 U/ml RNasein (Invitrogen). Cell suspensions were transferred to SS34 centrifuge 
tubes and lysostaphin (Sigma-Aldrich) was added to a final concentration of 20 mg/ml. The suspension 
was incubated for between 30-60 min at 37°C, until it became visibly viscous. The lysed cells were 
fractionated by centrifugation (30 000 x g, 30 min, 4°C) and the resulting supernatant was dialysed 
using Float-A-Lyzer G2 dialysis tubing (3500 MWCO) (Spectrum Laboratories, Breda, Netherlands) 
against buffer A supplemented with 60 mM potassium acetate. Dialysis was performed for 1 h and 
repeated three times. Samples were concentrated to 10mg/ml using polyethylene glycol 8000, flash 
frozen using liquid nitrogen and stored at ‒80°C. Protein concentration was determined using the 
Bradford assay (Section 2.4.6).    
E. coli S30 extract was purchased from Promega (E. coli T7 S30 Extract System for Circular DNA, L1130). 
2.5.2 In vitro transcription-translation assays 
The ability of Vga(A) and Lsa(A) to protect translation was investigated using the S30 extracts 
described in Section 2.5.1. An optimised quantity of S30 extract was added to a reaction mixture of 
amino acids (Promega), S30 pre-mix (Promega) and 1 μg p194SAluc/pBESTluc (Table 2.2). Antibiotics 
and purified proteins were added in accordance with assay requirements. Reactions were incubated 
for 1 h at 37°C and the level of transcription/translation was quantified by the addition of a saturating 
concentration of luciferase assay reagent (Promega) and subsequent measurement of luminescence 
using a FluoStar Optima plate reader (BMG labtech, Ortenberg, Germany). Concentrations of 
Virginiamycin M, fusidic acid and lincomycin were optimised to give 90% inhibition (IC90) compared to 
a drug free, exogenous protein free, control. 
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2.6 Assays of lincomycin binding to staphylococcal ribosomes 
2.6.1 Purification of staphylococcal ribosomes 
Staphylococcal ribosomes were purified using an l-cysteine Sulfolink (Thermo Scientific, Waltham, MA, 
USA) column and ultracentrifugation as previously described (Maguire et al., 2008).  
An l-cysteine Sulfolink column suitable for use with an ÄKTA purifier system (GE Healthcare) was 
prepared as follows. A total of 100 mL of a 50% (v/v) slurry of Sulfolink coupling gel was centrifuged 
(500 x g, 5 min), and the storage buffer carefully decanted. The gel was washed three times with 
200 ml of Sulfolink coupling buffer (50 mM Tris, 5 mM EDTA-Na; pH 8.5) using the centrifuge-decant 
method. Next, 100 ml of a 50 mM solution of l-cysteine in coupling buffer was added and the slurry 
gently shaken for 1 h at 25°C. Residual l-cysteine was removed by centrifuge-decant to afford l-cystein 
Sulfolink resin. A 50% (v/v) slurry of l-cystein Sulfolink resin was produced by addition of dH2O and the 
resin was packed into a XK 16/20 column (GE Healthcare) according to the protocol detailed in Column 
Packing the Movie (GE Healthcare).  The resulting column was stored in 20% (v/v) ethanol and reused 
multiple times. 
Staphylococcal cell pellets for extraction of ribosomes were prepared and stored as detailed in Section 
2.5.1. Pellets were thawed on ice and resuspended in 2 ml of Ribosome Lysis buffer (10 mM Tris 
acetate, pH 8.0; 20 mM magnesium acetate, 1 mM DTT) supplemented with 60 mM NH4Cl/ g of cell 
wet-weight. Cell suspensions were transferred to SS34 centrifuge tubes and lysostaphin (Sigma-
Aldrich) was added to a final concentration of 20 mg/ml. The suspension was incubated for between 
30-60 min at 37°C, until the cell pellet began to become visibly viscous. The lysed pellet was 
fractionated by centrifugation (30 000 x g, 30 min, 4°C) and the resulting supernatant was loaded onto 
an l-cystein Sulfolink column pre-equilibrated with ribosome lysis buffer using repeated applications 
of a 10ml superloop (GE Healthcare). The column was eluted using a 0-100% gradient (10 column 
volumes) of lysis buffer supplemented with 1 M NH4Cl. Eluted fractions containing protein were 
collected and subjected to ultracentrifugation (100 000 x g, 16 h at 4°C using a SW32Ti rotor and 
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Optima L-80 XP Ultracentrifuge (Beckman Coulter, Brea, CA, USA) to obtain ribosome pellets. Finally 
pellets were resuspended in Ribosome Lysis buffer and stored at ‒80°C. Ribosome concentration was 
determined as detailed in Section 2.6.2. 
2.6.2 Quantification of staphylococcal ribosomes 
For quantification of rRNA, serial dilutions of purified ribosomes (Section 2.6.1) were run on a 
denaturing agarose gel (Section 2.2.8) alongside serial dilutions of RiboRuler High Range RNA Ladder 
(Life technologies). Alternatively, ribosomal protein was quantified using SDS-PAGE to separate erial 
dilutions of purified ribosomes and of bovine serum albumin (BSA). Images of gels were captured with 
the use of a GeneGenius UV transilluminator (Syngene, Cambridge, UK) and analysed by 2D 
densitometry using AIDA software (Raytest, Straubenhardt, Germany). Ribosome concentration was 
determined through comparison of 16S rRNA with a standard curve calibrated with RiboRuler and 
comparison of ribosomal protein L3 with a BSA calibrated standard curve. Results obtained from 
quantification of rRNA and ribosomal protein were averaged. 
2.6.3 Lincomycin Ribosome binding assays 
The ability of LsaA to protect the ribosome from lincomycin binding was assessed using a modification 
of a previously described tetracycline binding assay (Wilson, 2014).  Ribosomes (500 nM) were pre-
incubated in 50 μl reactions with LsaA, BSA or unlabelled lincomycin (concentrations described in 
Section 4.4.4) in assay buffer (10 mM Tris, pH 7.5; 60 mM KCl, 10 mM NH4Cl, 300 mM NaCl, 6 mM 
MgCl2, 0.1 mM ATP) at 37°C. After 10 min, 3H-lincomycin (1 μM) was added, the reactions were 
incubated a further 10 min, vacuum-filtered through a 0.45 µm nitrocellulose filter and washed twice 
with 200 μl of ice-cold wash buffer (50 mM Tris-Cl, 50 mM KCl, 20 mM magnesium acetate) to remove 
unbound 3H-lincomycin. Ribosome-associated 3H-lincomycin was then quantified by scintillation 
counting. The ability of Lsa(A) to dissociate pre-bound lincomycin was investigated using the same 
assay conditions, however 3H-lincomycin was pre-incubated with ribosomes for 10 min at 37°C prior 
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to the addition of LsaA, BSA or unlabelled lincomycin, incubation for a further 10 min at 37°C, washing, 
and scintillation counting.  
2.7 Pull down assays 
Polyhistidine pull-down assays were performed to establish putative interactions of Vga(A), or Lsa(A), 
with intracellular components. Assays were performed as follows. Aliquots of 50 μl Ni-NTA agarose 
resin were equilibrated in lysis buffer (Table 2.4, 50 mM KH2PO4, pH 8.0; 300 mM NaCl; 10 mM 
imidazole) and 100 µg purified VgaA or LsaA was immobilised by incubation with resin for 15 min at 
4°C. Subsequently, immobilised protein was incubated with samples containing potential binding 
partners for 30 min at 37°C or 4°C. These samples were as follows: (i) S30 fraction derived from S. 
aureus RN4220 (Section 2.5.1), (ii) S30 fraction derived from E. coli (Section 2.5.1), and (iii) purified 
staphylococcal ribosomes (Section 2.6.1). Incubation was in the presence of 2 μg/ml virginiamycin M 
with 100 μM ATP or 100 μM AMP-PNP (Roche) as detailed in Section 4.4.5. Samples were applied to 
Pierce Micro-Spin Columns and centrifuged (100 x g, 1 min) to remove unbound protein. Columns 
were repeatedly washed (3 x 20 CV, 50 mM KH2PO4, pH 8.0; 300 mM NaCl, 20 mM imidazole) to 
remove non-specifically bound protein. SDS-PAGE loading buffer (Section 2.3.4) supplemented with 
100 mM EDTA was used to elute the column and samples were examined by SDS-PAGE. Bands 
corresponding to putative binding partners were excised from the gel and analysed by peptide-mass 
fingerprinting (Section 2.8). 
2.8 Peptide-mass fingerprinting 
Bands excised from SDS-PAGE gels were de-stained and subjected to tryptic digest. The resulting 
peptides were separated by liquid chromatography and identified by MALDI-TOF mass-spectrometry. 
De-staining, digest and LC-MS was carried out by Dr James Ault (Mass Spectrometry Facility, University 
of Leeds). 
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2.9 Screening for protein crystallisation conditions 
Crystal screens from Hampton Research (California, USA; Crystal Screen I/II, Index, Salt RX), Molecular 
Dimensions (Florida, USA; Midas, Morpheus), and Rigaku Reagents (Washington, USA; Wizard I/II) 
were assessed for their ability to confer conditions suitable for crystallisation. Conditions were tested 
in sitting drops (0.4 μl drops) using the vapour diffusion reagent (60 μl reservoir volume)  in the 
presence or absence of 100 μM AMP-PNP. Screens were set up in 3 drop,  96-well plates (Hampton 
Research, CA, USA) using a Formulatrix NT8 robot (Formulatrix, MA, USA) and incubated at 4°C or 25°C 
in a Rock Imager 1000 (Formulatrix). Crystal growth was examined after one day and then monitored 
at regular intervals up to two months. 
  
60 
 
3. Expression and purification of the ARE ABC-F proteins Vga(A) 
and Lsa(A) 
3.1 Abstract 
Efforts to determine the mechanism underpinning ABC-F-mediated antibiotic resistance 
would be facilitated by the production of homogenously purified ARE ABC-F proteins suitable 
for functional and structural studies. To date, only one ARE ABC-F has been purified in its 
native form; Vga(A). Here, an optimised method for purification of Vga(A) is described. 
Additionally, conditions conducive to the soluble expression and subsequent purification of 
a second ARE ABC-F protein, Lsa(A), are outlined. Attempts to crystallise the two proteins in 
order to pursue structural studies were unsuccessful, possibly due to proteolytic degradation 
observed even at low temperatures. However, optimised methodology for the homogenous 
purification of Vga(A) and Lsa(A) provides a platform from which to launch further structural 
and mechanistic investigations into the ARE ABC-F protein subfamily. 
3.2 Introduction 
To date, functional studies of ARE ABC-F determinants have concentrated on three proteins; 
Msr(A), Vga(A)and Ole(B), of which only Vga(A) and a fragment Ole(B) have previously been 
heterologously expressed and purified. The vga(A) resistance determinant is located on 
mobile genetic elements and mediates acquired resistance to streptogramin A and 
lincosamide antibiotics (with variants also conferring pleuromutilin resistance) (Lenart et al., 
2015, Novotna and Janata, 2006)) in several species of staphylococci (Allignet et al., 1992, 
Novotna and Janata, 2006, Lozano et al., 2012), whilst, the chromosomally encoded ole(B) 
gene confers self-protection in the oleandomycin producer, Streptomyces antibioticus 
(Olano et al., 1995). Functional studies of Ole(B) used only a fragment of the full-length 
protein, the N-terminal ABC domain, which was fused to the E. coli maltose binding protein 
(MBP) to promote solubility (Olano et al., 1995). In contrast, although Vga(A) has also been 
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expressed as an MBP-fusion (Chesneau et al., 2005), a Vga(A) construct modified solely by 
the addition of a C-terminal hexa-histidine tag that does not alter the proteins biological 
activity, has also been expressed and purified (Jacquet et al., 2008). Using purified protein, 
the ATPase activity of Vga(A) and the N-terminal domain of Ole(B) have been thoroughly 
characterised. However, functional studies of these two ARE ABC-F proteins have not 
provided a definitive explanation of the mechanism by which they mediate antibiotic 
resistance. Additionally, to date, no structural information is available for any member of the 
ARE ABC-F subfamily.  
3.3 Aims 
Work presented in this chapter provides optimised conditions for heterologous expression 
and purification of proteins belonging to the ARE ABC-F subfamily. Optimisation of a 
previously described method for production of Vga(A) is described. Conditions conducive to 
the production of soluble ARE ABC-F proteins other than Vga(A) were assessed and methods 
for purification of resulting soluble proteins was developed. Attempts to find conditions to 
promote crystallisation of ARE ABC-F proteins are outlined.  
3.4 Results 
3.4.1 Expression of Vga(A) 
The optimisation of conditions conducive to the production of soluble protein permits 
subsequent purification steps to be conducted under native conditions and removes any 
requirement for denaturation and refolding of the target protein. Previous work had 
reported low-level production of soluble of Vga(A) with a C-terminal hexa-histidine tag when 
the vga(A) gene was expressed from the IPTG-inducible pIVEX2.3d vector in E. coli BL21 
(DE3λ) Gold (Jacquet et al., 2008). The pIVEX plasmids are a somewhat unusual choice of 
vector for performing E. coli-based protein production given that they are primarily 
optimized for in vitro production of proteins. However, as pIVEX2.3d had been successfully
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used to produce soluble Vga(A), the pIVEX2.3d-vga(A) plasmid was constructed with the 
intention of optimising Vga(A) production (G. Cox, unpublished work). Auto-induction is an 
alternative method for production of proteins using the T7-system that has been shown to 
increase bio-mass and target-protein yield in comparison to IPTG induction (Studier, 2005). I 
therefore sought to establish whether the Vga(A) protein could be produced using auto-
induction of the pIVEX2.3d-vga(A) plasmid in E. coli BL21 (DE3) Gold (Jacquet et al., 2008). 
The pIVEX2.3d-vgaA plasmid was transformed into E. coli BL21 (DE3) Gold and subjected to 
small-scale auto-induction expression trials. Expression trials of vga(A) were performed 
alongside the ARE ABC-F gene msr(A) and tetracycline-resistance determinant tet(M), both 
of which had been codon optimised for expression in E. coli, synthesised, and cloned into 
pET28a by Genscript (New Jersey, USA), prior to transformation into E. coli BL21 (DE3λ) Gold.  
Initial expression trials tested the ability of two auto-induction media of differing 
composition (2ZYM 2X Lac and 8ZYM 4X Lac) to induce protein production when incubated 
for 2 d at 25°C. 8ZYM 4X Lac is designed to permit growth to a higher cell-density than 
2ZYM 2X Lac as it contains double the amount of glucose, lactose and glycerol, and four-
times the amount of yeast extract and tryptone, than 2ZYM 2XLac. Both media produced a 
small amount of soluble Vga(A) (60.2kDa) that was amenable to purification using a small-
scale Ni-NTA spin-column (Figure 3.1 A and B). The richer of the two media, 8ZYM 4X Lac, 
produced high-levels of insoluble Vga(A), Tet(M) (72.5 kDa), and Msr(A) (55.8 kDa). In an 
effort to increase the fraction of soluble protein generated using 8ZYM 4X Lac media, the 
incubation temperature was lowered to 18oC and growth time extended to 3-days, however, 
this did not produce detectable amounts of protein (Figure 3.1 C). 
As auto-induction with 8ZYM 4X Lac was able to produce soluble Vga(A), expression was 
scaled up and purification was attempted (Section 3.4.2). Expression of msr(A) was 
investigated further at a later point (Section 3.4.5). The tet(M) resistance determinant was 
not investigated further. 
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Figure 3.1. Small scale expression trials of vga(A) varying auto-induction media and temperature. (A) 2 ZYM 2X 
Lac at 25oC for 2days. (B) 8 ZYM 4X Lac at 25oC for 2days. (C) 8ZYm 4X Lac at 18oC for 3days.  
T - total cellular protein, I – Insoluble fraction, S – Soluble fraction, N – Eluate from Nickel-NTA mini-spin-column. 
M – Protein marker (Broad Range (2-212 kDa), New England Biolabs) showing molecular weight (Mw) in kDa.  
Molecular weights:- Msr(A) 55.8 kDa, Tet(M) 72.5 kDa, Vga(A) 60.2kDa.  
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3.4.2 Initial strategy for Vga(A) purification 
Initial efforts to purify Vga(A) utilised a three-step strategy; capture of Vga(A) using 
immobilised metal ion affinity chromatography (IMAC), followed by ion-exchange (IE) and 
gel filtration (GF) chromatography. Conditions for IMAC were optimised through evaluation 
of two resins, nickel-nitrilotriacetic acid (Ni-NTA) agarose (Expedeon) and TALON cobalt 
Affinity Resin (Clontech, CA, USA), washed with increasing concentrations of imidazole 
(Figure 3.2 A and B). A greater imidazole concentration was required to elute Vga(A) from 
Ni-NTA resin than cobalt  resin, suggesting that Ni-NTA exhibited higher affinity for Vga(A) 
(Figure 3.2 A vs. B). Ni-NTA agarose was therefore used for IMAC throughout this study in 
tandem with 20 mM imidazole in all IMAC wash buffers. Application of cleared auto-induced 
cell lysate to Ni-NTA agarose repeatedly showed that the most prominent band found within 
the eluted fraction migrated as if it had a similar molecular weight to that expected of Vga(A) 
(Figure 3.2 C). Analysis of this band by peptide mass fingerprinting (PMF) confirmed its 
identity as Vga(A) (Personal communication, J. Ault, Biomolecular Mass Spectrometry 
Facility, University of Leeds).  
Repeated attempts to further purify Vga(A) by cation-exchange were unsuccessful. After 
buffer exchange, the protein failed to bind the resource S IE column and was present in the 
flow through (Figure 3.2 D). Subsequent application of the flow through to an S200 GF 
column did not give a single peak corresponding to the molecular weight of Vga(A) (Figure 
3.2 E). Analysis of the fractions by SDS-PAGE revealed Vga(A) to be eluted in the void volume 
and present in fractions corresponding to a molecular weight higher than 60.2 kDa, 
suggesting aggregation of the protein (Figure 3.2 F).  
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Figure 3.2. Initial purification of Vga(A). SDS-PAGE showing optimisation of imidazole concentration for Vga(A) 
purification by IMAC using (A) Ni-NTA agarose and (B) TALON cobalt resin. (C) SDS-PAGE analysis of fractions 
generated by purification of an auto-induced, cleared, cell-lysate using Ni-NTA agarose, washed with the 
imidazole concentration as optimised in A. (D) Chromatogram resulting from application of Ni-NTA IMAC eluate 
from C to a resource S IE column. (E) Chromatogram resulting from application of flow through from Resource S 
described in D to an S75 GF column. (F) SDS-PAGE analysis of fractions 1-7 resulting from GF column described in 
E. 
Abbreviations used to annotate the SDS-PAGE gel images are as follows; M denotes protein marker (Broad Range 
2-212 kDa, New England Biolabs); I, insoluble cell fraction; S, soluble cell fraction; FT, flow through; W, wash; and 
E, eluate. The blue trace on the presented chromatograms represents absorbance at 280 nm, whereas the green 
trace indicates a 10-500 mM NaCl gradient. 
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3.4.3 Removal of nucleic acid during Vga(A) purification 
Jacquet et al.(Jacquet et al., 2008) reported that removal of nucleic acid contamination 
through incubation of the cell lysate with Benzonase nuclease (150 units / g wet-cell weight 
) (Merck Millipore) and protamine sulphate (0.8 mg / g wet-cell weight g wet-cell weight) 
(Sigma Aldrich) for one hour at room temperature, followed by an ultracentrifugation step 
(200 000 x g for 1 h) to precipitate protamine sulphate bound nucleic acid, improved the 
efficiency of the IE purification step (Jacquet et al., 2008). The purification protocol was 
modified to reflect these changes. As I observed auto-induction to produce a cell pellet of 
around 5x the wet-weight of a pellet resulting from an IPTG-induced culture of equivalent 
volume, the relative amounts Benzonase and protamine sulphate were adjusted accordingly. 
The cell lysate of the pellet resulting from 400 ml of auto-induced cleared culture was treated 
with Benzonase and protamine sulphate, then purified by IMAC. Following buffer exchange, 
the IMAC eluate was again applied to the resource S IE column (Figure 3.3 A), yielding a single 
eluted peak. Analysis of the fractions from IMAC, desalting and IE showed the eluted peak to 
correspond to Vga(A) (Figure 3.3 B), Purification using this methodology yielded 1.5 mg of 
purified protein (3.75 mg / litre culture); however, this amount was insufficient for screening 
of crystallisation conditions. Consequently, purification was scaled up to process 2.8 litres of 
auto-induced cultured and repeated; however, attempts to purify Vga(A) from larger culture 
volumes repeatedly failed to yield protein that was amenable to purification by IE 
(Figure 3.3 C). Protein produced using scale up through reversion to IPTG-induction also gave 
no eluted peak for IE (Figure 3.3 D). 
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Figure 3.3. Purification of Vga(A) using the method described in Jacquet et al. (Jacquet et al., 2008).  
(A) Chromatogram showing peaks resulting from application of IMAC eluate resulting from a small scale 
purification using 400ml auto-induced culture to a resource S IE column. (B) SDS-PAGE analysis of fractions from 
the same small-scale purification. Ni-NTA E denotes the eluted fractions from IMAC, Desalt E; the same sample 
following desalting using a HiTrap desalting column, IE FT 1, 2, and 3 are the fractions resulting from the IE column 
shown in A. Chromatograms (C) and (D) show Resource S IE purification of protein resulting from IMAC eluates 
generated from 1.2 L of auto-induced culture, and 2.4 L IPTG-induced culture, respectively. 
The blue trace on the presented chromatograms represents absorbance at 280 nm, whereas the red and green 
traces indicate 10-500 mM NaCl gradients. 
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After numerous attempts, it became clear that I was not able to consistently replicate the 
methodology developed by Jacquet et al. to remove contaminating nucleic acid from 
preparations of Vga(A). I therefore performed a series of purifications under different 
conditions and assessed their efficacy for removal of contaminating nucleic acid by 
monitoring the ratio of absorbance at 260 nm to absorbance at 280 nm (A260/280). Protein 
with an A260/280 ratio <0.7 was deemed free of contaminating nucleic acids (Ariza et al., 
2013). Results are summarised in Table 3.1. 
Monitoring the A260/280 ratio showed that although recapitulation of the conditions 
developed by Jacquet et al. caused a drop in A260/280, it did not produce protein free of 
nucleic acid (Table 3.1 condition B vs A). This explains the previously observed failure of 
desalted IMAC eluate to bind a cation-exchange column and subsequent elution of Vga(A) in 
the void volume during GF. Substitution of a large amount of DNase I and RNase A for 
Benzonase nuclease and increasing the incubation temperature to 37°C produced no 
alteration in A260/280 compared to the original method (Table 3.1 condition C vs B). 
However, the inclusion of 2 M sodium chloride in IMAC wash and elution buffers produced 
protein free of nucleic acid following IMAC (Table 3.1 condition C vs D). Unfortunately protein 
subjected to these conditions was prone to aggregation and could not be purified further. As 
increasing the sodium chloride concentration in IMAC buffers resulted in a decrease in 
A260/280, I included 2M sodium chloride in the GF buffer and removed initial steps to digest 
and precipitate nucleic acid IMAC (Table 3.1 condition E). This methodology was successful, 
removing nucleic acid across both purification steps and yielding protein with an A260/280 
<0.7 following GF. As a result this method was subsequently used for routine purification of 
Vga(A) (Section 2.4.3). A final condition that used streptomycin sulphate for precipitation of 
nucleic acid in place of protamine sulphate also yielded Vga(A) free of nucleic acid (Table 3.1 
condition F), however, due to the risk of residual streptomycin interfering with subsequent 
in vitro transcription-translation assays (4.4.3), this method was not used for routine 
purification of Vga(A) during this study. 
 
 
 
6
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Table3.1. Optimisation of conditions for removal of contaminating nucleic acid from preparations of Vga(A). With the exception of condition B, buffers were; Lysis; 50 mM NaH2PO4 (pH 8.0), 20 mM 
NaCl, 1 mM MgCl2, 10 mM imidazole; IMAC Wash, 50 mM NaH2PO4 (pH 8.0), 20 mM imidazole, supplemented with NaCl as described; IMAC Elution, 50 mM NaH2PO4 (pH 8.0), 250 mM imidazole, 
supplemented with NaCl as described; GF, 50 mM HEPES pH 7.4, 1 mM DTT, supplemented with NaCl as described.  
Buffers for condition B were from Jacquet et al. (Jacquet et al., 2008); Lysis, 50 mM NaH2PO4 (pH 7.0), 20 mM NaCl, 1 mM MgCl2, 1 mM imidazole, and 0.5% (v / v) Triton X-100. IMAC wash; 50 mM 
NaH2PO4, (pH 7.0), 400 mM NaCl, 20 mM imidazole; IMAC elution, 50 mM NaH2PO4, (pH 7.0), 400 mM NaCl, 250 mM imidazole; GF, 25 mM Tris-HCl pH 7.0, 150 mM NaCl, 7 mM β-mercaptoethanol 
Condition A260/280 of 
Ni-NTA eluate 
A260/280 of 
 GF eluate 
A  No steps taken to remove nucleic acid.  
 Ni-NTA eluate applied directly to S200 GF column. 1.9 
1.8 
Aggregate eluted in 
void volume 
B  Incubation of cell lysate at room temperature (RT) for 30 min with Benzonase (150 units / g wet-cell weight), addition of 
protamine sulphate (0.8 mg / g wet-cell weight) and further incubation at RT for 30 min. 
 Centrifugation at 200 000 x g for 1 h.  
 IMAC wash, IMAC elution and GF buffers supplemented with 300 mM NaCl. 
 Method from Jacquet et al. (Jacquet et al., 2008). 
1.2 
- 
Not assessed 
C  Incubation of cell lysate at 37°C with DNase I (600 units / g wet-cell weight)(Sigma-Aldrich) and  RNase A (140 units / g wet-cell 
weight)(Qiagen) for 30 min followed by addition of protamine sulphate (0.8 mg / g wet-cell weight) and incubation at RT for 30 
min. 
 Centrifugation at 200 000 x g for 1 h.  
 IMAC wash and elution buffers supplemented with 300 mM NaCl. 
1.2 
- 
Protein precipitated 
during dialysis. 
D  Treatment of cell lysate as described in condition C 
 Centrifugation at 30 000 x g for 30 min.                
 IMAC Wash and elution buffers supplemented with 2M NaCl.  
0.60 
- 
Protein precipitated 
during dialysis. 
E  Benzonase (25 units / wet-cell weight) added prior to cell lysis to reduce viscocity.  
 No incubation of cell lysate with nuclease or precipitant.  
 Centrifugation at 30 000 x g for 30 min. 
 IMAC wash, IMAC elution and GF buffers supplemented with 2M NaCl. 
 Ni-eluate dialysed into GF buffer overnight and applied to S200 GF column. 
0.95 0.65 
F  Incubation of soluble fraction at 4°C with Benzonase (300 units / g wet-cell weight) for 30 min followed by addition of 
streptomycin sulphate (5 mg / g wet-cell pellet weight) and incubation at 4°C for 30 min. 
 Centrifugation at 30 000 x g for 30 min. 
 IMAC wash, IMAC elution and GF buffers supplemented with 2M NaCl. 
 Ni-eluate dialysed overnight and applied to S200 GF column. 
0.68 0.68 
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3.4.4 An optimised method for Vga(A) purification 
The development of methodology to consistently remove contaminating nucleic acid from 
preparations of Vga(A) allowed us to optimise a purification protocol to reliably produce 
homogenous protein. The protocol involved four chromatography steps; initial capture of 
Vga(A) from cleared cell-lysate by Ni-NTA IMAC (Figure 3.4 A), removal of residual 
contaminating nucleic acid by GF (Figure 3.4 B), desalting (Figure 3.4 C), and a final polishing 
step using cation-exchange (Figure 3.4 D). Analysis of chromatograms from GF performed under 
high ionic strength revealed separation of the IMAC eluate into two distinct peaks. The initial 
peak eluted in the void volume and absorbed strongly at 260 nm, likely corresponding to 
aggregates of nucleic acid (Figure 3.4 B). This peak also repeatedly contained a small amount of 
Vga(A) and a contaminating band of higher molecular weight (Figure 3.4 C, lanes 1, 2 and 3). 
The second peak eluted corresponds to Vga(A) free of bound nucleic acid. In order to exchange 
the GF eluate into a buffer with lower-ionic strength suitable for IE, fractions were concentrated 
and applied to desalting columns. During desalting, two peaks were routinely observed; an 
initial larger peak with an A260/280 ratio <0.7 and a second peak that absorbs more strongly at 
260 nm. Although both peaks contained Vga(A) (Figure 3.4 F, lanes 7 and 8), only the initial peak 
was collected and further purified. At this point, although Vga(A) was close to homogeneity, I 
consistently observed feint bands of ~40 kDa. LC-MS analysis confirmed that these bands were 
the result of degradation of Vga(A) (Personal communication, J. Ault, University of Leeds). A 
final IE step was employed to purify Vga(A) away from degradation products. Chromatograms 
of the IE step showed a single peak, eluted at a sodium chloride concentration of ~ 300 mM, 
with a small tail. Analysis of the peak by SDS-PAGE revealed that IE was able to reduce 
contamination by degradation products, with full-length Vga(A) primarily eluting in the main 
peak (Figure 3.4  F, lanes 11, 12 and 13) and bands of a lower molecular weight predominantly 
eluting in the tail (Figure 3.4  F, lanes 14, 15 and 16). Homogenously purified Vga(A) was either 
used immediately for functional assays or stored at -80°C. This methodology resulted in yields 
of ~3mg of WT Vga(A) per litre of culture. 
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 Figure 3.4. An optimised method for purification of Vga(A). Representative acrylamide gels and chromatograms. 
(A) SDS-PAGE showing Vga(A) capture from cleared cell lysate using IMAC and washing / elution with a buffer 
containing 2M NaCl. (B) Chromatogram showing application of the IMAC eluate to an S200 GF column (C) SDS-PAGE 
analysis of fractions from GF. Lane numbers correspond to labelled fractions in chromatogram B. (D) Chromatogram 
showing application of second GF peak to a HiTrap desalting column. (E) Chromatogram to show binding and elution 
of Vga(A) to a resource S IE column. (F) SDS-PAGE analysis of fractions from desalting and IE. Lane numbers 
correspond to labelled fractions in chromatograms D and E  Abbreviations used to annotate the SDS-PAGE gel images 
are as follows; M denotes protein marker (Broad Range 2-212 kDa, New England Biolabs); conc., a protein that has 
been concentrated; I, insoluble cell fraction; S, soluble cell fraction; FT, flow through; W, wash; and E, eluate. 
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3.4.5 Expression of alternative ARE ABC-F proteins 
In order to investigate the mechanism of ARE ABC-F proteins other than Vga(A), I sought to 
establish conditions for the production of alternative ARE ABC-F proteins in a soluble form. 
To this end, a panel of expression constructs was generated for the production of ARE ABC-
F proteins fused to a variety of tags designed to enhance solubility and enable affinity 
purification. Specifically, small ubiquitin-like modifier (SUMO), maltose-binding protein 
(MBP), and glutathione S-transferase (GST) were chosen to be fused to the N-terminus of 
ARE ABC-F proteins. All three proteins have been reported to enhance solubility of the 
proteins to which they are fused. However, as it is not currently possibility to predict whether 
they will enhance solubility of the target protein, I chose to undertake an empirical approach 
and screen all three.  Cloning was performed using a traditional restriction enzyme-based 
approach and the orientation, sequence, and frame of each insert was verified by DNA 
sequencing. Expression constructs generated during this study are shown in Table 3.2. Small 
scale expression trials were performed using 8ZYM 4X Lac auto-induction media and the E. 
coli strain BL21-CodonPlus(DE3λ)-RIL, which was chosen as it contains an accessory plasmid 
encoding tRNAs shown to enhance expression of heterologous proteins derived from 
organisms with AT-rich genomes, such as S. aureus. 
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Table 3.2. Constructs generated for the expression of ARE-ABC protein-tag fusions. 
Plasmid ARE ABC-F gene Tag 
pET28a-Tev  vga(A) 
 vga(A)v 
 vga(E) 
 msr(A) 
 msr(C) 
 lsa(A) 
Cleavable N-terminal 10-histidine 
pET28a-SUMO  vga(A) 
 vga(A)v 
 vga(E) 
 msr(A) 
 msr(C) 
 lsa(A) 
Cleavable N-terminal 6-histidine 
and SUMO (Yeast SMT-3)  
pET28a-GST  vga(A) 
 vga(A)v 
 msr(A) 
 msr(C) 
 lsa(A) 
Cleavable N-terminal 6-histidine 
and Glutathione S-transferase 
(GST) 
pET28a-Mal  vga(A) 
 vga(E) 
 msr(A) 
 lsa(A) 
Cleavable N-terminal 6-histidine 
and maltose binding protein (MBP) 
pIVEX2.3d  vga(A)v 
 vga(E) 
 msr(A) 
Non-cleavable C-terminal 
6-histidine  
 
Expression of ARE-ABC-F proteins as N- or C- terminally his-tagged, GST tagged, and MBP 
tagged, fusions resulted solely in the production of insoluble protein (Figure 3.5, A, C, D, E, 
black arrows). However, expression of both Vga(A) and Lsa(A) with a SUMO tag resulted in 
the production of soluble protein (Figure 3.5 B, white arrows). Analysis of the SDS-PAGE band 
through to correspond to SUMO-Lsa(A) confirmed its identity and as a result, expression of 
the pET28a-SUMO-lsa(A) construct was scaled up and a protocol for purification was 
developed. 
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3.4.6 Purification of Lsa(A) 
Lsa(A) has a lower predicted pI than Vga(A) (5.77 vs. 9.06) and as a result purification of 
Lsa(A) was not complicated by a propensity to bind nucleic acid (Section 3.4.3). Lsa(A) was 
therefore amenable to purification using a simplified three-step strategy. Following initial 
capture and purification by IMAC using Ni-NTA agarose (Figure 3.6 A, page 76), 6-histidine 
and SUMO tags were cleaved, and the protein was reapplied to the IMAC column. Untagged 
Lsa(A) exhibited low affinity for Ni-NTA and was separated from the majority of cleaved 
histidine-SUMO tag using an imidazole gradient (Figure 3.7 B).  Finally Lsa(A) was applied to 
an S200 GF column, where it eluted as a single peak (Figure 3.7 C) corresponding to 
homogenous Lsa(A) (Figure 3.7 D). Using this methodology, yields of ~12mg of Lsa(A) per litre 
of culture were obtained. 
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Figure 3.5. SDS-PAGE analysis of expression trials of ARE ABC-F proteins conducted using E. coli BL21 (DE3) RIL 
transformed with constructs based on vectors; (A) pET28a-Tev; (B) pET28a-SUMO; (C) pET28aGST; (D) 
pET28aMal; (E) pIVEX2.3d. Proteins overexpressed in the insoluble and soluble fractions are indicated by black 
and white arrows respectively. Isoleucile tRNA synthetase (IleS) and spectinoymcin 3’ adenyltransferase (spw) 
were included as postivie controls for the production of  soluble protein. Abbreviations used to annotate the SDS-
PAGE gel images are as follows; M denotes protein marker (Broad Range 2-212 kDa, New England Biolabs); I, 
insoluble cell fraction; S, soluble cell fraction.  
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Figure 3.6. Purification of Lsa(A). Representative SDS-PAGE images showing analysis of (A) Initial capture using 
IMAC, (B) removal of cleaved 6-histidine-SUMO tag by IMAC (11 kDa), (C) gel filtration using an S200 column as 
shown in representative chromatogram D.  Abbreviations used to annotate the SDS-PAGE gel images are as 
follows; M denotes protein marker (Broad Range 2-212 kDa, New England Biolabs); Pre, protein sample prior to 
loading onto specified column; I, insoluble cell fraction; S, soluble cell fraction; FT, flow through; W, wash; and E, 
eluate.  
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3.4.7 Screening for crystallisation conditions 
Once methodology to purify Vga(A) and Lsa(A) to homogeneity was established, I attempted 
to find conditions for crystallisation of each protein with the intention of performing 
structural studies.  Vga(A) and Lsa(A) were amenable to concentration in 50 mM HEPES (pH 
7.4), 300 mM NaCl, 1 mM DTT buffer to a maximum of 5 and 15 mg/ml respectively. 
Concentrated protein was used to set up eight commercially available crystallisation screens 
as detailed in Section 2.9. The protein concentration, incubation temperature, and ratio of 
crystallisation reagent to protein in each drop, was varied for each screen. Additionally, 
screens were established in the presence and absence of the non-hydrolysable ATP analogue 
AMP-PNP. During this study, no conditions conducive to crystallisation of Vga(A) or Lsa(A) 
were found. For both Vga(A) and Lsa(A), the majority of wells showed the formation of 
granular precipitates within three days of incubation, either at 4°C or 25°C. The addition of 
AMP-PNP did not appear to alter the rate at which the proteins precipitated and did not lead 
to formation of any needles, microcrystals or phase separation. 
3.4.8 Degradation of Vga(A) and Lsa(A) 
Throughout this study I repeatedly observed a loss of activity (assessed by the ability to 
protect transcription-translation assays from antibiotic inhibition, Section 4.4.3) following 
storage of Vga(A) and Lsa(A) at 4°C. Lsa(A) maintained its activity for ~4 days, whereas Vga(A) 
only remained active for ~2 days. As a result, all functional studies described in Chapter 4 
were performed immediately following purification or using protein that had been stored at 
-80°C and thawed only once. Analyis of protein samples following storage at 4°C by SDS-PAGE 
revealed extensive degradation of the full-length proteins (Figure 3.7 A and B). Addition of 
neither protease inhibitors nor various compounds to the buffer during storage of Lsa(A) was 
able to prevent degradadation without causing precipitation of the protein (Figure 3.7 B). 
Analysis of degraded Vga(A) by SDS-PAGE (Figure 8A) revealed numerous protein fragments 
ranging in size from 25 to 40 kDa (Figure 3.7 A). As the N-terminal ABC, linker, and C-terminal 
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ABC domains of Vga(A) have masses of 17, 15 and 30 kDa respecitvely, the size range of 
fragments suggest non-specific cleavage within the linker, generating trucated protein 
composed of one ABC and differing lengths of linker. Peptide-mass fingerprinting analysis of 
the two distinct SDS-PAGE bands resulting from Lsa(A) degradation also revealed no distinct 
site of cleavage, with each band containing fragments corresponding to all three domains.  
 
 
 
Figure 3.7. SDS-PAGE analysis of protein degradation. (A) Vga following 7 days storage at 4°C and (B) Lsa(A) 
following 5 days storage at 4°C. Several additives were screened for ability to protect Lsa(A) from degradation; 
1, no additive; 2, 10% glycerol, 3, 0.1% (v / v) Tween 20; 4, 1mM MgCl2; 5, cOmplete EDTA-free protease inhibitors 
(Roche); 6, 5mM Proteoloc protease inhibitors (Expedeon); 7, 5mM Proteoloc + EDTA (Expedeon); 8, 1mM EDTA; 
9, 5% (v/v) EtOH. The final three conditions, 7, 8 and 9 caused precipitation of the protein.  
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3.4.9 Thermal stability of Vga(A)  
In order to optimise buffer conditions for future work requiring Vga(A), I assessed the 
thermal stability of the protein in the presence of a range of additives. Measurement of 
intrinsic tryptophan fluorescence is an established technique used to follow protein 
unfolding, as the maximum emission wavelength of tryptophan differs depending on its 
environment (Eftink, 1994). Measurement of the ratio of fluorescence intensities at 350 nm 
and 330 nm during heating of the sample allows determination of the protein melting point 
(Tm, where half of the protein is folded and the other half is unfolded). The data revealed 
that Vga(A) with no additives was marginally stable at 37°C (Tm of 37.8°C, Figure 3.8, Table 
3.3). Kosmotropes, glycerol and AMP-PNP increased the thermal stability of the protein, 
whereas chaotropes destabilised Vga(A) (Figure 3.8, Table 3.3). Of specific note was the 
addition of ammonium sulphate and glycerol, both of which increased Vga(A) thermal 
stability by more than 5°C. Future work requiring Vga(A) may benefit from inclusion of these 
additives in storage buffers. 
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Figure 3.8. The effect of buffer additives on thermal stability of Vga(A). Vga(A) concentrated to 5 mg /ml (83 
μM) was in GF buffer (50mM HEPES pH 7.4, 300 mM NaCl, 1 mM DTT), supplemented with additives to 500 mM, 
with the exception of AMP-PNP which was at 0.1 mM and glycerol (v/v) as shown below.  
 
 
Table 3.3. Melting temperatures (Tm) of Vga(A) supplemented with a variety of buffer additives. Tms were 
determined from the maximum of the first derivative of data shown in in Figure 3.8. 
Additive Concentration Tm (°C) 
No additive - 37.8 
AMP-PNP 0.1 mM 39.3 
(NH₄)₂SO₄, 500 mM 46.4 
KCH3COO 500 mM 40.7 
NaCl 500 mM 39.3 
LiCl 500 mM 37.7 
CaCl2 500 mM 31.2 
NaSCN 500 mM - 
Glycerol  10% (v / v) 40.4 
Glycerol 20% (v / v) 43 
Glycerol 40% (v / v) 43 
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3.5 Discussion 
An important step in attempts to elucidate the mechanism of ABC-F mediated antibiotic 
resistance is the production of homogenously purified proteins that are representative of 
the group. As Vga(A) is the best characterised of the ARE ABC-F proteins, I began this study 
with an attempt to replicate the expression and purification conditions previously described 
by Jacquet et al. (2008). However, despite numerous attempts, treatment of Vga(A) with 
Benzonase and protamine sulphate did not remove contaminating nucleic acid efficiently 
enough to facilitate reproducible purification of the protein. As a result, an alternative 
method of purification was developed, which uses high concentrations of sodium chloride to 
dissociate nucleic acid from Vga(A) and results in a marginally increased yield in comparison 
to that of Jacquet et al. (3 mg / l vs 1-2 mg / l). Similar methodology has previously been used 
in the purification of viral nucleocapsid proteins that specifically bind RNA (Ariza et al., 2013, 
Carter et al., 2012). However, the propensity of Vga(A) to bind nucleic acid throughout 
purification does not appear to be of functional significance. Although a ribosomal protection 
based resistance mechanism may involve interaction of Vga(A) directly with rRNA, 
purification of Lsa(A), which elicits a similar resistance phenotype to Vga(A) was not 
complicated by nucleic acid contamination. Instead, Vga(A) nucleic acid binding is likely 
non-specific and the result of its high isoelectric point (pI, predicted 9.06), a property not 
universally conserved amongst Vga-type determinants or ARE ABC-F proteins in general 
(Table 3.4).  
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Table 3.4. Predicted pIs of ARE ABC-F proteins found in non-producer organisms. The pI of each protein was 
predicted from its primary sequence using the ProtParam server (Wilkins et al., 1999). 
ARE ABC-F  Predicted pI 
Vga(A) 9.06 
Vga(A)v 6.54 
Vga(B) 8.89 
Vga(C) 8.69 
Vga(D) 7.26 
Vga(E) 6.21 
Msr(A) 6.05 
Msr(C) 9.12 
Msr(D) 6.28 
Msr(E) 6.02 
Lsa(A) 5.77 
Lsa(B) 5.79 
Lsa(C) 8.76 
Lsa(E) 6.36 
 
The optimised methodology for purification of Vga(A) and Lsa(A) described in this chapter 
yielded homogenously purified protein that was suitable for functional studies as outlined in 
Chapter 4. However, as there has been no structural determination of any ARE ABC-F protein 
to date, I attempted to find conditions for crystallisation of Vga(A) and Lsa(A) to permit 
structural studies. Despite conducting numerous screens under a variety of conditions, with 
or without ligand, no conditions conducive to crystallisation were found.  
Recently, the structure of the bacterial ABC-F protein EttA was determined by X-ray 
crystallography and cryro-electron microscopy (cry-EM) (Boel et al., 2014, Chen et al., 2014), 
providing the first structural information regarding an ABC-F protein. EttA, which regulates 
bacterial translation in response to changes in the relative levels of cellular ATP and ADP, 
shares 21% and 26% amino acid identity with Vga(A) and Lsa(A) respectively. Functional 
insights into the ARE ABC-F proteins obtained from analysis of the EttA structure are outlined 
in chapter 4, however, EttA also serves to demonstrate that despite the presence of a flexible 
interdomain linker, ABC-F proteins do possess the structural uniformity required for 
formation of X-ray diffracting crystals, even in the absence of bound nucleotide. It is likely 
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therefore, that the inability to find conditions to promote crystallisation of Vga(A) and Lsa(A) 
during this study is the result of a factor other than intrinsic disorder of either protein. 
Degradation of both Vga(A) and Lsa(A) at 4°C provides a simple alternative explanation. 
Although crystal screens were established within a day of purification, in the absence of any 
crystallisation condition that could effectively stabilise the protein and prevent degradation, 
the protein sample would quickly become heterogeneous and unable to form crystals. The 
cause of protein degradation observed during this study is not clear, neither the addition of 
a variety of commercially available protease inhibitor cocktails during and after purification, 
nor purification under aseptic conditions, prevented degradation. It is of note that truncated 
fragments resulted from cleavage of the interdomain linker in both Vga(A) and Lsa(A). As 
structural studies of the ABC-F EttA have revealed inherent flexibility in the interdomain 
linker and as proteases preferentially bind and cleave flexible or unfolded domains (Fontana 
et al., 2004), it is likely that the degradation pattern of Vga(A) and Lsa(A) is the result of 
cleavage of the interdomain linker by trace amounts of contaminating protease that are not 
sufficiently inhibited by the protease inhibitors tested in this study. 
Stabilisation of the globular structure of Vga(A) and Lsa(A) may decrease flexibility of the 
linker domain and thereby reduce proteolytic degradation. To this end, I assessed the 
thermal stability of Vga(A) under various conditions. At physiological temperatures purified 
Vga(A) was found to be partially unfolded, exhibiting a Tm of close to 38°C. Although 
examples of proteins that are unstructured in solution but are capable of mediating 
antibacterial resistance can be found, as exemplified by the heavy metal resistance 
determinants PcoE and SilE (Zimmermann et al., 2012, Gupta et al., 1999), the mechanisms 
by which ARE ABC-F proteins are proposed to act do not immediately suggest a role for 
transitions between a folded and unfolded state. It is therefore likely that the low Tm of 
Vga(A) is the result of sub-optimal buffer composition failing to adequately replicate the 
staphylococcal intracellular environment. As the thermal stability of Vga(A) was improved by 
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addition of kosmotropes and glycerol, future buffers for crystallographic studies of Vga(A) 
should be altered accordingly.  
3.6 Conclusions 
Work outlined in this chapter describes optimisation of methodology for the expression and 
purification of two ARE ABC-F proteins; Vga(A) and Lsa(A). Expression of Lsa(A) was facilitated 
through fusion of a solubility enhancing SUMO tag to the N-terminus of the protein and 
purification of Vga(A) was reliant upon successful removal of contaminating nucleic acid. 
Degradation of the two proteins was likely the result of proteolytic cleavage of the 
interdomain linker and may be the cause of a failure to identify conditions for crystallisation. 
The homogenously purified proteins generated using methods described in this chapter were 
used to conduct functional studies as described in Chapter 4.
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4. Investigating the mechanism of ARE ABC-F mediated antibiotic 
resistance  
4.1 Abstract 
The mechanism by which ARE ABC-F proteins mediate resistance to several antibiotic classes 
that target the 50S subunit of the bacterial ribosome is not understood. However, two 
competing hypotheses exist; antibiotic efflux and ribosomal protection. Here, this 
mechanism was investigated using a combination of biochemical and bacteriological 
techniques. Using bacteriological assays, the resistance phenotypes mediated by ARE ABC-F 
proteins were found to be negated by protection of the ribosome through methylation and 
shown to correlate with the overlap of antibiotic ribosome binding sites. For the first time, 
vga(A) and lsa(A) were shown to mediate cross-resistance to select antibiotics of the 
macrolide class. Preparation of staphylococcal cell extracts suitable for 
transcription-translation (T/T) assays allowed the function of ARE ABC-F proteins Vga(A) and 
Lsa(A) to be assessed in the absence of a cell-membrane. Addition of Vga(A) and Lsa(A) to 
staphylococcal T/T reactions subject to antibiotic inhibition caused a drug specific, dose-
dependent, rescue of translation. Several previously described Vga(A) and Lsa(A) conferred 
phenotypes were recapitulated in T/T assays, thereby verifying that rescue of translation 
observed in vitro is representative of the action of these proteins in whole cells. Finally, 
ribosome binding assays using radiolabelled lincomycin showed Lsa(A) to be capable of 
displacing the drug from staphylococcal ribosomes. Collectively, the experiments outlined in 
this chapter provide the first direct evidence to support a mechanism of ARE ABC-F resistance 
based on ribosomal protection. 
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4.2 Introduction 
Two models to explain the action of ARE ABC-F proteins have been suggested (Kerr et al., 
2005, Reynolds et al., 2003). In the first model, these proteins function as classical ABC 
transporters, associating with as yet unknown trans-membrane domains and use energy 
released by ATP hydrolysis to drive transport of antibiotics out of the cell. Alternatively, in 
the second model, ARE ABC-F proteins act to reduce the accessibility or affinity of the 
antibiotic binding sites within the 50S ribosomal subunit, thereby protecting the translational 
machinery. Experimental evidence permitting a definitive conclusion regarding the 
mechanism by which they mediate resistance is lacking; however, ARE ABC-F resistance 
determinants are most frequently cited as efflux proteins in the literature (Matsuoka et al., 
1993, Olano et al., 1995, Chesneau et al., 2005, Nunez-Samudio and Chesneau, 2013).  
The predominance of the efflux hypothesis perhaps stems from the characterisation of the 
first ARE ABC-F protein to be described; the macrolide and streptogramin B resistance 
determinant Msr(A) (Ross et al., 1989, Ross et al., 1990). The dual observations of Msr(A) 
homology to ABC-transporters and Msr(A) induced, ATP-dependent, decreased 
accumulation of erythromycin, understandably led to the conclusion that Msr(A) and 
subsequently other ARE ABC-F proteins mediate resistance through active efflux. However, 
the paper detailing this work included a cautionary note; that decreased accumulation of 
erythromycin could also result from ribosomal protection, a hypothesis that was later proven 
experimentally (Reynolds et al., 2003). More recently, as an increasing number of ARE ABC-
F proteins have been described, a correlation between the resistance phenotypes conferred 
by ARE ABC-F determinants and the positions at which antibiotics bind within the 50S 
ribosomal subunit has become apparent (Kerr et al., 2005, Dorrian, 2009). This is evident 
when comparing vga- and lsa- type determinants, which confer resistance to antibiotics from 
structurally unrelated classes that bind overlapping sites within the peptidyl-transferase 
centre, with msr-type genes, which show specificity for antibiotics binding within the peptide 
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exit tunnel. This observation, coupled with the fact that several ABC-F proteins not involved 
in antibiotic resistance have recently been shown to interact directly with the ribosome or 
with ribosomally-associated proteins (Kerr, 2004), has made the hypothesis that that ARE 
ABC-F proteins mediate ribosomal protection increasingly plausible.  
Methodology for the characterisation of antibiotic resistance proteins that act to protect 
translation has been previously established. For example, the mechanism underlying 
horizontally-transmissible fusidic acid resistance was initially determined using 
staphylococcal T/T assays, which showed FusB-type proteins were able to restore translation 
in the presence of fusidic acid (O'Neill and Chopra, 2006). Subsequently, pull-down 
experiments using immobilised FusB and staphylococcal cell-lysates identified a direct 
interaction with elongation factor-G (EF-G), the target of fusidic acid (O'Neill and Chopra, 
2006). Building on these findings, an X-ray crystallography based structural characterisation 
of two FusB-type proteins has been completed (Cox et al., 2012, Guo et al., 2012), the 
interaction with EF-G has been characterised (Cox et al., 2013), and an appreciation of the 
molecular basis of fusidic acid resistance mediated by FusB-type proteins now exists. 
Similarly, characterisation of the tetracycline ribosomal protection proteins (RPPs) began 
with cell-free protein synthesis assays that showed extracts derived from bacteria expressing 
the RPP Tet(M) were resistant to tetracycline inhibition, whilst extracts containing the 
tetracycline efflux protein, Tet(L), were not (Burdett, 1986). This mechanism was studied 
further using ribosome binding assays in which the ability of Tet(M) and Tet(O) to displace 
bound tetracycline was discovered (Trieber et al., 1998, Burdett, 1996), and, more recently, 
the structure of both Tet(M) and Tet(O) in complex with the E. coli ribosome has been 
determined using cryo-electron microscopy (cryo-EM) (Arenz et al., 2015, Li et al., 2013).  
Due to the paucity of evidence in support of ARE ABC-F mediated antibiotic efflux, and the 
increasing amount of indirect evidence indicating a mechanism of ribosomal protection, I 
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aimed to use the established biochemical methodology outlined above, in-tandem with 
bacteriological assays to investigate ARE ABC-F resistance phenotypes, to provide a definitive 
explanation of the ARE ABC-F resistance mechanism.   
4.3 Aims  
Work described in this chapter aimed to determine the mechanism by which ARE ABC-F 
proteins mediate antibiotic resistance.  
4.4 Results 
4.4.1 Probing the correlation between ARE ABC-F resistance phenotypes and the 
binding sites of 50S targeted antibiotics. 
In initial experiments using staphylococci expressing the Vga(A) protein, I sought preliminary 
support for a mechanism of resistance involving either ribosomal protection or efflux. 
Previous studies have noted a correlation between the resistance phenotypes mediated by 
ARE ABC-F proteins and the extent of overlap between binding sites of protein synthesis 
inhibitors within the 50S subunit (Reynolds et al., 2003, Kerr et al., 2005). A testable 
prediction is that, if ARE ABC-F proteins do mediate resistance through ribosomal protection, 
they would likely offer cross-resistance to further classes of structurally-unrelated antibiotic 
that bind the ribosome in close proximity to their target antibiotics.  
In order to test this hypothesis, the ARE ABC-F genes msr(A), lsa(A), and vga(A), were cloned 
using the S. aureus / E. coli shuttle vector pEPSA5 (Forsyth et al., 2002) and transferred into 
S. aureus RN4220. Whilst this study was in progress, a paper detailing a mutational 
characterisation of the Vga(A) interdomain linker was published (Lenart et al., 2015), in which 
an expanded spectrum mutant of Vga(A), Vga(A)K219T, was characterised. As Vga(A)K219T 
conferred increased levels of resistance to lincosamides and pleuromutilins, it follows that it 
may exert an effect on a larger area of the PTC than wild-type Vga(A) and therefore provide 
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an increased chance of finding previously undescribed cross-resistance. Consequently, 
pEPSA5-vga(A) was subjected to site-directed mutagenesis to generate pEPSA5-vga(A)K219T 
and following confirmation of the mutation by sequencing, pEPSA5-vga(A)K219T was included 
in the screen. Subsequently, the MICs of numerous protein synthesis inhibitors were 
determined against the four constructed strains and RN4220 containing only the pEPSA5 
vector (Table 4.1). 
As previously described, strains expressing vga(A) showed cross-resistance to streptogramin 
A (64 fold, virginiamycin M), lincosamide (8 fold lincomycin) and pleuromutilin (4 fold 
retapamulin) antibiotics. Strains expressing vga(A)K219 exhibited resistance to the same 
classes, but gained the ability to confer tiamulin resistance (512 fold) and showed elevated 
levels of resistance to lincomycin (LNC, 128 fold) and retapamulin (1024-fold). Similarly, 
expression of lsa(A) conferred resistance to virginiamycin M (VGM, 64 fold), LNC (64 fold), 
retapamulin (128 fold), and tiamulin (512 fold). In contrast, of the compounds tested, msr(A) 
only conferred resistance to erythromycin (256 fold). No cross-resistance to, fluorphenicol, 
blasticidin S, sparsomycin, or the 16-membered macrolides tylosin and spiramycin, was 
observed amongst any of the tested strains. However, expression of vga(A) was shown to 
elicit reduced susceptibility to the 16-member macrolides leucomycin A1 (4 fold) and 
carboymycin (4 fold), antibiotics with binding sites predicted to partially overlap that of VGM 
(Di Giambattista et al., 1987). In contrast, lsa(A) mediated reduced susceptibility to 
carbomycin (4 fold), but not leucomycin A1. To my knowledge this is the first report of a vga-
type or lsa-type resistance determinant mediating any degree of macrolide resistance. 
   
 
 
 
Table 4.1. Activity of protein synthesis inhibitors that target the PTC and peptide exit tunnel against S. aureus RN4220 expressing the ARE ABC-F genes msr(A), lsa(A), vga(A) and 
vga(A)K219T. All MICs were determined in the presence of 2% xylose in order to induce expression from the pT5X promoter of plasmid pEPSA5. 
Antibacterial 
compound 
MIC (µg/ml) against S. aureus RN4220 strain 
pEPSA5 (no insert) 
 
pEPSA5-msr(A) pEPSA5-lsa(A) pEPSA5-vga(A) pEPSA5-vga(A)K219T 
Virginiamycin M 1 1 64 64 64 
Lincomycin 0.25 0.125 8 2 32 
Retapamulin 0.03125 0.03125 4 0.125 32 
Tiamulin 0.25 0.125 128 0.125 64 
Erythromycin 0.5 128 0.5 0.5 0.5 
Linezolid 2 2 2 2 2 
Puromycin 8 4 8 8 8 
Blasticidin S 128 128 128 128 128 
Sparsomycin 32 32 32 32 32 
Fluorphenicol 4 4 4 4 4 
Leucomycin A1 0.25 0.25 0.25 1 1 
Carbomycin 0.5 0.5 1 2 2 
Tylosin 0.5 0.5 0.5 0.5 0.5 
Spiramycin 1 1 1 1 1 
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4.4.2 Function of vga(A) in cells with protected ribosomes 
A common feature of antibiotic resistance mechanisms involving efflux is that, when co-
resident in a bacterial cell with another determinant mediating resistance to the same 
antibacterial agent but which acts to protect the drug target, a synergistic or additive 
increase in resistance is observed. For example, S. aureus strains in which the tetracycline 
RPP, tet(M), and efflux pump, tet(K), are both present have been shown to engender higher 
tetracycline MICs than strains harbouring only one of these resistance determinants 
(Trzcinski et al., 2000). By contrast, no such enhancement in antibiotic resistance may be 
observed when two resistance determinants, both of which act at the level of the drug target, 
co-exist in a bacterial cell. As exemplified by the fact that carriage of both an endogenous 
fusA gene possessing mutations resulting an production of a fusidic acid resistant EF-G 
protein and a gene encoding FusB does not lead to a synergistic interaction between the two 
resistance mechanisms. Instead the level of resistance in strains co-expressing these 
resistance mechanisms is determined by the protein giving highest protection (O'Neill and 
Chopra, 2006). It is therefore reasonable to assume that failure of Vga(A) to exhibit an 
additive or synergistic effect when co-resident in a cell with a ribosomal protection 
mechanism of antibiotic resistance would suggest that Vga(A) does not mediate resistance 
by efflux.  
In order to establish a system in which this hypothesis could be assessed, I utilised the 
Cfr-ribosomal methylase. The cfr gene encodes an rRNA methyltransferase that methylates 
23S rRNA at position 8 of adenine 2503 (E. coli numbering), thereby protecting ribosomes 
from binding of several antibiotic classes including those encompassed within the spectrum 
of activity of Vga(A) (Long et al., 2006). The cfr gene was cloned into plasmid pEPSA5 under 
control of the inducible pT5X promoter and both pEPSA5 and pEPSA5-cfr were transformed 
into S. aureus CYL557. The vga(A) gene was cloned into plasmid pLL39 under control of the 
strong staphylococcal cap1a promoter and transformed into S aureus strain CYL557, 
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whereupon it integrated into the chromosome. Integration was confirmed by PCR using a 
primer pair specific for vga(A) and the ϕ11 attP site on the S. aureus chromosome. 
Subsequently, pEPSA5 and pEPSA5-cfr were separately transformed into strain 
CYL557containing integrated vga(A). 
Susceptibility to virginiamycin M, and linezolid was determined for S. aureus RN4220 
expressing vga(A) alone, or vga(A) and cfr. As expected, expression of vga(A) mediated 
resistance to virginiamycin M, but not to linezolid, whilst expression of cfr alone gave 
resistance to both drugs (Table 4.5). Co-expression of both resistance determinants did not 
confer a decrease in susceptibility for any of the drugs beyond that exhibited by the strain 
solely expressing cfr, establishing that co-expression of the two resistance proteins does not 
produce an additive or synergistic effect (Table 4.5), and further reinforcing the idea that 
resistance is more likely mediated through ribosomal protection than efflux. 
Table 4.5. The effect of Cfr-mediated ribosomal methylation on vga(A).  
 
Antibacterial 
compound 
MIC (µg/ml) against S. aureus CYL557strain 
pEPSA5  
(no insert) 
pLL39-vgaA pEPSA5-cfr pEPSA5-cfr 
+pLL39-vgaA 
Virginiamycin M 1 64 128 128 
Linezolid 2 2 8 8 
 
4.4.3 The activity of Vga(A) and Lsa(A) in transcription-translation assays  
Initial bacteriological work (Sections 4.4.1 and 4.4.2) was indicative of an ARE ABC-F 
mechanism based on ribosomal protection and prompted investigations to determine 
whether ARE ABC-F proteins could mediate antibiotic resistance in a system where efflux 
was not possible. This system was established through the generation of staphylococcal S30 
extracts, and their use to perform T/T assays (Section 2.5). During T/T assays, plasmid 
pC19Saluc provided a template for the expression of firefly luciferase and subsequent 
93 
 
 
9
3 
addition of luciferin allowed the level of translation to be assessed through measurements 
of luminescence. As I observed that different preparations of S30 extract showed varying 
levels of activity, all results described below are expressed as a percentage of an uninhibited 
positive control, run in parallel, which contained no exogenous proteins or antibiotics. 
Homogenously purified Vga(A) (Section 3.4.4) and Lsa(A) (Section 3.4.6) were introduced into 
inhibited T/T assays and the ability of these proteins to rescue translation from antibiotic 
inhibition was assessed.  
Introduction of 4 μM purified Vga(A) into T/T assays inhibited with the IC90 of VGM resulted 
in a restoration of translational activity to 59% of the uninhibited control (Figure 4.1 A, 
columns 1, 3 and 5). This effect was Vga(A) specific, as neither addition of the fusidic acid 
resistance protein FusB (Section 2.4.5) nor heat-denatured Vga(A) were able to protect 
translation (Figure 4.1 A, columns 4 and 10). Furthermore, addition of 4 μM Vga(A) to T/T 
assays inhibited with the IC90 of fusidic acid did not rescue activity, demonstrating Vga(A)-
mediated protection as specific to VGM (Figure 4.1 A, columns 8 and 9). Protection of 
translation from VGM by Vga(A) occurred in a dose-dependent manner between 1 and 4 μM 
Vga(A) (Figure 4.1 B). However, restoration was not complete and plateaued at 59% with no 
increase observed upon further addition of Vga(A) (Figure 4.1 B).  
In order to investigate whether the ability to protect staphylococcal translation in vitro was 
a common property of ARE ABC-F proteins and not exclusive to Vga(A), the phylogenetically 
distant ARE ABC-F protein Lsa(A) (25 % amino acid identity) was titrated into staphylococcal 
S30 extracts inhibited with an IC90 of VGM (Figure 4.1 C) or LNC (Figure 4.1 D). As with Vga(A), 
rescue of translation was concentration dependent, but not complete, reaching a maximum 
of 49% and 68% for VGM and LNC inhibited reactions respectively (Figure 4.1 C and 1D). A 
lower concentration of Lsa(A) was required to restore translational activity in LNC inhibited 
reactions (Figure 4.1 D) than those knocked down with VGM (Figure 4.1 C). As with Vga(A), 
heat denaturation of Lsa(A) resulted in a loss of ability to protect translation from VGM 
(Figure 4.1 A, columns 3, 6, 7). 
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Figure 4.1. Vga(A) and Lsa(A) rescue staphylococcal translation from antibiotic inhibition. (A) Numbered columns indicate 
reactions containing the following: 1, control with no exogenous protein or antibiotic; 2, 4 μM Vga(A) but no antibiotic, 3; 
IC90 of virginiamycin M (VGM) with no exogenous protein; 4, IC90 of VGM with 4 μM heat-denatured Vga(A) (Denat.); 5, IC90 
of VGM with 4 μM Vga(A); 6, IC90 of VGM with 4 μM heat-denatured Lsa(A); 7, IC90 of VGM with 4 μM Vga(A); 7, IC90 of VGM 
with 4 μM Lsa(A); 8, IC90 of fusidic acid (FA) with no exogenous protein; 9, IC90 of fusidic acid (FA) with 4 μM Vga(A); 10, , 
IC90 of VGM with 4 μM FusB. (B) The effect of Vga(A) (0–6 μM) on T/T inhibited by an IC90 of VGM. (C) The effect of Lsa(A) 
(0–6 μM) on T/T inhibited by an IC90 of VGM. (D) The effect of Lsa(A) (0–4 μM) on T/T inhibited by an IC90 of LNC. All data 
points derive from assays conducted at least in triplicate. All error bars correspond to standard deviations. 
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To provide confirmation that the observed ability of ARE ABC-F proteins to protect an in vitro 
translation assay from antibiotics reflects the activity of these proteins in whole cells, and to 
further explore this phenomenon of protection, I sought to recapitulate in the T/T assay 
several phenotypes that have been associated with these proteins in bacteria.   
The Vga(A) protein is not functional in E. coli, failing to confer any reduction in susceptibility 
to streptogramin A antibiotics even when detectably overproduced in this bacterium 
(Jacquet et al., 2008). This result was mirrored in an in vitro T/T assay using E. coli S30 extract; 
addition of increasing concentrations of Vga(A) (Figure 4.2 A) or Lsa(A) (Figure 4.2 B) to 
maximum of 4 μM into T/T reactions inhibited with ≥IC90 of virginiamycin M produced no 
rescue of translation. 
It has previously been demonstrated that substitution for glutamine of the catalytic 
glutamate residue following the Walker B motif in either nucleotide binding domain of 
Vga(A) results in a non-functional protein incapable of mediating resistance to virginiamycin 
M in cells of Staphylococcus epidermidis (Jacquet et al., 2008). I confirmed that this also holds 
true in S. aureus, with expression of Vga(A)E105Q in S. aureus RN4220 having no effect on 
virginiamycin M susceptibility (Figure 4.2 C). This same loss of ability of Vga(A)E105Q to mediate 
virginiamycin M resistance was also seen in vitro, with addition of up to 4 μM purified 
Vga(A)E105Q to a T/T assay employing S. aureus S30 extract producing no restoration of 
translational activity (Figure 4.2 D).  
A single amino acid substitution (K219T) in the linker region between the two nucleotide 
binding domains of Vga(A) has recently been reported to increase the level of phenotypic 
resistance to lincosamides from low-level (4-fold) to high-level (64-fold) (Figure 4.2 E) (Lenart 
et al., 2015). This shift in resistance profile was successfully recapitulated in the S. aureus T/T 
assay; addition of purified Vga(A)K219T to a T/T reaction inhibited with lincomycin resulted in 
restoration translation activity to ~30% of the uninhibited control, whilst 4 μM wild-type 
Vga(A) did not protect translation against lincomycin (Figure 4.2 F). 
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Figure 4.2. T/T assay results reconstitute previously described phenotypes.  Addition of increasing concentrations of exogenous (A) Vga(A) or (B) Lsa(A) to a coliform T/T reaction containing an IC90 of 
VGM. (C) Table showing MIC values of VGM against S. aureus RN4220 expressing wild-type vga(A), an ATPase deficient vga(A)E105Q mutant, or transformed with the pEPSA5 plasmid only.   (D) Addition 
of exogenous Vga(A)E105Q, or wild-type Vga(A), to a staphylococcal T/T reaction containing an IC90 of VGM. (E) Table showing MIC values of lincomycin against S. aureus RN4220 expressing wild-type 
vga(A), an expanded spectrum vga(A)K219T mutant, or transformed with the pEPSA5 plasmid only. (F) Addition of the exogenous Vga(A)K219T, or wild-type Vga(A), to a staphylococcal T/T reaction inhibited 
with a >IC90 of LNC. Data points derive from assays conducted at least in triplicate. 
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4.4.4 The activity of Lsa(A) in ribosome binding assays 
As both Vga(A) and Lsa(A) were shown to protect staphylococcal translation from antibiotic 
inhibition in vitro, it follows that these proteins may function by preventing the binding of 
antibiotics to the ribosome, or by causing dissociation of the drug once it has bound. As 
previous binding assays to investigate the function of tetracycline RPPs had used 
radiolabelled drug to follow binding, and as the neither VGM or LNC are intrinsically 
fluorescent attempts were made to procure radiolabelled VGM and LNC. As radiolabelled 
VGM was not commercially available, the ability of purified Lsa(A) to mediate changes in 
binding of tritium-labelled lincomycin (3H-LNC) to ribosomes was assessed. In order to 
establish an assay suitable to investigate this hypothesis, staphylococcal ribosomes were 
purified (Section 2.6.1) and quantified through comparisons of ribosomal protein L2 and 16S 
rRNA to known quantities of BSA (Figure 4.3 A) and RNA ladder (Figure 4.3 B). All binding 
assays were performed using a 2x molar excess of 3H-LNC to ribosomes in the presence of 
ATP. As I observed that radioactivity of 3H-LNC decreased over time, all results described 
below are expressed as a percentage of a positive control containing ribosomes and 3H-LNC, 
but no exogenous protein or unlabelled drug. 
Pre-incubation of staphylococcal ribosomes with between 1:1 and 8:1 Lsa(A) : ribosome 
molar ratios caused a dose-dependent decrease in ribosome associated 3H-LNC, before 
reaching a plateau past which addition of Lsa(A) at did not cause further reduction in binding 
(Figure 4.4 A [i], page 99). Addition of an 8-fold excess of Lsa(A) (0.5 μM ribosomes, 4 μM 
LNC) resulted in the largest decrease in LNC binding, to 43% of the level observed in Lsa(A) 
free ribosomes (Figure 4.4  A [ii]). In comparison, pre-incubation of ribosomes with 4 μM BSA 
or 4 μM denatured Lsa(A) did not cause any reduction in levels of ribosomally associated 3H-
LNC (Figure 4.4  A [ii]), whereas addition of a 50-fold excess of unlabelled LNC resulted in 
almost complete removal of 3H-LNC binding (Figure 4.4 A [ii]).  
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In order to test whether Lsa(A) might displace bound LNC, 3H-LNC was pre-incubated with 
ribosomes prior to the addition of 4 μM Lsa(A). Subsequent addition of Lsa(A) caused 
dissociation of 3H-LNC, resulting in a 73% reduction in the amount of ribosomally associated 
drug in comparison to the protein-free control (Figure 4.4 B). BSA had no effect on the 
release of 3H-LNC from ribosomes and 3H-LNC was exchanged with unlabelled LNC, resulting 
in almost complete removal of the radiolabelled compound from the ribosome (Figure 4.4 
B).  
 
 
 
Figure 4.3. Purification and quantification of staphylococcal ribosomes. Purified staphylococcal ribosomes were 
quantified through comparisons of ribosomal protein L2 with known quantities of BSA (A), and 16S rRNA with RNA ladder 
RiboRuler HR. 
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Figure 4.4. Lsa(A) protects ribosomes from 3H-LNC binding and displaces pre-bound drug. (Ai) Pre-incubation of increasing 
concentrations of Lsa(A) with 0.5μM staphylococcal ribosomes. (ii) Pre-incubation of 0.5μM ribosomes with either; a 50x 
excess of unlabelled LNC (Cold LNC), 4 μM BSA, 4 μM Lsa(A), or 4 μM denatured Lsa(A). (B) Addition of either a 50x excess 
of unlabelled LNC, 4 μM Lsa(A), or 4 μM BSA to staphylococcal ribosomes that have been pre-incubated with LNC. Error 
bars correspond to standard deviations. Data points derive from assays conducted a minimum of three times. 
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4.4.5 Screening for protein: protein interactions involved in ARE ABC-F mediated 
resistance 
As Vga(A) and Lsa(A) rescue S. aureus, but not E. coli, translation from antibiotic inhibition, I 
speculated that Vga(A) and Lsa(A) may directly interact with staphylococcal proteins to exert 
their protective effect, and that these proteins are either different or absent in E. coli. To 
examine this hypothesis, and to identify any putative binding partners of Vga(A) and Lsa(A), 
pull-down experiments were performed on cell lysates, using either Vga(A) or Lsa(A) as 
immobilised “bait”. In order to reproduce conditions in which Vga(A) and Lsa(A) mediate 
protection, experiments were performed at 37°C in the presence of 1 μg / ml (1.9 μM) VGM. 
Previously, studies of the ABC-F protein EttA, which regulates translation in E. coli through a 
direct interaction with the ribosome, have shown that a double EttA mutant incapable of 
hydrolysing ATP mediates pull-down of E. coli ribosomes whilst wild type EttA does not (Chen 
et al., 2014). Given the homology between Vga(A) and Lsa(A) with EttA (25% and 24.5% 
amino acid identity respectively), I predicted that pull-down of ribosomes by ARE ABC-F 
proteins may also require the proteins to be trapped in an ATP-bound conformation. 
Therefore, I generated pIVEX2.3d-vga(A)E105Q-E410Q using site-directed mutagenesis. This 
construct encodes vga(A) with a glutamate to glutamine substitution of the catalytic 
glutamate in each ABC domain; a double mutation that permits ATP-binding, but not 
hydrolysis, in other ABC proteins (Chen et al., 2014, Orelle et al., 2003). However, expression 
from the pIVEX-vga(A)E105Q-E410Q construct did not produce soluble Vga(A)E105Q-E410Q under the 
conditions that had successfully been used to express WT Vga(A), Vga(A)E105Q, or Vga(A)K219T. 
As an alternative, I conducted pull down experiments using WT Vga(A) or Lsa(A) in the 
presence of ATP, or, the non-hydrolysable ATP analogue adenosine 5′-(β,γ-
imido)triphosphate (AMP-PNP).  
The use of his-Vga(A) and his-SUMO-Lsa(A) as immobilised bait and staphylococcal cell-
extracts as prey resulted in pull-down of proteins that formed four distinct bands when 
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analysed by SDS-PAGE, none of which appeared in control experiments using E. coli cell 
lysates (Figure 4.5). These bands, plus an additional band present solely in pull-downs using 
E. coli cell-lysates, were excised and sent for identification by peptide mass fingerprinting. 
From each band, several proteins were identified (Personal communication, James Ault, 
University of Leeds) (Figure 4.5). Although analysis of SDS-PAGE bands though peptide 
fingerprinting and LC-MS does not give a direct measure of the proportion of each protein in 
a band, the percentage of coverage of each primary sequence by LC-MS identified peptides 
is indicative of prevalence of each protein in a sample (Personal communication, James Ault, 
University of Leeds). However, the identification of multiple proteins per band, and of the 
same protein in multiple bands (seemingly independent of molecular weight e.g. elongation 
factor Tu [EF-Tu], Pyruvate kinase, SlyD, Figure 4.5), complicates interpretation of the data 
arising from these pull-down experiments. It is therefore only possible to conclude from this 
data that Vga(A) and Lsa(A) appear to interact with proteins participating in a range of 
cellular processes, including translation, and that these interactions differ in S. aureus and E. 
coli. It is of note that a two-hybrid screen conducted in E. coli to investigate a possible 
interaction between Vga(A) and EF-Tu did not provide evidence of an interaction (Personal 
communication, Chris Randall, University Of Leeds). 
As Lsa(A) has been shown here to displace LNC from the staphylococcal ribosome (Section 
4.4.4) and ribosomal proteins were identified as putative binding partners for Vga(A) and 
Lsa(A) in both S. aureus and E. coli cell-lysates, a final set of pull-down experiments was 
conducted using purified staphylococcal ribosomes as prey and Lsa(A) or Vga(A) as bait. 
However, no pull-down of ribosomal proteins was observed (Figure 4.6, page 103).  
Pull down assays using cell-lysates identified EF-Tu as a potential binding partner of Vga(A) 
and Lsa(A). As Ef-Tu is a ribosomally associated protein, the possibility of the protein co-
purifying with ribosomes was assessed. A single band identified in preparations of 
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staphylococcal ribosomes that appeared to correspond to a protein with a similar molecular 
weight to Ef-Tu (black arrow, Figure 4.6) was sent for identification by peptide mass 
fingerprinting. However, the only protein detected in this band was Enolase (70% coverage, 
Personal communication, James Ault, University of Leeds), an enzyme associated with 
glycolysis and cell adhesion in S. aureus (Carneiro et al., 2004).  
 
103 
 
 
 
Figure 4.5. Pull down experiments using cell-lysates as prey to identify putative binding partners of Vga(A) and Lsa(A). SDS-
PAGE images showing the results of immobilisation of (A) His-Vga(A) or (B) His-SUMO-Lsa(A) on Ni-NTA agarose and their 
subsequent use as bait to identify putative binding partners from staphylococcal and coliform S30 extracts. Assays were 
performed in the presence of 1μg / ml virginiamycin M and included either ATP or AMP-PNP. Control experiments assessed 
non-specific biding of proteins in the S30 extract to Ni-NTA agarose. Four bands specific to staphylococcal S30 extracts (1, 2, 3, 
5) and one band specific to E. coli S30 extracts  were sent for analysis by peptide mass fingerprinting, the results of which are 
shown on the right of the figure. 
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Figure 4.6. Pull down experiments using purified staphylococcal ribosomes as prey to identify putative binding 
partners of Vga(A) and Lsa(A). SDS-PAGE images showing the results of immobilisation of His-Vga(A) or His-
SUMO-Lsa(A) on Ni-NTA agarose and their subsequent use as bait to identify putative binding partners from 
purified staphylococcal ribosomes. Assays were performed in the presence of 1μg / ml virginiamycin M and 
included either ATP or AMP-PNP. Control experiments assessed non-specific biding of ribosomal proteins to Ni-
NTA agarose. A single band of around 48 kDa (black arrow) was sent for identification by peptide mass 
fingerprinting and was identified as Enolase (70% coverage). 
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4.5 Discussion 
The mechanism by which ARE ABC-F proteins mediate antibiotic resistance has remained 
obscure since their discovery 25 years ago (Ross et al., 1990). Experiments described in this 
chapter were therefore designed to distinguish between the two proposed models of 
resistance. Previous studies using in vitro translation experiments to investigate tetracycline 
resistance in streptococci proved able to differentiate between functions of Tet(L), a 
tetracycline efflux protein, and Tet(M), a RPP (Burdett, 1986). Similar experiments conducted 
here found that Vga(A) and Lsa(A) mediated dose-dependent protection of a staphylococcal 
cell-free T/T system from inhibition by streptogramin A and lincosamide antibiotics, showing 
that these proteins confer resistance in a system where antibiotic efflux is not possible. The 
subsequent in vitro reconstitution of resistance phenotypes observed in whole cells indicate 
that results derived from the T/T assay are representative of the mechanism by which Vga(A) 
and Lsa(A) mediate antibiotic resistance in whole cells.  
It is of note that neither protein restored translational activity to its uninhibited level. This 
result is in contrast to that seen for the tetracycline RPP Tet(M), which when added to E. coli 
in vitro translation assays has been shown to restore activity to uninhibited levels (Burdett, 
1996). This may result from the proposed ability of Tet(M) to prevent rebinding of 
tetracycline by promoting alterations to the conformation of the drug binding site that 
persist following dissociation of Tet(M) from the ribosome (Connell et al., 2002, Connell et 
al., 2003b, Dönhöfer et al., 2012). In contrast, titration of the fusidic acid resistance protein 
FusB into staphylococcal fusidic acid inhibited T/T assays, resorted activity to a maximum of 
only 40% (O'Neill and Chopra, 2006). Fusidic acid inhibits protein synthesis by binding to 
ribosome associated EF-G and preventing its dissociation following GTP hydrolysis, leading 
to ribosomal stalling and cessation of translation (Bodley et al., 1969, Tanaka et al., 1968). 
FusB accelerates the release of EF-G from the ribosome and thereby overcomes the 
inhibitory effect of fusidic acid (Cox et al., 2012). As fusidic acid has a low affinity for non-
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ribosome associated EF-G (Bodley et al., 1969), the drug is released on dissociation of EF-G 
from the ribosome and is free to re-bind Ribosome : EF-G : GDP complexes. FusB mediated 
fusidic acid resistance is therefore the result of FusB driving the equilibrium of fusidic acid 
binding to EF-G towards dissociation. Although it is difficult to extrapolate from an in vitro 
T/T assay to whole cells, where both Vga(A) and Lsa(A) function effectively, it is possible to 
speculate that the incomplete restoration of activity in vitro could indicate that these 
proteins mediate resistance in a similar manner to FusB, driving the equilibrium of ribosome 
: drug binding towards dissociation, rather than modifying the ribosome to prevent drug 
re-binding as proposed for tetracycline RPPs (Connell et al., 2003b). ° 
An alternative explanation for the dose-dependent restoration of translational activity 
observed in staphylococcal T/T assays is direct sequestration of the drug by Vga(A) and 
Lsa(A). Previous studies of Vga(A) and the N-terminal ABC domain of Ole(B) have proposed a 
direct interaction of the proteins with their target antibiotic (Buche et al., 1997, Jacquet et 
al., 2008), which would permit protection through sequestration (although a more recent 
analysis of Vga(A) binding to VGM and LNC using surface plasmon resonance failed to detect 
this interaction (Lenart et al., 2015)). However, neither Vga(A) or Lsa(A) rescued activity in 
coliform T/T assays performed using identical materials and methods to staphylococcal T/T 
assays. Nor did the protective effect mediated by Vga(A) and Lsa(A) in staphylococcal T/T 
assays continue indefinitely as more protein was titrated into the assay. It is therefore 
possible to rule out a sequestration based mechanism and conclude that protection is 
mediated by a specific interaction between Vga(A) or Lsa(A) with a component of the 
staphylococcal S30 extract.  
Addition of Lsa(A) to staphylococcal ribosomes was shown to displace bound LNC. It follows 
that in order to drive displacement, Lsa(A) must interact directly with staphylococcal 
ribosomes or a co-purifying soluble factor. However, although several putative binding 
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partners involved in translation were amongst the proteins identified from pull-down 
experiments using staphylococcal S30 extract, comparable experiments using purified 
ribosomes did not suggest any Vga(A) or Lsa(A) mediated ribosomal binding. Due to time 
constraints, the specificity of the interactions found using cell extracts as bait could not be 
further investigated by repetition or through conducting pull down assays using immobilised 
putative binding partners as bait and cell extracts containing Vga(A) or Lsa(A) as prey. Similar 
pull down assays conducted to investigate the mechanism by which the ABC-F protein EttA 
regulates E. coli translation in response to relative cellular levels of ATP / ADP showed that 
only an EttA double mutant, able to bind but not hydrolyse ATP, captured ribosomes during 
pull-down experiments conducted in vivo (Boel et al., 2014). Equally, studies of Tet(M) and 
Tet(O) resistance determinants have shown that complexes amenable to purification by gel 
filtration only form between RPPs and E. coli ribosomes in the presence of the non-
hydrolysable GTP analogous guanosine 5'-O-[gamma-thio]triphosphate (GTPγS) and 5'-
Guanylyl imidodiphosphate (GMP-PNP) (Trieber et al., 1998, Dantley et al., 1998). However, 
as addition of AMP-PNP to Vga(A) and Lsa(A) pull down assays did not reveal an interaction 
between the ARE ABC-F proteins and the ribosome, further work is required to explain the 
discrepancy between Lsa(A) mediated displacement of lincomycin from ribosomes and the 
inability to detect ribosome binding in pull-down assays. Due to constrains of time and 
material, a dissection of the effects of various adenosine nucleotides on the ability of Lsa(A) 
to displace LNC from the ribosome was not conducted during this study. Such an experiment 
may inform the discovery of conditions conducive to formation of a stable ribosome : ARE 
ABC-F complex. Additionally, investigation of complex formation through analytical gel 
filtration using untagged, Vga(A) and Lsa(A), free of any conformational restrictions imposed 
by immobilisation on Ni-NTA agarose may lead to an understanding of the conditions 
required to promote binding to ribosomes.  
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Indirect evidence suggestive of a direct interaction of ARE ABC-F proteins with the ribosome 
stems from the apparent correlation between the resistance phenotypes conferred by ARE 
ABC-F determinants and the degree of overlap of their target antibiotic binding sites within 
the 50S subunit. During this study, determination of the MICs of a panel of antibiotics that 
bind the 50S ribosomal subunit against S. aureus expressing representative genes from the 
vga-type, lsa-type and msr-type groups confirmed several previously reported resistance 
phenotypes.  
The alignment of multiple crystal structures of ribosome : antibiotic complexes permits a 
structural representation of ARE ABC-F resistance phenotypes (Figure 4.7). Proteins 
belonging to the vga- and lsa- type groups confer resistance to antibiotics that overlap both 
the A-site and P-site (streptogramin As and pleuromutilins) or the A-site and entrance to the 
peptide exit tunnel (lincosamides) (Figure 4.7 B). In contrast, msr-type determinants confer 
resistance to 14- and 15-membererd ring macrolides, ketolides and type B streptogramins, 
all of which bind to overlapping sites in the nascent polypeptide exit tunnel (Figure 4.7 C). 
However, the msr(A) gene did not confer resistance to any of the 16-membered macrolides 
tested, a result also observed for msr(C) and msr(D) (Reynolds and Cove, 2005). Although the 
14- and 16- membered macrolides bind the ribosome in an overlapping position, 16-
membered macrolides are predicted to form an additional covalent bond with the ribosome, 
resulting in increased affinity for their binding site (Hansen et al., 2002), and perhaps 
explaining the lack of resistance to 16-member macrolides mediated by msr-type 
determinants.  
The recently characterised optrA gene confers resistance to phenicols and oxazolidinones, 
which share an overlapping binding site at the ribosomal A-site (Figure 4.7 D). During this 
study, vga(A) and lsa(A) did not confer any detectable level of resistance to fluorphenicol or 
linezolid, equally, optrA, has been shown to confer no resistance to type A streptogramins, 
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lincosamides, or pleuromutilins (Wang et al., 2015). It is evident, that although phenicols and 
oxazolidinones, share a degree of overlap in their binding sites with pleuromutilins, 
lincosamides, and type A streptogramins, it is not sufficient for a single ARE ABC-F protein to 
confer cross-resistance to antibiotics of every class, as is the case with the ribosomal 
methylase Cfr (Long et al., 2006). An explanation of this discrepancy in resistance phenotypes 
may lie in the precise interactions of ARE ABC-F proteins with elements of the PTC, details of 
which could be obtained through structural studies.  
No resistance to antibiotics binding in direct competition with tRNA within the PTC was 
observed amongst the ARE ABC-F determinants screened during this study (Figure 4.7 E). 
However, for the first time, vga(A) and lsa(A) genes were shown to confer decreased 
susceptibility to the 16-membered macrolides leucomycin A1 and carbomycin. A possible 
explanation of this phenotype can be gleaned from a detailed analysis of the ribosomal 
binding sites and structure-activity relationships of various macrolides. Macrolides are 
composed of a macrolactone ring of varying size to which differing numbers of sugars are 
attached (Figure 4.8 A). 14-membered macrolides, such as eryhtomycin, act by binding in the 
peptide exit tunnel and blocking the egress of nascent polypeptides (Schlunzen et al., 2001, 
Hansen et al., 2002, Tu et al., 2005). The 16-membered macrolides bind in an overlapping 
site to erythromycin and also block the peptide exit tunnel, however, in addition, these 
antibiotics inhibit peptidyl-transferase activity to various degrees (Omura et al., 1968, Haupt 
et al., 1976, Poulsen et al., 2000). The level of inhibition is determined by the extent to which 
the groups attached to the C5 position of the macrolactone ring protrude towards the A-site 
of the PTC. Erythromycin has a monosaccharide at this position and therefore does not 
inhibit peptidyltransferase activity, whereas spiramycin, tylosin, leucomycin A1, and 
carbomycin, possess disaccharides at this position and protrude further into the PTC, 
inhibiting peptidyltransferase activity (Hansen et al., 2002) (Figure 4.8 B). Leucomycin and 
carbomycin protrude furthest towards the A-site due to an isobutyrate extension of the 
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disaccharide. This results in greater degree of overlap with the binding site of type A 
streptogramins, the point at which Vga(A) and Lsa(A) appear to mediate displacement 
(Figure 4.8 B).  
The information derived from a structural analysis of antibiotic binding sites within the PTC 
and peptide exit tunnel supports the notion that the resistance phenotypes of ARE ABC-F 
proteins are determined not by the chemical composition of their target antibiotics, but by 
the precise molecular details of antibiotic binding sites within the 50S ribosomal subunit. 
Coupled with the dual findings of protection of translation in staphylococcal T/T assays and 
Lsa(A) mediated displacement of lincomycin from the staphylococcal ribosome, these results 
support a mechanistic model in which ARE ABC-F proteins bind directly to ribosome and 
displace antibiotics from their binding sites. Such a model is discussed in the context of 
information available within the scientific literature in chapter 5. 
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Figure 4.7. Binding sites of antibiotics within the peptidyl-transferase centre and peptide exit tunnel of the 50S 
subunit. (A) The Thermus thermophilus ribosome with tRNA occupying the A-site (blue), P-site (green) and E-site 
(yellow). The 50S and 30S subunits are shown in red and black respectively. Co-ordinates from PDB: 4V5C. Magnified 
view of antibiotics at the peptidyl-transferase centre and peptide exit tunnel. (B) Binding sites of antibiotics to which 
vga-type and lsa-type ARE ABC-F proteins confer resistance; dalfopristin (streptogramin A, orange, PDB: 1SM1), 
retapamulin (pleuromutilin, pink, PDB: 2OGO), and clindamycin (lincosamide, blue, PDB: 4V7V). (C) Binding sites of 
antibiotics to which msr-type determinants confer resistance; erythromycin (14-membered macrolide, light brown, 
PDB: 4V7U) and quinupristin (streptogramin B, dark yellow, PDB: 1SM1). (D) Binding sites of antibiotics to which OptrA 
confers resistance; chloramphenicol (phenicol, yellow, PDB: 4V7T) and linezolid (oxazolidinone, red, PDB: 3DLL). (E) 
Antibiotics to which no identified ARE ABC-F confers resistance; blasticidin S (black, PDB: 1K8A), puromycin (green, 
PDB: 1Q82) and sparsomycin (green, PDB: 1M90). Figure generated in PyMOL through alignment of co-ordinates for 
antibiotic:ribosome complexes with PDB: 4V5C.  
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Figure 4.8. Macrolides that bind at the peptide exit tunnel of the 50S ribosomal subunit. (A) Chemical structures 
of macrolides used during this study (B)  Binding sites of macrolide antibiotics; erythromycin (light brown), tylosin 
(grey, PDB:1KD1), spiramycin (white, PDB: 1KD1) and carbomycin (black, PDB: 1K8A). A transparent surface 
representation of tRNA occupying the A-site (blue), P-site (green) is shown (Co-ordinates from PDB: 4V5C). No co-
ordinates describing the ribosomal binding site of leucomycin A1 are currently available. 
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4.6 Conclusions 
The experiments described within this chapter provide direct and indirect evidence to 
support a mechanism of ARE ABC-F mediated resistance that acts at the level of translation, 
rather than through efflux. The observations of Lsa(A) mediated displacement of lincomycin 
from staphylococcal ribosomes and dependency of ARE ABC-F resistance phenotypes on the 
precise details of antibiotic binding sites, suggest a mechanism involving direct binding of the 
ribosome by ARE ABC-F proteins. However, further work will be required to confirm, and 
elucidate the molecular basis of, such an interaction. These results are discussed together 
with information from the scientific literature regarding the ARE ABC-F mechanism of action 
in Chapter 5.  
114 
 
 
5. Discussion 
The experimental findings of this thesis, which are discussed in detail in Sections 3.5 and 4.5, 
provide strong support for a mechanism of ARE ABC-F mediated antibiotic resistance based 
on ribosomal protection. However, at present the prevailing view held by the scientific 
community is that ARE ABC-F proteins mediate antibiotic resistance through efflux 
(Wondrack et al., 1996, Matsuoka et al., 1993, Roberts et al., 1999, Chesneau et al., 2005, 
Jacquet et al., 2008, Nunez-Samudio and Chesneau, 2013). Here, the results obtained during 
this study are considered alongside information derived from the published scientific 
literature in order to re-evaluate the evidence proposed to support a mechanism of 
ARE ABC-F mediated efflux. In addition, the homology of ARE ABC-F proteins to other ABC 
proteins involved in translation is used to propose a model describing the details underlying 
the ribosomal protection mechanism. Finally, the plausibility of a blanket application of the 
ribosomal protection hypothesis to all proteins within the ARE ABC-F subfamily is discussed. 
5.1 A re-evaluation of the evidence proposed in support of antibiotic efflux 
The genesis of the efflux hypothesis lies in the 1990 study in which the deduced amino acid 
sequence of the first ARE ABC-F protein to be identified, Msr(A), was used to search an early 
protein sequence database developed at the University of Leeds (Bleasby and Wootton, 
1990, Ross et al., 1990). This bioinformatics approach revealed a high degree of homology 
between Msr(A) and the ABC domains of ATP transport proteins, leading the authors to infer 
a mechanism of resistance through efflux and subsequently conduct transport experiments 
to assess the accumulation of erythromycin in strains expressing msr(A) (Ross et al., 1990). 
In the intervening 25 years, due to the accumulative body of work regarding ABC proteins 
and the dramatic expansion in the size of protein databases, it has become increasingly 
apparent that Msr(A) and other ARE ABC-F proteins exhibit the greatest degree of homology 
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not with the ABC domains of transporters, but with ABC proteins that participate in cellular 
processes other than transport (Kerr, 2004, Dorrian, 2009, Lenart et al., 2015). 
Nevertheless, a cursory inspection of the transport experiments conducted during early 
studies of Msr(A) and, more recently, of Vga(A), leads even an informed reader down the 
road of antibiotic efflux. Only upon closer inspection do the pitfalls in these studies become 
clear. It has been consistently shown the expression of msr(A) and vga(A) results in an 
energy-dependent reduction in intracellular drug accumulation (Ross et al., 1990, Wondrack 
et al., 1996, Matsuoka et al., 1999, Novotna and Janata, 2006). However, experimental 
evidence that the expression of Erm-type methylases results in decreased accumulation of 
macrolides (Canton et al., 2005, Piatkowska et al., 2012), along with the observation that 
addition of an excess of an unlabelled macrolide or streptogramin B antibiotic to transport 
experiments using radiolabelled erythromycin also results in decreased accumulation (Barre 
et al., 1986, Reynolds et al., 2003), demonstrates that such accumulation experiments are 
inherently flawed: they are unable to distinguish between efflux and ribosomal protection.  
Although decreased drug accumulation due to ARE ABC-F expression is the only direct 
experimental evidence proposed in support of the efflux hypothesis, studies in which ARE 
ABC-F determinants have consistently been found within the membrane fraction of lysed 
cells have frequently been cited as indirect corroborative evidence for resistance through 
efflux (Matsuoka et al., 1993, Olano et al., 1995, Chesneau et al., 2005, Nunez-Samudio and 
Chesneau, 2013). This observation suggests, that like the ABC domains of ABC transporters, 
ARE ABC-F proteins may be peripherally associated with the membrane. Furthermore, a 
study in which the presence of Vga(A) in ribosome preparations was assessed showed no 
co-localisation of Vga(A) with the L24 ribosomal protein in S. epidermidis and was interpreted 
as an absence of evidence for ribosomal protection (Chesneau et al., 2005). The significance 
of membrane localisation of ARE ABC-F proteins in the context of ribosomal protection 
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remains unclear. It is of note however, that a portion of the ARE ABC-F proteins assessed in 
these cellular localisation studies has repeatedly been found within the soluble fraction when 
the proteins are overproduced (Chesneau et al., 2005, Nunez-Samudio and Chesneau, 2013, 
Olano et al., 1995). Additionally, a fraction of cellular ribosomes has previously been shown 
to be membrane associated in S. aureus (Adler and Arvidson, 1984). 
An important prediction of the efflux hypothesis is that in order for ARE ABC-F proteins to 
participate in efflux, they must associate with TMDs. Two studies have been undertaken in 
an effort to identify such TMDs in S. aureus. In the first such study, DNA sequence analysis of 
the S. epidermidis plasmid on which the msr(A) gene was originally identified (pUL5050) 
revealed a putative ABC transporter upstream of msr(A) that was proposed as a candidate 
to provide the missing TMDs (Ross et al., 1995). Two open reading frames were identified 
within this region; a single ABC domain (designated stp) and a single TMD (smp). These 
sequences were consistently found to be associated with msr(A) on staphylococcal plasmids, 
and are also present on the chromosome of erythromycin sensitive S. aureus (Ross et al., 
1995). It was therefore suggested that an interaction between Msr(A) and this ABC 
transporter could explain the observation that msr(A) isolated from S. epidermidis was able 
to mediate resistance in S. aureus in the absence of any other plasmid encoded sequences 
(Ross et al., 1995). However, subsequent work showed that the msr(A) resistance phenotype 
was unaffected following inactivation of the endogenous S. aureus RN4220 stp and smp 
sequences through allelic replacement (Ross et al., 1996), establishing that these sequences 
are not required for Msr(A)-mediated resistance. The second study to search for Msr(A) 
associated TMDs utilised transposon mutagenesis of an S. aureus RN4220 strain containing 
a single chromosomal copy of msr(A). Despite screening of over 3000 mutants for reduced 
susceptibility to macrolides, no such TMDs were identified (Reynolds, 2005).  
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Although efforts to identify TMDs of ABC transport proteins with which ARE ABC-F proteins 
may interact have not been successful, a recent study of the streptococcal macrolide 
resistance determinants msr(D) and mef(E) provided the first report of an interaction 
between an ARE ABC-F protein and a membrane-located MFS transporter (Nunez-Samudio 
and Chesneau, 2013). The use of fluorescently labelled Msr(D) and Mef(E) in a heterologous 
host, E. coli, allowed an analysis of the cellular localisation of the two proteins. In the absence 
of msr(D) expression, Mef(E) was distributed unevenly into several focal points throughout 
the cytoplasm, a result which was also observed when a catalytic mutant of Msr(D), 
Msr(D)E434Q, was co-expressed with mef(E). However, when functional msr(D) and mef(E) 
genes were co-expressed, Mef(E) localised to the poles of the cell. Unlike msr(A) (Ross et al., 
1990) or vga(A) (Chesneau et al., 2005), and contrary to a previous report regarding msr(D) 
(Reynolds, 2005), heterologous expression of msr(D) in a macrolide susceptible E. coli strain 
conferred erythromycin and azithromycin resistance (16-fold). By contrast, heterologous 
expression of mef(E) in E. coli resulted in only a two-fold increase in erythromycin MIC and 
no azithromycin resistance, compared with the high-level resistance (up to 200-fold) to both 
drugs observed in its native host, S. pneumoniae (Wierzbowski et al., 2005). Co-expression 
of both determinants had a synergistic effect, increasing levels of erythromycin and 
azithromycin resistance 32 fold. Subsequently, an in vitro pull-down assay using histidine 
tagged Msr(D) as bait detected an interaction between Msr(D) and Mef(E) through Western 
blotting.  
From these observations the authors concluded that in the absence of Msr(D), the Mef(E) 
protein is predominantly aggregated. Co-expression of msr(D) is proposed to ensure the 
correct integration of Mef(E) into the cell membrane and Msr(D) is thought to enhance or 
hijack the Mef(E) pump, broadening its substrate specificity. Although the observation that 
expression of msr(D) alone conferred macrolide resistance was noted, a result previously 
described in S. pneumoniae (Daly et al., 2004) and S. aureus (Reynolds and Cove, 2005), the 
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authors did not speculate as to the mechanism underlying this phenotype. Analysis of the 
data arising from this study with the assumption that Msr(D) is acting to protect the 
ribosomes offers an alternative interpretation. The large decrease in the level of macrolide 
resistance conferred by mef(E) when expressed in E. coli in comparison to S. pneumoniae, 
together with the detection of several focal points throughout the cytoplasm, suggests that 
mef(E) is poorly expressed in E. coli in the presence of macrolide antibiotics and the Mef(E) 
protein is predominantly aggregated. Lifting of macrolide-mediated protein synthesis 
inhibition by co-expression of msr(D) may permit higher levels of mef(E) expression and 
correct folding of the transport protein, allowing membrane integration and promoting a 
synergistic effect between efflux and ribosomal protection. Although pull-down assays 
analysed through western blotting showed an interaction between Msr(D) and Mef(E), both 
determinants have previously been shown to function as independent resistance 
determinants in S. pneumoniae (Daly et al., 2004). In order to establish the specificity of this 
interaction it would be useful to see an SDS-PAGE analysis of the pull-down assays, as work 
outlined in Section 4.4.5 of this thesis showed Vga(A) and Lsa(A) to pull-down multiple 
proteins from cell-extracts, unfortunately no such analysis was included in the paper (Nunez-
Samudio and Chesneau, 2013).  
The msr(D) determinant was not included in the screen to obtain conditions for soluble ARE 
ABC-F proteins conducted during this study (Section 3.4.5); however, the use of E. coli 
expressing msr(D) to conduct pull-down assays suggests that this protein may be amenable 
to large scale purification. Future work in which homogenously purified Msr(D) could be 
tested for its ability to protect E. coli and S. aureus T/T assays would be beneficial. I predict 
such experiments would show Msr(D) to act in the same manner as Vga(A) and Lsa(A), and 
that any interaction with Mef(E) is secondary to the primary function of Msr(D) as a 
ribosomal protection protein. 
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5.2 Resistance through ribosomal protection 
5.2.1 A re-evaluation of the lack of evidence for ribosomal protection 
The work outlined in this thesis provides several lines of indirect and direct evidence that 
together offer support for a mechanism of resistance involving ribosomal protection. By 
contrast, previous studies in which attempts have been made to provide evidence of 
ribosomal protection have been unsuccessful. Possible explanations for these failures are 
provided below. 
Previously, translation assays composed of centrifugally purified ribosomes, S150 fractions, 
and poly(A) transcripts, have shown no difference in the erythromycin sensitivity of assays 
derived from msr(A) expressing drug resistant strains and wild-type drug sensitive strains 
(Wondrack et al., 1996). Perhaps the key difference between these translation experiments 
and the T/T assays described in this thesis is the addition of exogenously purified protein. It 
is possible to speculate that due to the membrane association of Msr(A), the centrifugation 
steps required for purification of ribosomes and S100/150 fractions remove the majority of 
the ARE ABC-F protein from the system, resulting in sensitivity of these translation assays to 
the drug (Matsuoka et al., 1993, Wondrack et al., 1996). This poses questions regarding the 
effect of membrane localisation of the protein may have upon resistance mediated through 
protection in vivo. Is there sufficient protein within the cytoplasm to mediate ribosomal 
protection? Can results obtained through addition of exogenously purified protein to T/T 
assays be said to accurately depict events occurring in whole cells? The results described 
within Section 4.4.3 of this work are therefore of particular importance. The recapitulation 
of phenotypes observed in whole cells within the T/T assays allows conclusions drawn from 
these in vitro experiments to be extrapolated to events occurring in vivo, and eliminates the 
possibility that these results are merely an artefact of the T/T assay. The relationship 
between membrane localisation of ARE ABC-F proteins and their ability to mediate ribosomal 
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protection remains an open question, however, it is of note that when cellular localisation 
of GFP-tagged Msr(D) in E. coli was assessed in vivo the protein was seen to be evenly 
distributed throughout the cytoplasm, whereas within the same study, analysis of 
centrifugally derived cell fractions by western blotting showed that the protein was present 
in both the soluble and membrane factions (Nunez-Samudio and Chesneau, 2013). Although 
speculative, it is possible to suggest that in the case of ARE ABC-F proteins, results obtained 
from cellular fractionation may not necessarily reflect events in whole cells. This is in contrast 
to studies of tetracycline RPPs, in which ribosomes and S150 fractions isolated from strains 
expressing tet(M) have proven to be refractory to the inhibitory action of tetracycline 
(Burdett, 1986, Burdett, 1991). An in vivo assessment of the cellular localisation of a 
fluorescently labelled ARE ABC-F protein in its native host may provide useful insights with 
which to reconcile the ribosomal protection model and previous cellular fractionation 
studies.   
5.2.2 A model for ribosomal protection mediated by ARE ABC-F proteins 
The results described in this thesis, coupled with the lack of conclusive evidence in support 
of efflux, indicate that ARE ABC-F proteins mediate their effects at the level of translation, 
through displacement of the drug from its ribosomal binding site. The observation that Lsa(A) 
mediated displacement of lincomycin from a preparation purified staphylococcal ribosomes, 
in which ribosomally associated proteins such as EF-Tu did not appear to be present, suggests 
that ARE ABC-F proteins act directly upon the ribosome and mediate resistance in a manner 
analogous to the tetracycline RPPs. 
The tetracycline RPPs show homology to the ribosome-associated GTPases EF-G and EF-Tu 
(Doyle et al. 1991), and bind the ribosome at the same position as these elongation factors 
(Li et al., 2013, Arenz et al., 2015). Analysis of the literature pertaining to ABC proteins not 
involved in transport yields three characterised proteins that have been shown to directly 
121 
 
 
bind the ribosome: ABCE1, a highly conserved protein that plays a role in ribosome recycling 
and rescue of stalled ribosomes in eukaryotes and archaea (Andersen et al., 2006); eEF3, a 
fungal protein that plays an essential role in elongation and recycling (Becker et al., 2012); 
and EttA a widely distributed bacterial protein involved in energy dependent regulation of 
translation (Boel et al., 2014, Chen et al., 2014). Of these proteins both eEF3 and EttA fall 
into the ABC-F subfamily, whereas ABCE1 belongs to the closely related ABC-E subfamily, a 
group of dual ABC domain proteins that also lacks TMDs. All three proteins contain tandemly 
repeated ABC domains separated by a linker. However, ABCE1 and eEF3 contain additional 
N-terminal HEAT repeat and iron-sulphur cluster (FeS) domains respectively, which are 
essential to their interaction with the ribosome (Andersen et al., 2006, Becker et al., 2012). 
Of these three proteins, the predicted domain architecture of ARE ABC-F determinants most 
resembles that of EttA (Figure 5.1 A).  
EttA regulates translation in E.coli in response to changing cellular energy levels, specifically 
the ATP/ADP ratio of the cell (Boel et al., 2014, Chen et al., 2014). The protein is thought to 
contribute either to survival of the organism in stationary phase, or to aid its transition from 
stationary phase to logarithmic growth. In order to perform these functions, EttA binds to 
the ribosome at the E-site, bringing the L1 stalk and P-site, and modulates the conformation 
of the PTC through contracts with ribosomal proteins, rRNA and P-site fMet-tRNA 
(Figure 5.1 B [i] and [ii]) (Boel et al., 2014, Chen et al., 2014). It is currently thought that the 
ADP-bound form of EttA, which is predominant in stationary phase, binds to the vacant E site 
of ribosomes positioned at the start codon and inhibits translation. Whereas ATP-bound 
EttA, which is predominant during logarithmic growth, promotes formation of the first 
dipeptide bond, hydrolyzes ATP and dissociates from the E site (Boel et al., 2014, Chen et al., 
2014). Although this model provides an initial framework for understanding EttA function, 
there is an open question as to exactly how ATP hydrolysis can promote the release of EttA 
from the ribosome, whereas ADP can stabilize EttA and cause translation inhibition.
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The functional and structural characterisation of EttA (Boel et al., 2014, Chen et al., 2014) 
infomred the conclisions drawn during a recent study of Vga(A) conducted by Lenart et al. 
(2015). Using site-directed mutagenesis mapping of Vga(A), they demonstrate that the 
spectrum of antibiotic resistance mediated by the protein can be altered by mutations to an 
8-residue variable region within the interdomain linker (Lenart et al., 2015). Lenart et al. 
point out that the PtIM of EttA is conserved in Vga(A), with an extension of 30 amino acids 
inserted at its centre, into which the 8-amino acid antibiotic specificity determining region 
falls. They therefore propose that the Vga(A) linker acts analogously to the EttA linker, but 
the extension allows further penetration towards the PTC, where it causes dissociation of its 
target drugs either directly, or through contacts with the P-site tRNA (Figure 5.1 B [ii]) (Lenart 
et al., 2015). This model of ribosomal protection fits with the data outlined in this study. 
However, it is important to note that EttA interaction with the ribosomal L1-stalk is mediated 
by a second functionally important structural motif, a 44 amino acid insertion between the 
Q-loop and signature motif of the N-terminal ABC domain referred to as the arm region, 
which is not present in ARE ABC-F proteins. This position is important for determining the 
protein : protein interactions in which ABC proteins participate (Dassa and Bouige, 2001, 
Davidson et al., 2008, Dassa, 2011), insertion of a chromodomain into the equivalent position 
of the C-terminal ABC domain of eEF3 mediates interaction with a different region of the 
ribosome (Andersen et al., 2006). Therefore although the interdomain linker of ARE ABC-F 
proteins may interact with the P-site tRNA in a similar manner to EttA, the position of ARE 
ABC-F ribosomal binding may not be identical.  
EttA preferentially binds to ribosomes containing fmet-tRNA at the A-site and competes with 
deacetylated tRNA within the E-site for its binding position (Boel et al., 2014, Chen et al., 
2014). Although 14-membered macrolide antibiotics such as erythromycin are unable to 
inhibit elongating ribosomes (Andersson and Kurland, 1987), at least one example of an 
antibiotic that inhibits the peptidyl-transferase reaction, lincomycin, exhibits inhibitory 
action against ribosomes in the post-translocation conformation. 
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Figure 5.1. (A) Domain architectures of ABC proteins that directly bind the ribosome. A comparison between 
the ARE ABC-F subfamily, represented here by Vga(A), to other ABC proteins that directly bind the ribosome. 
Unlike the ARE ABC-F proteins ABCE1 and eEF3 lack an extended inter ABC linker and possess additional N-
terminal domains important for their interaction with the ribosome. In contrast, like ARE ABC-F proteins, EttA is 
composed by two ABC domains separated by an extended interdomain linker, which is recognised as a 
ABC_tran_2 conserved domain. (B) The interaction of EttA with the ribosome. (i) EttA (blue) binds at the E-site 
of the 70S ribosome where it contacts the acceptor arm of the P-site tRNA (red) as shown in (ii). ARE ABC-F 
proteins possess an extended linker domain which may protrude further towards the PTC (depicted as green 
circle) in order to displace 50S targeted drugs from their binding sites. Figure adapted from Starosta et al. (2014).  
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(Kallia-Raftopoulos et al., 1994). This poses the question of how an ARE ABC-F protein would 
mediate antibiotic displacement from an elongating ribosome. Although EttA preferentially 
binds pre-translocation ribosomes, in vitro peptide synthesis assays have shown the protein 
as capable of binding post-translocation complexes albeit at a lower affinity. The ribosomal 
E-site was shown not to stably retain deacetylated tRNA in these assays, providing an 
opportunity for the EttA to bind (Boel et al., 2014). Perhaps ARE ABC-F proteins act in a 
similar manner in vivo, binding the vacant E-site and promoting displacement of the 
antibiotic. Such a system would not prevent rebinding of the displaced antibiotic and would 
therefore require cyclic ARE ABC-F association, antibiotic displacement, and dissociation of 
the ARE ABC-F protein, processes likely to be driven by the different conformational states 
resulting from binding and hydrolysis of ATP. The plausibility of this model is dependent on 
peptide bond formation occurring at a faster rate than rebinding of the antibiotic. Further 
work is required in order to establish the precise details of such a model. 
5.2.3 Do all ARE ABC-F proteins mediate ribosomal protection? 
The work described in this thesis provides strong support for a mechanism of ribosomal 
protection for the Lsa-type and Vga-type ARE ABC-F proteins. Previously, the efflux 
hypothesis was derived predominantly from experiments concerning Msr(A), Vga(A) and 
Ole(B) and applied to all ARE ABC-F proteins. Is it equally appropriate to apply the ribosomal 
protection hypothesis to all members of the subfamily? The homology exhibited by ARE ABC-
F proteins found in Gram-positive pathogens, coupled to the consistent correlation of 
resistance phenotypes amongst this group with the precise ribosomal binding sites of their 
target antibiotics, suggests that the ribosomal protection model can be applied to this entire 
group. Efforts to identify conditions conducive to the soluble expression of an Msr- 
determinant during this work were unsuccessful; however, work in which strains expressing 
Msr(D) have been used in pull down assays suggests that purification of this protein may be 
possible (Nunez-Samudio and Chesneau, 2013), analysis of this protein in the T/T assay may 
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further validate the application of the ribosomal protection hypothesis to all ARE ABC-F 
proteins found in Gram-positive pathogens. 
Observations derived from experiments regarding ARE ABC-F proteins found in Gram-
positive antibiotic producers makes application of the ribosomal protection model to this 
group of proteins more difficult. For example, deletion of either the N- or C-terimal ABC 
domains of the oleandomycin resistance determinant Ole(B) has been shown not to affect 
its ability to confer resistance (Olano et al., 1995). Similarly, macrolide resistance conferred 
by the LmrC lincomycin resistance determinant from Streptomyces lincolnensis expressed 
within the heterologous host Lactococcus lactis has been shown to occur independently of 
the proteins ability to bind ATP (Dorrian et al., 2011). Heterologous expression, purification, 
and analysis within a T/T assay of one or more of the ARE ABC-F determinants found within 
antibiotic producing bacteria would prove useful in an effort to determine whether all 
ARE ABC-F proteins mediate ribosomal protection. 
5.3 Future work 
An important step to enable further characterisation of the ribosomal protection model is 
the isolation of stable ARE ABC-F : ribosome complexes. In order for this to be achieved, an 
analysis of the relative effects of different adenosine nucleotides on Lsa(A) binding to 
ribosomes should be performed and examined through analytical gel filtration or surface 
plasmon resonance using an immobilised ARE-ABC-F protein. Similar experiments have 
previously been used to identify the requirements for binding of tetracycline RPPs to the 
ribosome (Dantley et al., 1998, Trieber et al., 1998). Other parameters that could be varied 
are salt concentration (as increasing ionic strength has been shown to cause dissociation of 
tetracycline RPPs from ribosomes (Burdett, 1991)) and magnesium concentration. Attempts 
to purify a Vga(A) double catalytic mutant(Vga(A)E105Q,E410Q), that is capable of binding but not 
hydrolysing ATP, were not successful during this project. A similar mutant, EttA-EQ2, was 
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used to obtain complexes of EttA bound to the ribosome, however, rather than attempting 
pull down assays using purified EttA-EQ2 these complexes were isolated through an “in vivo 
pull-down” in which induction of a tightly regulated construct encoding EttA-EQ2 followed by 
cell lysis and IMAC resulted in a one-step purification of the EttA-EQ2 : ribosome complex 
(Chen et al., 2014). A similar experiment could be conducted in S. aureus using 
vga(A)E105Q,E410Q present in a tightly regulated vector such as pAJ96 (O'Neill et al., 2007).  
The isolation of a stable ARE ABC-F : ribosome complex would permit structural studies of 
the complex using cryo-EM. Similar investigations have yielded structural information 
regarding the interactions of tetracycline RPPs and translation associated ABC proteins, 
including EttA, with the ribosome (Boel et al., 2014, Li et al., 2013, Arenz et al., 2015, 
Andersen et al., 2006, Becker et al., 2012). Further attempts to crystallise Vga(A) and Lsa(A) 
may benefit from the analysis of buffer components for stabilisation of Vga(A) described in 
Section 3.4.9, although it is clear that the problem of protein degradation will need to be 
solved in order to obtain a high-resolution structure of either protein. If such a structure was 
obtained, in tandem with information derived from a cryo-EM study of the protein : 
ribosome complex, this information could potentially prove useful in the rational 
modification of 50S targeted antibiotics to circumvent ARE ABC-F mediated resistance. Such 
work would translate the dissection of the fundamental biology underlying the resistance 
mechanism described within this thesis into useful intelligence in the ongoing fight against 
antibiotic resistance.   
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